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Chapter 1 
INTRODUCTION AND PROBLEM STATEMENT 
1.1 Introduction 
( R Ì Sal icyl azosul f a p y n d i n e (sul f asal azine» Sal azopyrin v , Azul-
fidine v ', SASP) was introduced by Nanna Svartz in 1942 for the 
treatment of rheumatoid arthritis. Taking the line that in this 
condition both infection and inflammation played a role, it was 
planned to develoo a druq that had both an antibacterial and an 
anti-inf1ammatory effect. One of the drugs that was synthesized 
based on this consideration was SASP. Sulfapyridine ( S P ) , in 
those days a much used chemotherapeutic agent, was coupled to 
salicylic acid by means of an azo link. During the treatment 
of patients with arthritis and ulcerative colitis with SASP it 
appeared, however, that a remarkable improvement of the colitis 
occurred(Svartz, 1 9 4 2 ) . Since that time SASP has become an 
important drug for the treatment of inflammatory bowel disease 
In patients with ulcerative colitis, the efficacy of SASP has 
been convincingly demonstrated, both in the treatment of mild 
and moderately active colitis (Baron et al, 1962; Dick et al, 
1964) and in the prevention of relapses (Misiewicz et al, 1965, 
Dissanayake and Truelove, 1 9 7 3 ) . 
In spite of wide-spread use for more than 30 years there was, 
until recently, only little known about the metabolism of SASP. 
SASP was generally regarded as belonging to the group of poorly 
absorbed sulfonamides. In 1972 Peppercorn and Goldman showed in 
animal experiments that the intestinal flora plays an essential 
role in the metabolism of SASP. This was confirmed in the same 
year by Schroder and Campbell who used healthy volunteers for 
their study. They demonstrated that SASP, administered orally, 
is only slightly absorbed from the small intestine. Thus the 
greater part of SASP reaches the colon. Here cleavage of 
the azo link takes place under the influence of bacteria whereby 
SASP is split into SP and 5-aminosalιcylic acid (5-ASA) SP is 
almost completely absorbed from the colon while 5-ASA is excreted 
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for the qreater part with the stools. The publications of 
Peppercorn and Goldman and of Schröder and Campbell and some 
articles on improved methods of determination of SASP and its 
metabolites (Sandberq and Hansson, 1973; Hansson and Sandberg, 
1973; Hansson, 1973) strongly stimulated further research into 
the metabolism and mode of action of SASP (Peppercorn and Goldman, 
1973; Schröder et al, 1973; Das et al, 1973). 
1.2 Problem Statement 
SASP is a much used drug in the treatment of patients with 
ulcerative colitis or Crohn's disease. In the daily prescription 
of SASP a number of questions and problems emerge 
which have been the instigation of the investigations that are 
described in this thesis. 
SASP is particularly effective in the treatment of inflamma-
tory disease of the large bowel, thus at the site where splitting 
chiefly occurs. Therefore it has been suggested that not SASP but 
one of the split products is the active component. SASP serves 
then, as it were, as a vehicle for delivering the active meta-
bolite, SP or 5-ASA, at the site of inflammation in the colon 
where it exerts its beneficial effect. 
It is not known whether SP or 5-ASA is the active moiety. An 
insight into this is of considerable practical significance. The 
use of SASP is not infrequently limited by the appearance of 
side effects which are almost all attributable to SP. Should 
5-ASA be the active component and SP only the carrier then it 
would be of great value to synthesize a new compound in which 
SP is replaced by a less toxic (preferably inert) carrier. On 
the other hand if it appears that SP is the active component 
then a new drug could be synthesized by coupling a less toxic 
sulfonamide via an azo link to a carrier. 
Experience has taught, furthermore, that SASP is especially 
effective in mild and moderately active colitis, while in severe 
colitis, which is usually accompanied by profuse diarrhoea, the 
same or even a higher dose of SASP is much less effective. It is 
possible that differences in splitting of SASP, both from patient 
to patient and in the same patient under different circumstances, 
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play a role in the varying efficacy of this drug One can, for 
example, wonder whether the splitting of SASP, and therefore 
also its effect, is reduced by severe diarrhoea. 
The question can also be asked as to whether concomitant 
administration of other drugs can reduce or negate the effect 
of SASP. For example, patients with inflammatory bowel disease 
are sometimes treated with a combination of SASP and antibiotics 
Patients who have undergone an ileocoecal resection, besides 
taking SASP, often use cholestyramine. Can these drugs influence 
the effect of SASP in an unfavourable way' 
It is remarkable that some patients can tolerate high doses 
of SASP (for example 6 g per day) whilst in others only a low 
dosage can be given because of side effects such as headache, 
nausea or haemolysis. Is this caused by ιnterindividual diffe­
rences in the metabolism of SASP or its split p r o d u c t s 7 
Another experience gained in practice is that SASP appears to 
be initially quite effective but seems to become less effective 
with time. Does there arise some sort of tolerance to the drug 
or is SASP only apparently ineffective because in the course of 
time the patient is taking the drug at irregular intervals or 
even not at a l l 7 In other words can patient "non-compliance" 
offer an explanation for this phenomenon 7 
In order to be able to answer the questions posed above the 
following investigations were carried out. 
1^  First of all the methods given in the literature for the deter­
mination of SASP, SP and 5-ASA in serum and urine were examined 
for reliability and suitability for regular use. In order to obtain 
good insight into the metabolism of SASP under normal and pathologi­
cal conditions it was also necessary to determine SASP and metaboli­
tes in the faeces. Besides a reliable method for determination it is 
necessary to prevent azo reduction of SASP in the faeces samples du­
ring storage. Therefore we investigated which method of preservation 
was the most effective in this respect (chapter 3 ) . 
2 Subsequently several aspects of the metabolism of SASP were stu­
died, both after a single dose of SASP and during maintenance 
therapy. This experiment was largely carried out in healthy 
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volunteers with the intention to obtain an impression of the 
interindividual differences in SASP metabolism under normal-
circumstances (chapter 4 ) . 
3 The influence of the following factors on the metabolism of 
SASP was examined: the dosage form of SASP; the intestinal tran-
sit time; the inflammatory activity of the bowel; concomitant 
administration of amoxycillin and of cholestyramine; the use of 
an elemental diet; total colectomy; bacterial overgrowth in the 
small intestine (chapter 5 ) . 
4 Starting from the assumption that one of the split products 
of SASP is the active component, a double-blind prospective study 
was carried out to compare the effect of local administration of 
SP, 5-ASA and a placebo in patients with idiopathic proctitis 
(chapter 6 ) . 
5^  The incidence of side effects and their relation to the serum 
levels of SASP and SP were studied in patients with Crohn's 
disease or ulcerative colitis who were on a maintenance treatment 
with SASP (chapter 7 ) . 
6^  In order to determine the patient compliance the concentration 
of SP was regularly determined in serum and urine of patients using 
maintenance dose of SASP,both during clinical observation and out-
patient treatment (chapter 0 ) . 
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Chapter 2 
REVIEW OF THE LITERATURE 
2.1 The metabolism of sulfasalazine 
2.1.1 Introduction 
SASP is formed by diazotation of SP and coupling of this 
diazo salt to salicylic acid(fig 2 . 1 ) . It is an orange-yellow 
powder, practically insoluble in water or in acid media and 
reasonably soluble in alkaline media (Nygard, 1966). 
HOOC 
HO^Q) H2N^Obs02-NH^O> 
salicylic acid 
HOOC 
suHapyridme 
H O
- ( Q } - N = N ^ ( Q ) - S O 2 - N H - / Q ) 
salicyl -azo - sultapyndme 
F i g . 2.1 T h e s t r u c t u r e of s a l i c y l i c a c i d , suI f a p y r i d i ne and 
sal i c y 1 a z o s u 1 f a p y r i d i n e 
Svartz (1942) assumed that SASP was absorbed from the small 
intestine and deposited in the tissues where SP and 5-ASA were 
gradually liberated. This assumption was based on the fact that 
after oral administration of SASP not only SASP but also SP was 
found in the blood. At the usual dosage of 5 to 6 g per day the 
blood level of SP was generally lower than 10 to 20 pg/ml. She 
noticed that these SP levels were considerably lower than after 
administration of pure SP. However, higher levels at this 
dosage were found by others.Böttiger and Möllerberg (1959) found 
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a mean serum SP level of 65 ug/ml after the administration of 
5 g SASP per day. The serum SASP concentration was considerably 
lower: on averane 20 yq/ml . 
Until recently SASP was oenerally regarded as belonging to 
the group of poorly absorbed sulfonamides (Harrison, Principals 
of Internal Medicine, 1 9 7 4 ) . Not until 30 years after introduc-
tion of SASP it appeared that only a small proportion of SASP 
is absorbed from the small intestine while the greater part of 
SASP reaches the colon. There the diazo bond of SASP is 
split by colonic bacteria liberating SP and 5-ASA. Sp is 
then largely absorbed from the colon (Schröder and Campbell, 
1972; Peppercorn and Goldman, 1 9 7 3 ) . 
2.1.2 ^i£tri^ut^ion ігі^  t^ he .tis^ues^ 
Helander (1945) was able to show by means of fluorescence m i ­
croscopy that SASP had a pronounced affinity for elastic and 
collagenous structures of connective tissue, just as was the 
case with other acid azo compounds such as Prontosil and salicyl-
azosulfathiazole. 5-ASA also appeared to possess this proper­
ty (Helander 1 9 4 9 ) . 
Somewhat more extensive studies on the behaviour of SASP after 
intravenous and oral administration were conducted by Hanngren 
et al (1963a, 1 9 6 3 b ) . 1 4 C - 1 a b e l 1 ed SASP was administered intrave­
nously to mice. The mice were killed at different times after 
injection. They were then cut into sections and layed on photogra­
phic plates. SASP showed a pronounced affinity to connective 
tissue everywhere in the body, including the intestinal wall. 
Furthermore, several hours a f t e r intravenous injection there 
was a cumulation of SASP in the intestinal mucosa and in the 
lumen of the small and large intestine. According to the authors 
this was caused by excretion of SASP via the intestinal wall. 
The same distribution was found after oral administration of 
l^C-SASP with, however, a higher activity in the intestinal lumen. 
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Intravenously administered C-5-ASA showed the same distribu­
tion pattern as C-SASP. After both oral and intravenous admini­
strations of C-SASP, SASP and 5-ASA (partly acetylated) were 
present in the urine. 
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In order to compare the distribution of SASP and SP these sub-
35 
stances were labelled with S. As expected the tissue distri­
bution of 1 4 C - S A S P and 3 5 S - S A S P was the same. 3 5 S - S P showed no 
accumulation in connective tissue but was distributed dif­
fusely through the organism. The activity in the intestinal lu-
35 
men was very low. After administration of S-SASP, SASP, SP 
and acetyl-SP could be demonstrated in the urine. When compared 
with intravenous administration, the urinary excretion of SASP 
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after oral administration of S-SASP was clearly lower and 
that of SP considerably higher. On the basis of this data 
Hanngren et al suggested that in patients with ulcerative coli­
tis SASP was effective thanks to the azo bond. SASP was 
concentrated in the connective tissue of the intestinal wall, 
whereby SP and 5-ASA were gradually liberated locally by means of 
splitting of the azo bond. They left undecided whether SP or 
5-ASA is the therapeutically active component (Hanngren et al, 
1963b). 
2.1.3 The І п£Ijjence ^ — ^ Л * ! 5 ! ^ ! ! . 3 ! ^ a c t e H a 
Besides SASP a number of colorants used in the food industry 
contain azo bonds. It has been known for a long time that the 
azo bonds in a number of these colorants are split by intestinal 
bacteria (Radomski and Mellinger, 1962; Fore, 1967; Walker, 1 9 7 0 ) . 
It is therefore remarkable that a study on the role of the intes­
tinal flora in the splitting of the azo bond of SASP was published 
for the first time in 1972. 
Peppercorn and Goldman (1972) investigated the azo reduction 
of SASP in rats. After oral administration of SASP none of the 
drug was recovered in urine or faeces but the excreta contained 
the products of azo bond reduction, SP and 5-ASA. SP was chiefly 
excreted in the urine whereas 5-ASA was found mainly in the 
faeces. When SASP was given to germ-free rats, lacking an intes­
tinal microflora, the greater part of SASP was excreted in 
the stools. Only a small amount of SASP was excreted in the 
urine. Neither SP nor 5-ASA was found in urine or faeces. 
Besides SP and 5-ASA, SASP was also present in the faeces of 
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rats whose intestinal flora had been reduced by administration 
of neomycin. When germ-free rats were infected with bacteria 
normally found in the intestinal tract of rodents or were in-
troduced into a non sterile area, SASP was metabolised as in 
conventional rats. On the basis of these experiments Peppercorn 
and Goldman concluded that the metabolism of SASP is initiated 
by reduction of the azo bond mediated by the intestinal flora. 
Schröder and Gustafsonn (1973) came to the same conclusion. 
The azo reduction of SASP could also be demonstrated in vitro. 
Incubation of SASP with suspensions of different bacteria showed 
considerable or complete disappearance of SASP together with 
the appearance of SP and 5-ASA in the incubation mixture 
(Peppercorn and Goldman, 1972; idem 1973). Azad Khan et al 
(1975) showed by means of in vitro studies that almost 
all the bacteria isolated from the gastrointestinal tract of 
man are capable of splitting the azo bond of SASP. Sonically 
disrupted bacteria showed greater activity than intact bacteria. 
Therefore they concluded that the azo reduction was mediated 
by bacterial enzymes. 
Schröder and Campbell (1972) studied the metabolism of SASP 
in 10 healthy volunteers. The most important results are summa-
rized in table 2.1. 
Table 2.1 SERUM LFVELS AMD EXCRETION IN URINE AND FAECES 
OF SASP AND METABOLITES IN 10 HEALTHY VOLUNTEERS TAKING 
A MAINTENANCE DOSE OF 4 G SASP PER DAY (SCHRODER AND 
CAMPBELL, 1972). 
serum concentration recovery in urine recovery in faeces 
yg/ml % ' I ' 
mean range 
SASP 12 
SP 50 
5-ASA < 2 
4 .7 -45 
7 -92 
1.7-10 
84 
34 
0 
5.2+2.5 
not determined 
1 percentage of the daily dose 
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SASP could already be demonstrated in the blood 1.5 hours after 
ingestion of a single oral dose of 4 g SASP. The maximal blood 
levels were reached after 3 to 5 hours. SP metabolites were not 
detected in the serum until 3 to 5 hours after ingestion. In a 
steady state situation after taking 1 g SASP four times a day 
for 5 days the mean serum SASP and SP levels were 12 yg/ml and 
50 ug/ml , respectively. The serum level of 5-ASA was always 
lower than 2 yg/ml. Only 1.7 to 10% of the administered dose of 
SASP was present in the urine in unchanged form. The mean recove-
ry of SP and 5-ASA in the urine was 84% and 34% respectively. 
An average of 5.2% of the administered dose of SASP was found as 
SP in the stools. No unchanged SASP was found. The recovery of 
5-ASA in the faeces was not measured. 
Both the serum levels of SASP and of SP thus show great 
interindividual differences during the use of the same dose of 
SASP. As far as the recovery in the faeces is concerned it should 
be noted that the faeces samples were stored at -20 oC. This me-
thod of preservation seems to be insufficient to prevent azo re-
duction of SASP during storage (§ 3 . 4 ) . 
Schröder and Campbell also studied the metabolism of 5-ASA 
and SP after oral administration. A single dose of 1.52 g 5-ASA 
(equivalent to the amount of 5-ASA in 4 g SASP) was administered 
to 6 healthy volunteers. The recovery in the urine was on average 
74% which points to a good absorption, probably in the small in-
testine. After administration of SASP the recovery of 5-ASA in 
the urine was only 34%. On the basis of this data the authors 
concluded that an important part of 5-ASA liberated in the 
colon after splitting of SASP was excreted with faeces or was 
further metabolized by the colon flora.Five healthy volunteers 
took a single oral dose of 2.48 g SP (equivalent to the amount 
of SP in 4 g S A S P ) . After ingestion of SP, SP was detectable in 
serum within 1.5 hours, which indicates absorption in the proxi-
mal part of the small bowel. When SP was administered in the 
form of SASP then SP could not be demonstrated in the serum until 
3 to 5 hours after ingestion (fig. 2 . 2 ) . 
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1 5 10 20 48 1 5 10 20 
Time ( h ) 
Fig. 2.2 Total serum c o n c e n t r a t i o n s of all Ί SP metabolites for 
5 subjects after ingestion of a single 2.k8 g dose of 
SP and after ingestion of an equimolar single dose of 
SASP {Ц g). 
From: Schröder and Camp b e l l : A b s o r p t i o n , metabolism 
and excretion of sa 1 tcyI azosu1 f аруridi ne in man. Clin 
Pharmacol Ther 13: 539-551, 1972. Reproduced with 
permission of the editor 
This period is consistent with the small intestinal transit 
time (Soergel, 1971). Since SP itself is rapidly absorbed from 
the small intestine, these findings suggest that SP is not for­
med in the small intestine but in the colon after splitting of 
SASP. The mean recovery in the urine after administration of SP 
was 81%. This corresponds with the recovery of SP after adminis­
tration of SASP (84%). SP is thus well absorbed both in the 
small intestine and in the colon. 
The data in fig. 2.2 give some information about the amount 
of SASP that is absorbed in the small intestine. The area under 
the serum concentration curves (AUC; area under the curve) for 
SP during the first 24 hours after the administration of a 
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single dose of 4 g SASP was about 2/3 of that obtained when an 
equimolar dose of pure SP (2.48 g) was given to the same sub­
jects. The divergency of the curves observed during the initial 
hours after dosage disappeared after 12 hours. One explana­
tion for this difference in AUC mioht be that about 1/3 of the 
administered dose of SASP was absorbed in the small intestine. 
The recovery of unsplit SASP in the urine was, however, only 
1.7 to 10% of the administered dose. Therefore the authors assumed 
that the remaining part of the absorbed amount of SASP might be 
excreted via the bile back to the intestine. This assumption is 
supported by experiments in animals which showed that SASP is 
indeed excreted via the bile (Hanngren et al, 1963a, Zapp et al, 
1976). 
Concerning the role of the colon flora on the metabolism of 
SASP other investigators (Peppercorn and Goldman, 1973; L e w k o m a , 
1973) came to the same conclusion as Schroder and Campbell. 
2.1.4 The influence of_t.tie_l_n/er 
After absorption the liver plays an important role in the 
metabolism of SASP (Schroder and Campbell, 1972). Part of the 
absorbed SASP re-enters the intestine by excretion with the bile. 
The remaining part of the drug is excreted unchanged by the 
kidneys. After absorption from the colon SP is partially meta­
bolized in the liver by acetylation (Гг) and/or gl u c u r o m d a t i o n 
(after ring hydroxylation in position 5 of the pyridine r i n g ) . 
Therefore, in serum and urine, besides SP, Ν 4-acetyl-SP (ac-SP), 
SP-O-gl u c u r o m d e (SP-gl uc ) and N 4-acetyl-SP-O-gl ucu r o m d e (ac-
SP-gluc) are present (fig. 2.3) The renal clearance of the SP 
metabolites, especially that of the gl u c u r o m d a t e d compounds, 
is much higher than that of free SP. 5-ASA is metabolized only 
by N-acetylation. In the urine almost exclusively acetyl-5-ASA 
is recovered. The excretion of ac-5-ASA via the kidney is so rapid 
that the serum levels are very low (<2 yg/ml) 
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2.1.5 £onc U r i o n s 
The metabolism of SASP is a complicated matter. Fig. 2.4 
gives a schematic picture of this. 
After oral administration a variable proportion of SASP, 
up to a maximum of 30%, is absorbed unchanged in the small in-
testine. A small proportion of the absorbed SASP is excreted in 
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the urine. At least 2/3 of the absorbed SASP re-enters the intes­
tine by excretion with the bile. 
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Fig. 2.k Scheme showing the absorption, metabolism and excretion 
of SASP. 
Thus there exists an enterohepatic circulation for SASP. The 
most important step in the metabolism of SASP is the reduction 
of the azo bond by colonic bacteria whereby SASP is split into 
SP and 5-ASA. Under normal circumstances the splitting of SASP 
is practically complete so that none or only small amounts of 
SASP are recovered in the stools. The larger part of SP is ab­
sorbed from the colon. Therefore SASP may not be classified as 
belonging to the group of poorly absorbable sulfonamides. At 
most 1/3 of 5-ASA is absorbed: the rest, perhaps after further 
metabolic conversion(e.g. acetylation) is excreted in the stools. 
In the liver SP is partly acetylated and/or glucuronidated. 
These metabolites are, as free SP, excreted by the kidneys. In 
serum, mainly free SP and ac-SP are present.The serum levels 
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of the glucurom'dated compounds are low because of the high renal 
clearance. 5-ASA is almost completely acetylated in the liver and 
excreted rapidly via the kidneys. The serum levels are therefore 
very low. 
Both SASP en 5-ASA have a special affinity to connective tissue. 
The consequences of this for the therapeutic effect are not clear. 
2.2 The value of sulfasalazine in the treatment of inflammatory 
bowel disease 
2.2.1 Ul cerati ve_colUj_s 
In 1948 N.Svartz published the results of treatment with 
SASP (6 g/day) in 124 patients with active ulcerative colitis. 
75 Patients became free of symptoms, 41 patients improved and in 
only 8 patients SASP was ineffective. Later studies generally 
showed less favourable results. Morrisson (1953) treated 60 pa-
tients with active ulcerative colitis with 6 to 8 g SASP per day. 
The effect of this therapy was compared to that in an equally 
large group of patients which prior to the study with SASP, was 
treated with the then usual therapy (diet, succinylsulfathiazole 
or chioramfenicol combined with spasmolytics or sedatives). Du-
ring treatment with SASP 18% of the patients became free of symp-
toms whilst 52% showed clear improvement. In the control group 
these percentages were 5 and 32. 
Moertel et al (1959) described a study in which three methods of 
treatment in patients with ulcerative colitis were compared. 131 
Patients were treated with general and supportive measures alone 
such as bed rest and diet, when needed supplemented with antispas-
modics and sedatives, 183 patients received in addition 6 to 8 g 
SASP per day and 109 patients were treated with other sulfonamides. 
The effect of treatment by general measures and general measures 
plus sulfonamides was about the same; 9% and 8% respectively of 
the patients were free of symptoms and 30% and 38% respectively 
improved distinctly. However, during treatment with SASP 22% of 
the patients became free of symptoms and 42% showed a clear 
improvement. Both Morrison and Moertel et al point to the frequent 
occurrence of side-effects during SASP therapy. 
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The first study in which was convincingly shown that SASP was 
indeed effective in ulcerative colitis was carried out by Baron 
et al (1962). In this double-blind prospective study the effect 
of SASP was compared with another sulfonamide (salicylazosulfa-
dimidine) and a placebo in patients with mild to moderately severe 
ulcerative colitis. The administered dosages of SASP and salicyl-
azosulfadimidine were 4 g per day in the first week and 2 g in 
the next 2 weeks. 
After 3 weeks treatment 16 of the 20 patients given SASP had im-
proved both symptomatica!ly and sigmoidoscopically. Of the 20 
patients receiving control treatment, only 7 improved symptoma-
tically and 8 sigmoidoscopically. Of the patients given salicyl-
azosulfadimidine, 3 improved symptomatica!ly and 5 sigmoidoscopi-
cally. The results with salicylazosulfadimidine were no better 
than those with a placebo. 
Approximately the same results (improvement in about 75% of 
the patients during SASP therapy) were described by Dick et a! 
(1964) who compared the effect of SASP (4-6 g per day) with a 
placebo in a double-blind trial. All the patients had mild to 
moderately severe colitis. 
Subsequently it was shown that combined oral and topica! 
corticosteroid treatment was more effective than SASP in produ-
cing a prompt remission. After 2 weeks treatment 44 of 58 pa-
tients (76%) with mild to moderately severe colitis using corti-
costeroids(20 mg prednisolone per day and 100 mg hydrocortisone 
as a retention enema nightly) showed a considerable improvement, 
compared to 31 of 60 patients {52%) using SASP (8 g per day for 
the first week, 4 g for the second) (Truelove et al, 1962). When 
evaluated after 3 to 6 months therapy it appeared, that the re-
sults of treatment with SASP were almost the same as those achie-
ved by corticosteroids (Lennard-Jones et al, 1960). 
There are no studies published concerning the value of SASP as 
the only therapy in patients with severe ulcerative colitis. It 
is the opinion of many clinicians that in these cases corticoste-
roids, whether combined with SASP or not, are to be preferred. 
SASP has emerged as a valuable agent for long-term maintenance 
therapy. Misiewicz et al (1965) have shown that maintenance treat-
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ment with SASP in a dose of 2 g daily sharply reduced the relapse 
rate when used for a period of 1 year. The relapse rate in pa-
tients continuing to receive SASP was 30% (10 out of 34 patients), 
whereas 76% (25 out of 35 patients) of those receiving a placebo 
relapsed. By contrast, corticosteroids (50 mg cortisone or 15 mg 
prednisolone daily) were totally ineffective in reducing the re-
lapse rate (Truelove and Witts, 1959; Lennard-Jones et al, 1965). 
From a therapeutic trial carried out in Oxford it can be conclu-
ded that maintenance treatment of ulcerative colitis with SASP 
should be continued for at least a number of years and probably 
indefinitely (Dissanayake and Truelove, 1973). These authors 
studied 64 patients with ulcerative colitis who had been main-
tained on 2 g SASP daily as their sole form of treatment for a 
minimum period of one year. All the patients were in complete 
remission.31 Patients were allotted to dummy tablets, the others 
continued to take 2 g SASP per day. In the placebo group 54.8% 
of the patients relapsed within 6 months, compared to only 12.1% 
of those receiving SASP. 
It is not known whether 2 g SASP per day is the optimal dose for 
the prevention of relapses. It would seem safest to reduce the 
dose of SASP only very gradually and not to prescribe less than 
2 g per day once renission has been achieved. 
2.2.2 Crohn's disease 
In view of the favourable results of SASP treatment in ulcera-
tive colitis it is not surprizing that SASP has been given to 
patients with Crohn's disease. There is, however, very little 
objective evidence of its effectiveness in this disease. The 
general impression is that SASP has a favourable effect in a 
considerable number of patients. Some authors claim that SASP 
is especially useful in colonic inflammation (Lennard-Jones, 1970; 
Nugent, 1971). Other studies suggest that SASP is particularly 
effective in patients with early disease (Goldstein and Murdock, 
1971; Kyle, 1971). Goldstein et al (1976) reported clinical and 
radiographic improvement in 10 out of 24 patients with Crohn's 
disease during SASP treatment (up to 4 g per d a y ) . 
The results of the first controlled therapeutic trial were 
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not reported until 1974 (Anthonisen et a l ) . Two groups of patients 
were studied by a double-blind double-crossover technique with 
four treatment periods of one month each. Each patient was treated 
alternatively with SASP (3 g per day) and a placebo for one month. 
The first group consisted of 12 patients who had undergone earlier 
intestinal resection and had developed recurrent disease. SASP 
therapy was not superior to placebo. The second group consis-
ted of 13 patients who had not been operated upon. In these pa-
tients treatment with SASP resulted in a significant reduction 
in symptoms. The most important objections to this study are the 
small number of patients and the short period of treatment (one 
month). 
A double-blind study to test the value of SASP, prednisone and 
azathioprine in patients with Crohn's disease has been initiated 
in the United States (National Cooperative Crohn's Disease Study). 
The preliminary results indicate that in patients with active 
symptomatic disease both SASP (1 g per 15 kg body weight) and 
prednisone(0.75 to 0.25 mg per kg body weight) were more effec-
tive than a placebo. In patients with disease involving the 
small bowel only response to SASP was no different than that to 
placebo. Patients with disease involving colon only responded to 
SASP but not to prednisone (Singleton, 1977; Summers et al, 1978). 
An important objection to this study is that the assessment of 
the effect of therapy was based on a predominantly subjective 
scoring system (CDAI, Crohn's Disease Activity Index). 
It is still an open question whether SASP has any effect on 
the recurrence rate in patients with Crohn's disease. A randomi-
zed study on patients who had undergone complete resection for 
Crohn's disease showed no difference in recurrence rate between 
those treated with SASP and a placebo group at 1,2 or 3 years 
after resection (Bergman and Krause, 1976). In two further double-
blind trials on the value of SASP in preventing recurrence after 
resection or in asymptomatic patients, negative results were 
also found (Anonymous, 1977; Wenckert et al, 1978). 
In the studies mentioned the maintenance dose of SASP was 
maximally 3 g per day. It seems therefore useful to investigate 
whether a higher maintenance dose (4 to 6 g per day) would have 
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a more favourable effect on the relapse rate. 
2.2.3 Othe]l i_nf 1 ammatO£y_d2Sorders_of Vhe^ j _ n ^ . e ^ 2 . n ± 
Siebner and Bryde (1975) reported good results of SASP admini­
stration in patients with diverticulitis. In almost all patients 
the signs of inflammation (pain, abdominal mass, fever, increased 
ESR, 1eucocytosis) disappeared within a few weeks after the admini­
stration of 2 or 4 g SASP per day. 
Rauch and Weiland (1972) described a favourable effect of com­
bined oral and rectal administration of SASP (orally 5 g per day 
and suppositories of 0.5 g t.i.d.) on the severe diarrhoea in 41 
out of 50 patients with radiation induced colitis. During this 
treatment exposure pauses because of diarrhoea were not neces­
sary any more in most of the cases. Goldstein et al (1976) observed 
striking clinical and radiographic improvement in 3 of 4 patients 
with severe chronic radiation enterocolitis who were treated with 
2 to 3 g SASP per day. 
Oral or local administration of SASP have been used with some 
success in the treatment of idiopathic proctitis (Wilson, 1970; 
Hanke and Schulz, 1970). 
However, for all the diseases mentioned, it must be noticed 
that controlled therapeutic trials are lacking. 
2.2.4 Cone Ui £i ο η s^  
Controlled trials have demonstrated that SASP is an effective 
drug in the treatment of mild and moderately severe ulcerative 
colitis and in maintenance treatment to reduce the relapse rate. 
The value of SASP in Crohn's disease and other inflammatory dis­
orders of the intestine has not been established as yet. 
2.3 Assumptions concerning the mode of action of sulfasalazine 
2.3.1 _I_n troduс t i on 
The mechanism of action of SASP in ulcerative colitis is not 
known. Svartz (1942) herself attributed the action of SASP to its 
particular affinity for the connective tissues including those 
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of the intestine. This idea gained some support from studies of 
Hanngren et al (1963)which showed such an affinity for SASP and 
5-ASA, but not for SP. The studies of Schröder and Campbell (1972) 
and of Peppercorn and Goldman (1973) have demonstrated that the 
larger part of SASP reaches the colon. In the colon azo reduction 
by bacteria splits SASP into SP and 5-ASA. As SASP is particularly 
effective in inflammatory disease of the large bowel, it has been 
suggested that one of the metabolites, rather than SASP itself, 
is responsible for the drug's activity at the site of breakdown. 
SASP should serve as a vehicle to deliver SP and 5-ASA to the 
colon in higher concentrations than can be achieved by oral ad-
ministration of these metabolites alone (Peppercorn and Goldman, 
1973; Das et al, 1 9 7 3 ) . 
In the following paragraphs the ideas about the mode of action 
of SASP and its metabolites that have been mentioned in the li-
terature are described. 
2.3.2 S u j_f a^ s a 1 £Z^n e 
SASP could have some influence on the diarrhoea in patients 
with ulcerative colitis by its effect on water and electrolyte 
transport by the human colon. The healthy colon absorbs water 
and sodium and excretes potassium. In ulcerative colitis it 
fails to absorb sodium and water efficiently. Harris et al (1972) 
observed a reversal from the secretion of water and sodium into 
the lumen of patients with ulcerative colitis to their absorp-
tion during treatment with SASP. 
Prostaglandins have a role in the inflammatory process. Pros-
taglandins E and F are known to elicit diarrhoea and affect mu-
cosal transport. Certain drugs have anti-inflammatory properties 
as a result of their ability to suppress prostaglandin produc-
tion. Serum levels of prostaglandin like material and urinary 
metabolites of prostaglandins were found to be raised in patients 
with ulcerative colitis. These levels were suppressed with either 
the use of SASP or 5-ASA (Butt et al, 1974; Gould, 1975; Gould 
et al, 1977; Sharon et al, 1 9 7 8 ) . Collier et al (1976) have found 
that SASP inhibits prostaglandin synthesis but SP and 5-ASA were 
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less effective. Sharon et al (1978) demonstrated that addition 
of SASP, SP and 5-ASA to a culture medium of ulcerative colitis 
mucosa resulted in inhibition of prostaglandin E2 production by 
34%, 32% and 62% respectively, compared to rectal specimens cul-
tured in drug free medium. These results suggest that at least 
some of the SASP effect is due to prostaglandin inhibition, par-
ticularly of 5-ASA. 
Another possibility is that SASP (via SP?) may affect the in-
testinal microflora and may excert its therapeutic action through 
this mechanism. Studies in the past (Gorbach et al, 1968; Cooke, 
1969) were unable to show significant changes in the faecal flora 
of patients with inflammatory bowel disease during SASP therapy. 
Recently, West et al (1974) have shown that SASP decreases the 
number of Clostridia, enterobacteria and total non-sporing anae-
robes in patients with ulcerative colitis and Crohn's disease of 
the colon. However, it is still uncertain whether bacteria have 
any role in the aetiology of inflammatory bowel disease. 
Preliminary results of a study by Das et al (1976) have shown 
that SASP has some immunological actions. 
2.3.3 Su]/£P£ruMne 
As an analogue of SASP in which sulfadimidine was substituted 
for SP was found to be ineffective in ulcerative colitis (Baron 
et al, 1962) it has been assumed that the pyridine radical is 
essential for the effect of SASP. 
After splitting of SASP in the colon, SP is largely absorbed. 
At dosages of 4 to 6 g SASP per day serum SP levels up to 100 
ug/ml can be reached. It is possible that SASP exerts its beni-
ficial effect via an antibacterial action of SP in the intesti-
nal lumen, during passage through the intestinal wall or as a 
result of its tissue concentration. 
In a study of Das et al (1973) a positive correlation was 
found between the serum levels of total SP and the clinical 
response. The serum SP level was determined in a large group of 
patients with ulcerative colitis who were on maintenance therapy 
with SASP. It was found that patients in remission had higher 
SP levels than those seen in a relapse of colitis. Moreover, it 
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appeared that the serum SP level in patients'who went in tb r e 1 
mission during administration of SASP was higher than in those 
who failed to respond to the drug. On the basis- of this data Das 
et al suggest that SP is the therapeutically active moiety, of SASP.
2.3.4 5 -Am in os al jcy 1 1c_a c i d_
A considerable portion of 5-ASA formed by the azo reduc- 
tion of SASP in the colon is excrétèd in’ the faeces, possibïy 
after further metabolic conversion. The absorbed part of 5-ASA 
is rapidly excreted by the kidneys so that the serum concentra- 
tion of 5-ASA is negligible (Schröder and Campbell, 1972). If 
5-ASA is the active component of SASP, its effect is probably 
based on a direet action on-the inflamed mucosa.
. There is hardly anything known about the properties of 5-ASA. 
Although 5-ASA belongs to the group of salicylates"and like 
SASP inhibits the synthèsis of some prostaglaridins (Sharon et 
al, 1978) it probably has no anti-inf 1 ammatory activit'y (Loveless,
1974);
As far'as the structural formula is concerned, 5-AS'A resembles 
the tuberculostatic drug PAS (4-(para)aminosalicylic acid). In 
this context it is interesting to note that atypical mycobacte- 
ria have been mentioned as a possiblé cause of Crohnfi jdisease.
2.3.5 Cancl usi^ojis
Nothing is known with any certainty about the mode of action 
of SASP in inf1ammatory bowel disease.
It is likely that not SASP, but one of the split products is 
the therapeutically active moiety.
2.4 Adverse reactions to sulfasalazine
A 1 i m i t a t i o n ,to the clinical use of SASP is the occurrence of 
adverse si d e - e f f e c t s . Minor adverse reactions are. frequently 
recognized but serious reactions are considered to be rare. A 
good review of the nature and jncidence of side-effects during 
SASP therapy has been published by Collins (1968).
The adverse reactions to SASP can be divided into two groups,
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dose-related and n o n-dose-related.
2.4.2 Do^e^re1ated_side-effe£t£
The most common side-effects during SASP theKfpy are nausea, 
with or without vomiting, anorexia, epigastric discomfort, head*- 
ache and general malaise. The frequency of. occurrence has varied 
in reports from 9 to 60% (Lennard-üones et al, 1960; Misiewicz 
et al, 1965). Most side-effects occurred in the first weeks of 
therapy. The majority of patients manifesting toxicity were ta- 
king 4 g or more SASP per day. Das et al (1973) have shown that 
most of the side-effects ascribed to SASP can be related to high 
serum coneentrations of total SP {>50 y g / m l , mostly contributed 
by free SP). No correlation was observed between toxic symptoms 
and serum concentrations of SASP, SP metabolites or 5-ASA. Most 
of the patients who experienced side-effects were slow acetyla- 
tors. The SP related adverse effects could be overcome if SASP 
was stopped temporarily or reduced in dosage.
It is well known that sulfonamides.particularly sulfanilamide 
and SP may cause oxidative haemolysis of the e r y th r o c y t e s . As 
early as 1940 Moeschlin described 7 patients with frank haemoly­
sis associated with the use of SP. The erythrocytes of some of 
these patients contained inclusion bodies (He^i.n^-bodies). Haemoly- 
tic anaemia during SASP therapy has been described by several 
authors (Spriggs et a l , 1959; Böttiger et al, 1963; Gardner and 
Bargen, 1964; Böttiger and Westerholm, 1973; Das et al, 1973) but 
the incidence seems to be low.
However, Miller et al (1971) described mild haemolysis without 
anaemia in 28% of the patients taking 2 to 8 g SASP per day. 
Pounder et al (1975) found contracted red cells in 23 of 50 pa­
tients with ulcerative colitis who were taking a mean dose of
2.5 g SASP as maintenance therapy. Patients with contracted red 
cells had a significantly higher serum level of total SP than 
those with undamaged red cells.
The results from recent studies by Franklin and Rosenberg (1973 
and Selhub et al (1978) suggest that SASP inhibits intestinal 
folate transport.
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Das et al (1973) observed bluish discoloration of the skin and 
mucous membranes in 10 of 133 patients who were on maintenance 
therapy with SASP. All the patients who developed "cyanosis" had 
serum levels of total SP of more than 50 yg/ml . The cause of this 
skin discoloration is not known. The patients described by Das et 
al did not show methaemoglobinaemia or sul fhaemoglobinaemia . 
2.4.3 Noji-do¿e^r£l£t£d_S2de^ ef.fec^ 
Idiosyncratic reactions produced by SASP are usually seen 
within a few weeks after its institution but can occur at any 
time during the course of maintenance therapy. The most common 
non-dose-related adverse reactions of SASP are skin rashes. The 
incidence can be estimated at 1 to 5%. Occasionally serious skin 
complications have been described such as Stevens-Johnson syn-
drome (Cameron et al, 1966) and toxic epidermal necrolysis 
(Ström, 1969). 
Agranulocytosis is a rare complication of SASP therapy. Up 
till now 22 cases have been published (Collins, 1968; Jamshidi 
et al, 1972; Cockrane et al, 1973), with at least 5 deaths. 
A variety of other rare complications have been described 
in case reports: pulmonary disease (Jones and Malone, 1972; 
Davies and MacFarlane, 1974; Thomas et al, 1974; Tydd et al, 
1976), acute pancreatitis (Block et al, 1970) polyneuritis 
(Wallace, 1970) and severe hepatotoxicity (Sotolongo et al, 
1978; Kanner et al, 1978). 
2.4.4 Co ne ljJ.s i о П£ 
Mild side effects (nausea, headache, epigastric discomfort) 
during SASP therapy are fairly common (in about 20% 
of the patients) and are related to high serum SP concentrations. 
Severe adverse reactions, however, are rare. 
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Chapter 3 
DETERMINATION OF SULFASALAZINE AND METABOLITES IN SERUM, URINE 
AND FAECES 
3 .1 De_termj nation of sul f asalazine 
3.1.1 Introduction 
In broad outline SASP was determined according to the method 
described by Sandberg and Hansson (1973). Determination in serum 
and urine is based on the measurement of the orange colour of 
SASP disodium salt following extraction from the different fluids. 
In faeces SASP is determined via SP after splitting of the azo 
link. 
3.1.2 J5eterm2na_t_i_on^ 2n_seri^m_ar^d_ur^ijie 
A 1 ml sample (serum or urine) is transferred to a stoppered 
tube containing 1 ml 1 M HCl. Five ml methyl isobutylketone are 
added (fig 3.1) . 
methyl isobutyl 
ketone SASP 
ЛС 
ac 
Л С 
SP 
S P 
S P 
S P 
5 
- 5 
glue 
-qlJC 
A S A 
A S A 
О 5 M NaOH 
w v_y 
Fig. 3-1 D e t e r m i n a t i o n of SASP in se r u m and u r i n e . 
The tube is shaken vigorously for about 15 seconds and then cen-
trifuged at 2000 r.p.m. for 10 minutes. Three ml of the organic 
phase (containing SASP) are transferred to another tube containing 
4 ml 0.5 M NaOH. By shaking and centrifugation SASP 
is re-extracted from the organic phase into the aqueous solution. 
The organic phase is drawn off completely with vacuum and the water 
phase is transferred to a 1.0 cm cuvette. The absorbance of the 
orange coloured SASP solution is measured spectrophotometrically 
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at 455 nm with distilled water as reference. The absorbance is 
compared with a standard curve obtained from the absorbance of 
solutions with known amounts of SASP determined together with 
each series of samples. 
3.1.3 Detennj_n£t_i_on. l n_fiL e£ e! 
SASP cannot be determined directly in the stools. By adding 
titanous chloride (TiCl 3, 10% in 15% HCl) the azo link of SASP is 
reductively cleaved to SP and 5-ASA. In faeces, the SP concentra-
tion is determined before and after addition of TiCl.,. The diffe-
rence in SP concentration gives the amount of SASP. To 1 g of 
wel 1-homogenized, and if necessary diluted, faecal suspension 
50 yl T i C l 3 are added. The solution is shaken vir]n r o u siy 
for 15 seconds. After 10 minutes 50 ul 6 M NaOH are 
added in order to neutralize the acidic TiCl, solution. SP is 
then determined as described in §3.2.3. 
3.1.4 E.val ijation_o£ t^ he method 
All assays were performed in duplicate. The blank values in 
serum and urine of healthy subjects were low: corresponding with 
0-1 and 2-5 pg SASP/ml , respectively. In faeces the blank value was 
usually 0 yg/ml. The standard curve was linear up to a SASP level 
of at least 100 pg/ml . In urine the SASP concentration is often 
higher. Both the aqueous solution of SASP after extraction and the 
original sample can be diluted U D to 20 times. 
In urine samples with a high SASP concentration there is a 
considerable risk for precipitation of SASP during storage at 
low temperature. If precipitation of SASP is expected, the samples 
should be treated with alkali to pH 10 in order to dissolve all 
SASP, and neutralized with HCl, before analysis. 
The recovery in serum and urine assays ranged from 76 to 86% 
and 96 to 104%, respectively. 
The precision of the method was examined by assaying serum, 
urine and faeces samples in duplicate (interassay duplicate 
variation) and by carrying out replicate assays in pooled sam-
ples of serum, urine and faeces (interassay replicate variation) 
on separate days over a 6 month period. The results are given in 
table 3.1 and 3.2. 
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Table 3.1 INTERASSAY DUPLICATE VARIATION OF SASP IN SERUM, URINE 
AND FAECES 
sample number of ranoe of SASP relative duplo SD 
duplicate assays concentration 
yg/ml % 
serum 65 5-100 4.1 
urine 11 10-100 2.5 
faeces 12 20-100 6.3 
Table 3.2 INTERASSAY REPLICATE VARIATION OF SASP IN SERUM, URINE 
AND FAECES 
pool number of SASP concentration coefficient 
replicate assays (mean + SD) of variation 
yg/ml % 
serum 10 62.4 + 3.1 5.0 
urine 10 51.2 + 1.9 3.8 
faeces 6 134.9 + 7 . 3 5.4 
3 . 2 Determination of sulfapyridine 
3.2.1 2n.È.rod.!JCt.io.n 
The determination of SP and metabolites was carried out accor-
ding to the method described by Hansson and Sandberg (1973). Fol-
lowing extraction, SP is determined with the aid of the Bratton-
Marshall reaction (1939). In serum and urine, ac-SP, SP-gluc and 
ac-SP-gluc are present as well as SP. The glucuronides are hydroly-
sed enzymatically before the extraction step and the acetylated 
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Fig. 3-2 D e t e r m i n a t i o n of SP and m e t a b o l i t e s in s e r u m , u r i n e and 
f a e c e s . SASP in f a e c e s is d e t e r m i n e d via SP after re­
d u c t i o n of the azo bond by Τ i С I .. . 
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compounds are hydrolysed in acid before the reaction. 
3.2.2 Determination in serum and urine 
One ml aliquots of the sample are transferred to each of 2 
stoppered tubes, A and В (fig 3 . 2 ) . One ml 0.1 M Na-acetate buffer 
(pH 4.7) is added to both tubes. After addition of 20 μΐ ß-glucu-
romdase/aryl sul f atase to tube В the mixture is incubated at 
37 С for 4 hours. In this way the g l u c u r o m d e group is removed 
from SP-gluc and ac-SP-qluc. Sodium chloride (0.5 g) is then 
added to both tubes and the solutions are extracted with 5 ml 
methyl ιsobutylketone by shaking vigorously for 15 seconds and 
centri fugation at 2000 r.p.m. for 10 minutes. Three ml of the 
organic phase (containing SP and ac-SP) from tube A and В are 
transferred to two other tubes containing 3 ml 4 M HCl. As de-
acetylation of ac-SP readily occurs in acid media the tubes are 
placed in ice-water to prevent this reaction. After shaking and centri-
fugation the tubes are placed in ice-water again. The organic 
phases are drawn off, 1 ml aliquots from the HCl phase of tube A 
are transferred to test-tubes A, and Ap and 1 ml aliquots of tube 
В to B, and B-· Tubes A, and B, are placed in ice-water. By 
placing tubes Ap and Bp in a boilinq water bath for 15 minutes 
the acetyl group of SP is split off. To avoid evaporation the 
tubes should be provided with stoppers. Finally, tubes A,, A-, 
B, and B- are coloured by the Bratton-Marshal1 reaction. This me­
thod is based on a reaction of the NHp-qroup of SP with N-(1-
naphthyl )ethyl eendiami ne di hydrochl o n d e . One ml NaNO- 0.12? 
solution is added to each of the tubes which are allowed to 
stand for 3 minutes before adding 1 ml ammonium sulphamate 0.8%. 
Tubes A. and B, are removed from the ice-water About 3 minutes 
later 1 ml N-( l-naphthyl)ethyl eendiamine di hydrochl o n d e 0.8% 
is added to each of the tubes. The absorbances are measured spec-
trofotometncally at 542 nm using a 1.0cm cuvette with distilled 
water as reference. From these analysis, the following four absor-
bance values are obtained: 
no deacetyl ati on ; no g l u c u r o m d e deconjugation •* free SP, 
deacetyl ation ; no deconjugation •*• SP from free SP and ac-SP, 
no deacetyl ation ; deconjugation -»• SP from free SP and SP-gluc, 
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В-: deacetyl ati on and deconj ligation > SP from free SP, ac-SP, 
SP-gluc and ac-SP-qluc 
The absorbances are compared with a standard curve obtained from 
measuring the absorbance of solutions with known amounts of SP 
The concentration of the four SP compounds can be calculated as 
fol 1ows : 
A, free SP 
ac-SP 
SP-qluc 
ac-SP-gluc 
total SP 
4 
4 
В. 
B 2 - B 1 + А 2 
3.2.3 De term2n¿t20£ 1 п_^£ е^. е1 
In faeces almost exclusively free SP is found. The determina­
tion in faeces therefore takes place via A -»• A, (fig 3 2 ) . Addi­
tion of 0.5 g NaCl is not necessary in case of faeces samples. 
One g of a wel 1-homogenized faecal suspension is used for the 
determination. 
3.2.4 £v£l£at^i£n_o£ t^ he method 
All assays were performed in duplicate. The blank values in 
serum, urine and faecal suspensions (10 times diluted) corres-
ponded with 0-2 цд, 1-3.5 ид and 0.6-1.9 ид SP/ml, respectively. 
The standard curve was linear up to a SP level of 80 нд/ml · Both 
the aqueous solution of SP after extraction and the original sam­
ple could be diluted up to 20 times. 
The recovery in serum and urine assays ranged from 98 to 104% 
and 95 to 105%, respectively. In 10 times diluted faecal suspen­
sions with a SP concentration higher than 10 vg/mi the recovery 
ranged from 65 to 73%. At lower SP concentrations the recovery 
was 50-65%. By using a faecal suspension for the standard solu­
tions a good correction was possible for the low recovery of SP 
in faeces. 
The precision of the method was examined by assaying serum, 
urine and faeces samples in duplicate (interassay duplicate vari­
ation) and by carrying out replicate assays in pooled samples of 
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serum, urine and faeces (interassay replicate variation) on sepa-
rate days over a 6 month period. The results are given in table 
3.3 and 3.4. 
Table 3.3 INTERASSAY DUPLICATE VARIATION OF SP IN SERUM, URINE 
AND FAECES 
sample number of range of SP relative duplo SD 
duplicate assays concentration 
pg/ml % 
serum 89 10-100 2.5 
urine 24 10-100 1.9 
faeces 26 20-100 3.5 
Table 3.4 INTERASSAY REPLICATE VARIATION OF SP IN SERUM, URINE 
AND FAECES 
pool number of SP concentration coefficient 
replicate assays (mean + SD) of variation 
yg/ml % 
serum 10 58.7 + 1.9 3.3 
urine 10 110.6 + 7.6 6.9 
faeces 6 49.8 + 2.9 5.8 
3.3 Determination of 5-aminosalicy!ic acid 
3.3.1 2n!r£d.!±c!''£n 
Hansson (1973) described a spectrof1uorometric method for 
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determining free and acetylated 5-ASA after extraction from serum 
and urine specimens also containing SASP and its SP metabolites. 
One of the disadvantages of this method was the low and incon­
stant recovery of 5-ASA in urine specimens which might be attri­
buted to quenching of the fluorescence of ac-5-ASA by extractable 
urinary constituents. Moreover, no mention was made of the suita­
bility of the method for faecal specimens. 
Pieniaszek and Bates (1975) described a colorimetrie method 
for the determination of 5-ASA and ac-5-ASA in urine and faeces. 
They used the same extraction procedure as Hansson (1973). The 
authors were of the opinion that this extraction procedure was so 
complete that interference by SASP and its SP metabolites was 
negligible. However, our own experience was that after extrac­
tion small amounts of SP and especially ac-SP in the sample cau­
sed an obvious interference in the colorimetrie determination 
of 5-ASA (fig 3.3) . 
Extinction (560 nm) 
4 0 0 -
300-
200-
100-
ι ι ι ι 
40 60 100 150 
(>ig/ml) 
Fig. 3-3 I n t e r f e r e n c e by SP and ac-SP ¡n the c o l o r i m e t r i e d e t e r -
m i n a t i o n of 5*ASA. The a b s o r b a n c e of solutions with 
c o n c e n t r a t i o n s of SP or ac-SP as indicated on the X-axis 
w a s , after c o l o u r i n g , m e a s u r e d at the w a v e l e n g t h used 
for 5-ASA (560 nm) . 
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To diminish this interference we introduced an extra extraction 
step. A further correction was possible by making use of the 
fact that after colouring by the Bratton-Marshal1 reaction, 
SP colours immediately (pink) while the colour of 5-ASA (violet) 
develops slowly and has a maximum after about 4 hours. By sub-
tracting the absorbance in a sample measured immediately after 
addition of the colour reagents from the absorbance obtained 4 
hours later a good correction was possible for the interference 
from SP metabolites still present in the sample. This method was 
found to be suitable for determination of 5-ASA and ac-5-ASA in 
serum, urine and faeces. However, determination in serum is not 
meaningful because after administration of SASP levels of 5-ASA 
and ac-5-ASA are always very low (<2 p g / m l ) . 
3.3.2 2ele£.mÍn£tÍ0]l Ín_u.!liüe_aJ!d_'':Ae£e.L 
The first extraction step is the same as that for SP. To a 
1 ml sample of urine or a wel 1-homogenized faecal suspension 1 ml 
0.1 M Na-acetate buffer (pH 4.7) and 5 ml methyl isobutylketone 
are added (fig 3 . 4 ) . The mixture is shaken vigorously for 15 se-
conds and centrifuged at 2000 r.p.m. The organic phase is drawn 
off completely with vacuum. One ml aliquots from the aqueous solu-
tion are transferred to tube A and B. To tube В 20 μΐ of acetic 
anhydride are added. In this way free 5-ASA is completely acety-
lated. After mixing 1 ml 1 M HCl is added to both tubes and the 
samples are extracted with 5 ml methyl isobutylketone. After cen-
trifugation 3 ml of the organic phase from tube A and В are 
transferred to two other test-tubes containing 4 ml 0.5 M phosphate 
buffer (pH 6 ) . By shaking and centrifugation ac-5-ASA is re-ex­
tracted from the organic phase into the aqueous solution. The 
organic phase is drawn off completely with vacuum. 0.5 Ml ali­
quots of the aqueous phase of tube A and В are transferred to 
tube A, and B,, mixed with 0.5 ml of a Ρ M HCl-solution and 
heated at 100 oC for 45 minutes to effect deacetylation of ac-
5-ASA. To avoid evaporation the tubes should be provided with 
stoppers. After cooling to room temperature the tubes are colou­
red by the Bratton-Marshal1 reaction (§3.2.2). The absorbance is 
measured spectrofotometrically at 560 nm, using a 1.0 cm cuvette 
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with distilled water as reference, both immediately after colou-
ring and after storage in the dark for 4 hours. The amount of 
5-ASA in the samples is determined from the differences in absor-
bance measured after 4 hours and immediately after colouring. 
The absorbances are compared with a standard curve obtained from 
the absorbance of solutionswith known amounts of 5-ASA determined 
together with each series of samples. The amount of ac-5-ASA is 
determined from the assay results of tube A,; the amount of free 
5-ASA from the difference between A- and A,. 
3.3.3 .Eva.l.uat.ion_of th^. ület.h°.d 
All assays were performed in duplicate. Blank values in urine 
and faeces corresponded with 1-6 \ig and 0-0.5 pg 5-ASA/ml , respec-
tively. The standard curve was practivally linear up to a 5-ASA 
level of 75 yg/ml. Both the aqueous solutions of 5-ASA after ex-
traction and the original sample could be diluted up to 20 times. 
The recovery in urine assays ranged from 92 to 100 %. In 10 
times diluted faecal suspensions with a 5-ASA concentration 
higher than 20 ug/ml the recovery ranged from 66 to 78 %. For 
5-ASA concentrations less than 20 pg/ml the recovery was con-
siderably lower: 30 to 60 %. By using faecal suspensions for the 
standard solutions a good correction was possible for the low 
recovery of 5-ASA in faeces. 
The precision of the method was examined by assaying urine 
and faeces samples in duplicate (interassay duplicate variation) 
and by carrying out replicate assays in pooled samples of urine 
and faeces (interassay replicate variation) on separate days 
over a 6 month period. The results are given in table 3.5 and 
3.6. 
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Table 3.5 IMTERASSAY DUPLICATE VARIATION OF 5-ASA IN URINE AND 
FAECES 
sample number of range of 5-ASA relative duplo SD 
duplicate assays concentration 
μ g/ml % 
urine 48 10-100 3.8 
faeces 18 20-100 Z · 9 
Table 3.6 INTERASSAY REPLICATE VARIATION OF 5-ASA IN URINE AND 
FAECES 
pool number of 5-ASA concentration coefficient 
replicate assays (mean + SD) of variation 
yg/ml % 
urine 10 4 7 . 8 + 2 . 0 4.2 
faeces 6 37.3 + 1.8 4.8 
3.4 Comparison of various methods for preserving faeces samples 
3.4.1 J^ tTodu.'-t.i o n 
The colon plays an important role in the metabolism of SASP. 
Azo reductases of bacterial origin which are present in the bowel, 
split the azo bond of the SASP molecule,1iberating SP and 5-ASA 
(Schröder and Campbell, 1972; Azad Khan et al, 1975). 5-ASA is 
largely excreted with the faeces. In studying SASP's metabolism 
and factors which may influence it, a reliable method for deter-
mination of SASP and its metabolites is of major importance. 
As is described in the first part of this chapter, determina-
tion of SASP, SP and 5-ASA in faeces, as such, presents no seri-
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ous problems. Besides a reliable method for determination it is 
necessary to prevent azo reduction of SASP in the faeces samples 
during storage. Therefore we investigated which method of preser­
vation was the most effective in this respect. 
Results of a preliminary study showed that the enzyme inhibi­
tor HgClp in a concentration of 0.1% (0.03 mol) was able to in­
hibit the azo reduction of SASP in a faecal suspension complete­
ly. Thanks to this data it was possible to investigate the ef­
fect of solutions with a lower concentration of HgClo and of 
other methods of preservation on the splitting of SASP in faeces. 
In fact, during storage of faeces samples under different condi­
tions it was possible to stop the continuing azo reduction of 
SASP at any time by adding an equal amount of a 0.2% НдСІ2 solu­
tion to the faeces sample. In this way, using a known concentra­
tion of SASP in faecal suspensions it is possible to get a good 
impression of the value of various methods of preservation by 
determining the amount of SP that is formed. 
Regarding the storage of faeces samples the following ques­
tions were posed. 
1 Is it possible to prevent splitting of SASP with lower concen­
trations of HgCl- or with another enzyme inhibitor as PCMB: para-
chlore mercurybenzoate? 
2 Is the method described in the literature (Schröder and 
Campbell, 1972; Peppercorn and Goldman, 1973; Sandberg and 
Hansson, 197 3 ) , storing faeces at -20 oC, really adequate for 
preventing the azo reduction of SASP? 
3 Is it possible to inhibit the splitting of SASP by adding 
antibiotics to the faeces? 
3.4.2 Method¿ 
Faeces of a healthy subject not taking any drugs was diluted 
with a 0.9% NaCl solution and veronal buffer (1.0 M, pH 7.5) and 
homogenized immediately after defaecation. Then a SASP solution 
was added up to a final concentration of 100 pg/ml faecal suspen-
sion. Subsequently, 40 ml aliquots of this faecal suspension were 
transferred to each of 8 tubes. Three tubes contained 10 ml of a 
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0.9% NaCl solution, 4 were filled with 10 ml of a 2.5%, 0.5%, 
0.05% and 0.005% HgCl« solution, respectively and 1 tube con­
tained 10 ml of a neomycin solution (130 m g / m l ) . An outline 
of the trial protocol is given in table 3.7. 
The final faecal dilution was 2.5 times. For the tubes containing 
a HgClp solution, the final H g C ^ concentration in the faecal 
suspension was 0.5%, 0.1%, 0.01% and 0.001%, respectively; for 
neomyci η 30 mg/ml. 
One ml aliquots from each of the faecal suspensions were trans­
ferred to a large number of test-tubes. The 3 series of tubes 
containing a 0.9% NaCl solution were stored at -20 oC, 4 0C and 
room temperature, respectively. The other series were stored 
at room temperature. The 1 ml faecal suspensions from each of 
the series were stored for varying periods of time (table 3 . 7 ) . 
After elapse of these periods 1 ml of a 0.2% HgClo solution was 
added to stop the continuino azo reduction of SASP (if present). 
The faeces samples stored at -20 oC were defrosted before adding 
HgClp. Finally all the faeces samples were stored at -20 oC 
awai ti ng analysi s. 
In each of the faeces samples the SP concentration was determined. 
Just before storage 50 μΐ T i C l 3 (10% in 15% HCl) was added to 
two 1 ml faeces samples from each of the 8 series. In this way 
SASP is completely split. The amount of SP present in these sam­
ples was used as reference value (100°/! free SP, no unsplit S A S P ) . 
Using this reference value the percentage of free SP (related to 
the amount of SP present in 100 \ig SASP) could be determined for 
each of the faeces samples. 
A similar study was performed with 10 ml solutions of PCMB 
(4xl0" 3 mol, 4 x l 0 " 4 mol and 4.10" 5 m o l ) . 
The experiment described above was carried out under aerobic 
conditions. During homogenisation, dilution and addition of SASP 
the faeces samples were intensively exposed to air. No measures 
were taken afterwards to prevent the entry of oxygen. In the 
colon of man the conditions are in fact anaerobic. Esoecially after 
defaecation of solid stools, the greater part of the faeces will 
remain anaerobic for a long time (probably several hours). For 
that reason it seemed useful to compare the azo reduction of SASP 
50 
Table 3.7 OUTLINE OF EXPERIMENTS TO DETERMINE THE AZO REDUCTION OF SASP IN FAECES SAMPLES 
STORED UNDER DIFFERENT CIRCUMSTANCES 
s e n e s faecal susp. 
with SASP 
(100 ug/ml) 
preservative stored at 1 ml H g C ^ 0.2% solution added to 
1 ml faecal suspension after 
1 
2 
3 
4 
5 
6 
7 
8 
40 ml 
40 ml 
40 ml 
40 ml 
40 ml 
40 ml 
40 ml 
40 ml 
+ 10 ml 0.9% NaCl 
+ 10 ml 0.9% NaCl 
+ 10 ml 0.9% NaCl 
+ 10 ml HgCl 2 2.5% 
+ 10 ml HqCl 2 0.5% 
+ 10 ml HgCl 2 0.05% 
+ 10 ml HgCl 2 0.005% 
+ 10 ml neomycine 
130 mg/ml 
-20oC 
40C 
roomtemp. 
roomtemp. 
roomtemp. 
roomtemp. 
roomtemp. 
roomtemp. 
3,10,30 min, 1,2,6 hrs, 1,2,7 days 
30 min, 1,2,3,4,8 hrs, 1,2,7,21 days 
20 min, 1,2,3,4,8 hrs, 1,21 days 
30 min, 1,2,3,4,8 hrs, 1,2,7,21 days 
30 min, 1,2,3,4,8 hrs, 1,2,7,21 days 
30 min, 1,2,3,4,8 hrs, 1,2,7,21 days 
20,30 min, 1,2,3,4,8 hrs, 1,2,7,21 days 
15,30 min, 1,2,3,4,8 hrs, 1,2,7,21 days 
stored under anaerobic and aerobic conditions. The study was 
roughly desifined in the same way as described above. Immediately 
after defaecation part of the faeces of a healthy subject was 
placed in anaerobic "glove box", diluted (12.5 times) with a 
prereduced solution of 0.9% NaCl and veronal buffer (1.0 M, pH 
7.5).and homogenized. Then SASP was added up to a concentration of 
100 ug/ml. Another part of the faeces was processed in the same 
way but under aerobic conditions. After an incubation time of 2, 
10, 30 minutes, 1,2,3 and 4 hours, 1 ml 0.2% HgCl 2 solution was 
added to four 1 ml samples from each of the faecal suspensions 
and the SP concentration was determined. 
3.4.3 R.e.sults a^d cHs^ss.i£n 
The effect of various methods of preservation on azo reduction 
of SASP in faeces is shown in fig. 3.5. In faeces stored at room 
temperature about 10% of SASP was already split after 20 minutes 
and after 3 hours the splitting was virtually complete. Addition 
of solutions with a low concentration of HgCl- (faecal suspensions 
with 0.01 and 0.001% H g C l 2 ) , neomycin or PCMB did not prevent the 
azo reduction of SASP: after 20 to 30 minutes 10-35% of SASP was 
split; after 2 hours 85-100%. Storage of the faecal suspension: 
at 4 0C reduced the reduction rate of SASP. After 8 hours about 
55% of SASP was split. Storage of faeces at -20 oC is clearly 
more effective in preventing azo reduction. However, the amount 
of SASP which was split is not negligible (about 1 0 % ) . In the 
faecal suspensions containing 0.1% or 0.5% HgCl^ stored at room 
temperature for up to 3 weeks, the amount of split SASP was very 
small : 0-4%. 
With the exception of the faecal suspensions containing 0.1 and 
0.5% НдСІ2 and those stored at -20 oC the SP concentration in the 
faeces was considerably decrefsed after 3 weeks. This is probably 
due to further metabolic conversion of SP into metabolites which 
are not measured with determination of SP. 
The results of the comparative study about the azo reduction 
of SASP under aerobic and anaerobic conditions are summarized in 
fig 3.6. 
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Fig. 3-5 The effect of various methods of preservation of faeces 
on azo reduction of SASP . The SASP concentration in 
each faeces sample was 100 ug/ml. The concentration of 
SP was measured and expressed as percentage of the 
amount of SP present In 100 pg SASP. 
HgCl. concentration in faecal suspension 
room tempe rature 
i,0C 
- 0 . 5 1 
- 1.1 % 
- 0.01 % 
-^  0 . 0 0 1 % 
•20OC 
-* neomycin (30 mg/ml 
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Fig. 3-6 Azo reduction of SASP in faeces under aerobic and 
anaerobic conditions. The SASP concentration in each 
faeces sample was 100 pg/ml. The concentration of SP 
was measured and expressed as percentage of the amount 
of SP present in 100 yg SASP. 
U n d e r a n a e r o b i c c o n d i t i o n s t h e r e d u c t i o n r a t e o f SA S P was c o n s i -
d e r a b l y h i g h e r t h a n u n d e r a e r o b i c c o n d i t i o n s . T h i s f i g u r e a l s o 
s h o w s t h a t the r e p r o d u c i b i l i t y of the s p l i t t i n g e x p e r i m e n t s in 
fa e c a l s u s p e n s i o n s w a s q u i t e g o o d . 
In e x p e r i m e n t s of o t h e r i n v e s t i g a t o r s ( S c h r ö d e r and C a m p b e l l , 
1 9 7 2 ; P e p p e r c o r n and G o l d m a n , 1 9 7 3 ) w h o d e t e r m i n e d S A S P and m e t a -
b o l i t e s in f a e c e s , t h e s t o o l s w e r e s t o r e d at - 2 0 o C . The r e s u l t s 
of t h e s e s t u d i e s s h o u l d be r e g a r d e d w i t h s o m e r e s e r v e as azo 
r e d u c t i o n of S A S P in the s t o o l s m i g h t h a v e b e e n c o n t i n u e d d u r i n g 
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the process of freezing. Concerning the azo reduction of SASP at 
-20 oC in our study it should be noted that these results give a 
too favourable impression of this method of preservation. SASP 
was added after the faeces had been diluted and homogenized. Then 
the faeces was frozen in 1 ml samples. Under these circumstances 
the faeces will have reached a temperature of -20 С within a few 
minutes. In case of handling faeces of patients using SASP the 
conditions are less favourable. At storage of the total amount 
of faeces, the greater part of the stools will remain anaerobic 
for a long time. Both in freezing the total amount of faeces and 
storage of small amounts after dilution and homoqenization it will 
take some time (at least 30 minutes) before a temperature of -20 ο0 
is reached. As shown in fig. 3.5 a considerable amount of SASP 
can be split during this period. Before determination of SASP 
and metabolites the faeces have to be defrosted. Expecially when 
the total amount of faeces is frozen this process is time-consu­
ming and further splitting of SASP will be the result. 
To get an impression of the splitting of SASP under condi­
tions which are more adapted to practice the following experi­
ment was carried out. 
Faeces of a healthy subject was diluted and homogenized immedia­
tely after defaecation. SASP was added up te a concentration of 100 
gg/ml. To three 1 ml samples of the faecal suspension 1 ml 0.2% 
HgClp was added. The remaining part (125 g) was stored at -20 oC 
for 24 hours. Time between addition of SASP to the faecal sus­
pension and storing at -20 С was less than 5 minutes. Before 
determination of SP the faeces stored at -20 oC was allowed to 
defrost at room temperature. This process lasted about 1 hour. SP 
was determined immediately afterwards. In the faecal suspension 
to which HgClp was added 0.7% SP was present, in the faeces stored 
at -20 oC this was 69%! 
3.4.4 £o nc_l_u s^i ο η s^  
The azo reduction of SASP in faeces can be blocked completely 
by adding an approximately equal amount of a 0.2% HgClo solution. 
In practice this can easily be done by asking the patient to 
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empty his bowels in a stoppered pot containing about 200 ml of 
a 0.2% HgClp solution. By shaking vigorously the faeces will be 
mixed with the HgCl« solution within a few minutes. In case of 
very solid stools it is sometimes necessary to use a spatula or 
mixer. The faeces can then be stored at room temperature for at 
least 3 weeks. Solutions with a HgCl- concentration less than 
0.1% cannot prevent azo reduction of SASP in faecal suspensions. 
The same applies to addition of neomycin or PCMB to faeces. 
At a temperature of -20 oC SASP probably will not be split. How-
ever, during the process of freezing and defrosting a considera-
ble amount of SASP will be split. Consequently this method of 
preservation is not suitable for faeces containing SASP. 
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Chapter 4 
PHARMACOKINETICS AND METABOLISM OF SULFASALAZINE 
4.1 Introduction 
This chapter describes the results of a number of studies made 
in an effort to obtain more information on the way in which oral-
ly administered SASP is absorbed, metabolized and excreted. Much 
information of this kind can be obtained by pharmacokinetic stu-
dies after administration of a single dose or repeated doses. 
Schröder and Campbell (1972) were the first (and have so far been 
the only investigators) to carry out kinetic studies of SASP. The 
results presented in §4.4, §4.5 and §4.6 partly confirm, and partly 
supplement the findings reported by Schröder and Campbell. 
The principal metabolites of SASP are SP and 5-ASA. In the li-
terature there is no consensus about the influence of the acety-
lator phenotype on the serum SP level. This is why the effect of 
the acetylator phenotype on the serum concentrations and мгіпагу 
excretion of SP and its metabolites was studied both in healthy 
subjects and in patients using SASP (§4.7). This study also resul­
ted in the development of a simplified method of determining the 
acetylator phenotype. 
Finally, the faecal excretion and the total recovery of SASP 
and its metabolites were studied in healthy subjects (§4.8) 
The symbols and abbreviations used in §4.2 through §4.6 are 
explained in table 4.1. The plasma curves and urinary excretion 
curves presented in figures 4.1, 4.2, 4.3 and 4.4 were obtained 
by a fit procedure with the aid of computer programmes. 
Table 4.1 SYMBOLS AND ABBREVIATIONS USED IN CHAPTER 4 
Symbol or Meaning 
abbreviation 
С Serum concentration. 
t Interval after ingestion of the drug. 
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Apparent initial concentration obtained by extrapola­
tion of the plasma concentration curve or urinary 
excretion curve (A
r
) to time t=o, assuming the total 
amount of the drug absorbed to be taken up within a 
very short time. 
Absorption half-life, calculated from plasma concen­
tration curve or urinary excretion curve (t, ). 
г
а r 
Elimination half-life, calculated from plasma concen­
tration curve or urinary excretion curve (t, , ) . 
Half-life of metabolism. 
Lag time (or dead time): interval between ingestion 
of drug and time of its first appearance in blood or 
urine. 
Mean permanence time. 
Area under the curve. 
Dose administered. 
That fraction of the dose administered that reaches 
the systemic circulation. 
Steady-state distribution volume. 
Total clearance or elimination clearance. 
Renal clearance. 
Clearance regarded as constant. 
The time at which the maximum serum concentration is 
observed following a single extravascular dose. 
Maximal serum concentration. 
Total amount of drug excreted in urine. 
Renal clearance constant. 
Rate of elimination: the change in the amount of drug 
in the organism over a very short time. 
Mean plasma concentration. 
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4.2 Theoretical principles underlying the plasma curve and the 
urinary excretion curve after oral administration of a single 
dose and during administration of repeated doses 
4.2.1 The £l a^ma_c£n£entrat^on_curve 
After oral administration, the profile of most drugs shows the 
following characteristic features: 
a) the ascending leg, which mainly characterizes absorption; 
b) a maximum or peak concentration; 
c) the descending leg, which reflects elimination 
If the plasma or serum concentration is plotted on a logarithmic 
scale, then the descending leg is often rectilinear (fig 4.2, 
page 6 8 ) . 
The plasma concentration curve can generally be described by a 
sum of exponential terms: 
η 
Σ A. e 
i = l 
•t/Ti 
(1) 
In this equation A. stands for the coefficients with the dimension 
of concentration, and τ . for the time constants (hours or minutes). 
4.2.2 Ph¿rmacoJ<i£eJ:i£ £arame_te£s 
Independent of the adoption of pharmacokinetic models, the area 
under the curve (ADC) and the mean permanence time (τ) can be cal­
culated from the curve (Rescigno and Segre, 1975): 
AUC = ƒ C.dt= ι Α
 τ 
o i = i i i 
(2) 
and 
ƒ t . C . d t / A U C = Σ Α , τ . /Σ Α , τ , 
O l i l i 
(3) 
In statistical terms, AUC and τ are to be regarded as the statis­
tical moments (Yamaoka et al, 1978). 
Assuming that the drug is cleared by liver and/or kidney, the 
mean clearance can be calculated from the AUC if the amount of the 
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drug which has entered the systemic circulation is known: 
'Cel D.F/AUC (4) 
In this equation V p · , stands for clearance, D for the dose admi­
nistered, and F for that fraction of the dose that reaches the 
systemic circulation. In the case of intravenous administration, 
F = 1. In the case of oral administration, F is unknown. This 
means that the clearance value calculated according to equation 
(4) after oral administration is usually too high. 
The so-called steady-state distribution volume of the drug is 
the product of clearance and mean permanence time: 
Vf = V C e T T (5) 
The distribution volume, too, can be overestimated after oral ad-
mi nistration. 
Mean permanence time, clearance and distribution volume can be 
regarded as pharmacokinetic baseline parameters (van Rossum, 19 7 9 ) . 
The mean permanence time is in fact a composite of the mean 
lag time in the gastrointestinal tract (t ) , the mean time required 
for absorption (τ ) and the mean time required for elimination 
(τ el 
τ = t + τ , + τ , O a el (б) 
Particularly for an agent such as SP (administered as S A S P ) , of 
which the absorption mostly takes place in the large intestine, 
t is relatively long. 
When a metabolite is measured, its permanence time is longer 
than that of the mother substance. The permanence time of SASP is 
shorter than that of its metabolite SP. If the metabolite is rela­
tively quickly eliminated, the permanence time of the mother sub­
stance and that of the metabolite are virtually the same in actual 
practice. We have mainly used the plasma concentration curve of 
metabolite SP to deduce the kinetics of SASP (fig 4.2,page 68).The lag 
time (t ) is in order of 4 hours. 
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4 . 2 . 3 The £ lasma_con£entra_t ion_curve_wHh^ on2y_ two_exponen t i¿ l 
terms^ 
The curve shown in fig 4.2 can be completely described with two 
exponential terms, so that only a time constant for absorption 
(τ, =τ ) and one for elimination ( τ ^ = τ .) are required. The mean 
overall permanence time for SASP, measured as SP in the subject 
of fig 4.2, is 20.3 hours. 
The equation for the plasma concentration curve is uncompli­
cated situations, like that in fig 4.2, is: 
-t*/ τ , - f / τ -t /t, , - f / t , 
С = A(e e l - e a ) = A (2 * e l-2 É a ) (7) 
In this equation, t* is the time measured from the onset of ab-
sorption, and t is the time measured from ingestion. Therefore, 
* * • * - V 
In this situation there is a simple correlation between the time 
constants and the widely used half-life: 
tjel = 0 · 6 9 Tel (8> 
4.2.4 Депа^ excretù)^ i n_ r£lätu>£ .to_Plasma £0£C£nt^r£t20ji £ur^v£ 
In the most simple case, the rate of renal excretion (dQr/dt) 
of SASP and its metabolites is directly proportional to the plasma 
concentration: 
d Q r = V С 
In this equation, V stands for renal clearance. The curve for 
the rate of excretion therefore takes the same course as the 
plasma concentration curve, and consequently the permanence times 
and half-lifes can also be calculated from the renal excretion 
curves (fig 4.1, page 64). 
The amount of the drug ultimately excreted in the urine is: 
Q
r
 = V
r
 ƒ C.dt = Vr.AUC = DF V r / V C e l (10) 
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The fraction of the dose administered that is excreted by the 
kidneys therefore depends on total clearance, renal clearance, 
and the fraction that is absorbed or formed. 
V 0 = F-VVCel t11) 
The overall permanence time calculated from the urinary data, 
equals that calculated from the plasma data, provided that equa-
tion (10) retains its validity. 
The so-called bioavailability indicates which fraction of the 
dose administered enters the systemic circulation. If a metaboli-
te is measured, then F also incorporates the fraction of the amount 
absorbed that is converted to the metabolite in question. 
4.2.5 £1 a^ma_con£ej^tra^t i on_curve_and_rena^_e^cretÍ£n_dur2n¿ 
mu^t2pl_e_dos2n£ 
During multiple dosing when a particular dose is repeated at 
a fixed interval (e.g. 1 g every 6 hours) over an extended period 
of time, a steady state is attained after some time in which 
during each dose interval (At) as much of the drug is absorbed as 
is eliminated. The input in mg/hour equals DF/At, and the mean 
rate of elimination equals the product of the mean plasma concen-
tration during the dose interval and total clearance: ^„-..C
 η 
3
 Cel pi . 
In that case the mean plasma concentration is: 
S i = D F / V'cel- A t (12> 
This equation also applies to the metabolites, always allowing 
for a different F and different clearance. In view of the high 
clearance of the acetylated and glucuronidated SP metabolites, 
the plasma concentrations of these metabolites are low. 
During multiple dosing, the renal excretion (e.g. in 24-hour urine) 
also becomes constant. 
4.3 Test subjects and methods 
The study of the pharmacokinetics of SASP after a single dose 
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(§4.4, §4.5 and §4.6) was carried out in б healthy male subjects 
aged 19-24. Subject no. 5 was give 2 g SASP, while the others re­
ceived 3 g.The subjects fasted from midnight on. On day 1, the 
dose of SASP (wafer-sealed powder) was ingested at 8 A.M. No 
food was permitted for 12 hours before and for 4 hours after in­
gestion of the drug. To ensure a sufficient production of urine, 
about 100 ml water or tea was ingested every hour until midnight 
on day 1. Blood samples were drawn on day 1 at 9.30 A.M., 11 A.M., 
noon, 2 P.M., 4 P.M., 8 P.M. and 11 P.M. and on day 2 at 10 A.M. 
and 8 P.M. Urine was collected in two-hour samples from 8 A.M. 
to midnight on day l; at 4 A.M., 8 A.M., 2 P.M. and 8 P.M. on 
day 2 and at 2 A.M., 3 A.M. and 8 P.M. on day 3. SASP, SP, ac-SP, 
5-ASA and ac-5-ASA were measured in each serum sample and SASP, SP, 
ac-SP, SP-gluc, ac-SP-gluc, 5-ASA and ac-5-ASA were measured in 
each sample of urine. 
In order to gain an impression of the serum levels of SASP and 
metabolites, and for determination of the renal clearance constants 
during SASP maintenance medication, 11 healthy male subjects (aged 
20-30) were given 4.5 g SASP per day(1.5 g at 8 A.M., 4 P.M. and 
midnight) during б days. On days 5 and 6, blood samples were taken 
at 11 A.M. and 24-hour urine was collected for determination of 
SASP and metabolites. The data obtained after SASP maintenance 
medication are presented in §4.4 (SASP), §4.5 (SP and metaboli­
tes) and §4.6 (5-ASA). 
The methods of investigation and the test subjects used in 
the study of the influence of the acetylation phenotype on the 
pharmacokinetics of SP and of the recovery of SASP and metaboli­
tes in urine and faeces, are described in §4.7 and §4.8, respec­
tively. 
4.4 Pharmacokinetics of SASP 
The number of blood samples obtained within the first 6 hours af­
ter ingestion of a single dose of SASP was too small to allow 
calculation of the ti from the plasma concentration curves. Con­
sequently, A and t could not be calculated either. 
The elimination half-life (t -j ) of SASP could be determined from 
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the plasma concentration curve in three subjects. The values 
were 3.0, 3.3 and 2.4 hours (2.9 + 0.5 hours; mean + S D ) . 
Maximum serum SASP concentrations were observed 4-6 hours after 
ingestion. In the five subjects given 3 g SASP, the maximum se­
rum SASP levels showed marked inter-individual differences: 7.8, 
8.6. 12.5, 13.3 and 38.0 g/ml (16.0 + 12.5 g/ml , mean + S D ) . 
The kinetic data obtained from the urinary excretion curves 
are presented in table 4.2. The renal clearance constant k. 
was calculated with the aid of the available serum SASP concen­
trations and corresponding rates of urinary excretion, and the 
cumulative excretion. Fig 4.1 presents an example of a urinary 
excretion curve (subject no. 5 ) . 
SASP (μς/ηηιη) 
100 π 
= 0.3 h 
ti¿,, = 2.3h 
»Vi«» 7 3 h 
τ ; 14.4 h 
A = 76 μ9 / m m 
т — ι — ι ι ι ι ι ι 
32 40 
hours after ingestion 
Fig. ^ • 1 Urinary excretion curve of SASP after ingestion of a 
single dose of 2 g SASP (subject no. 5 ) . 
In subject no. 6, the kinetic parameters could ^ot be calculated 
because the urinary SASP excretion was too small (cumulative 
excretion: 0.4% of the dose administered). Table 4.2 shows that 
there was good agreement between the calculated and the cumula­
tive urinary SASP excretion (Q ). 
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Table 4.2 PHARMACOKINETIC PARAMETERS OF SASP IM HEALTHY SUBJECTS AFTER INGESTION OF A SINGLE 
ORAL DOSE, CALCULATED FROM THE URINARY EXCRETION CURVES 
subject dose of 
no. SASP 
(g) (h) (h) 
Jrel 
(h) 
'Cr Q Q 
calcul . cumul 
(h) (μα/ππ'η) (ml/min) (%) (%) 
σι 
O l 
1 
2 
3 
4 
5 
6 
m e a n + S D 
3 
3 
3 
3 
2 
3 
0.8 
1.6 
2.0 
0.8 
0.3 
-
1 . 1 + 0 . 6 
1.4 
1.6 
2.0 
2.2 
2.3 
-
1 . 9 + 0 . 4 
3.1 
5.1 
4.0 
8.4 
7.5 
-
5 . 6 + 2 . 3 
7.3 
1 1 . 2 
1 0 . 7 
1 6 . 1 
1 4 . 4 
-
1 1 . 9 + 3 
183 8.4+1.4 0.9 
117 6.3+2.2 1.2 
500 4.5+0.5 2.9 
93 5.1+1.2 1.7 
76 4.8+1.3 1.7 
1.0 
1.0 
3.0 
2.0 
1.5 
0.4 
The recovery of SASP in urine was low: 0.4% to 3.0% of the dose 
administered. In all subjects, SASP was demonstrable in the 
urine within 2 hours of ingestion (t ). This indicates that SASP 
is absorbed in the proximal part of the small intestine. The 
elimination half-life of SASP calculated from the plasma con­
centration curve ( t i n ) was significantly shorter than that from 
the urinary excretion curve (*і
ге
і)» t,le respective values being 
2.9 + 0.5 and 5.6 + 2.3 hours. 
Table 4.3 compares the principal kinetic parameters of SASP 
with the data published by Schröder and Campbell (1972). 
Table 4.3 PHARMACOKINETIC PARAMETERS OF SASP IN HEALTHY SUBJECTS 
AFTER INGESTION OF A SINGLE ORAL DOSE, COMPARED WITH THE 
THE RESULTS OF SCHRODER AND CAMPBELL (1972). 
Schröder this study 
number of subjects 9 5 
dose of SASP (g) 4 2-3 
t j e l (h) 5.7+0.7 2.9+0.51) 
t i r e l ( h ) - 5.6+2.3 
t (h) 1.5 1.1+0.6 
о — 
k C r (ml/min) - 5.8+1.9 
t (h) 3-5 4-6 
m ' 
С (yg/ml) 26+14 16.0+12.5 2) 
m — — 
1) mean value of 3 subjects 2) after ingestion of 3 g SASP 
The values for t and t are in good agreement. The elimination 
half-life (t,-,) found by Schröder and Campbell was significantly 
longer. Mo satisfactory explanation of this fact could be found. 
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It is to be borne in mind, however, that the t, , in our study is 
based on only three subjects. 
The differences in maximum serum SASP concentration (C ) can be 
v
 m ' 
explained by the difference in dose administerd: Schröder and 
Campbell gave their test subjects 4 g SASP, while ours received 
3 g. 
The serum SASP levels showed marked interindividual differen-
ces during maintenance medication. In 11 healthy subjects given 
4.5 SASP per day, the serum SASP levels ranged from 8.2 to 65.7 
ug/ml (25.3 + 18.7 pg/ml; mean + SD). The renal clearance for 
SASP during maintenance medication was 4.1 + 3.6 ml/min. This is 
in agreement with the findings of Schröder and Campbell (1972) 
(table 4.4). 
Table 4.4 RENAL CLEARANCE FOR SASP AND METABOLITES AFTER INGES-
TION OF 4.5 G SASP DAILY, COMPARED WITH THE RESULTS 
OF SCHRODER AND CAMPBELL (1972). 
Schröder this study 
number of subjects 9 11 
dose of SASP (g) 4 4.5 
renal clearance (ml/min) 
SASP 
SP 
ac-SP 
SP-gli 
ac-SP 
ac-5-, 
uc 
-glue 
ASA 
7 .3+1.7 
9 .9+1.9 
30 .4+5.2 
258+71 
61.1+10.5 
_ 
4 .1+3.6 
8 .8+5.6 
25.2+9.4 
250+40 
63 + 20 
100+20 
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4.5 Pharmacokinetics of SP and metabolites 
The principal pharmacokinetic parameters of free SP, obtained 
from the plasma concentration curves, are summarized in table 
4.5. An example of a plasma concentration curve is given in fig 4.2 
(subject no . 2) . 
SP ( ц д / т і ) -
100-
1 0 
Ч · ^ 
SP 
D 
tn 
tv,, 
ι
ν>, 
τ 
A 
= 3 g 
: 4 0 h 
r 2 9 h 
; 8 4 h 
: 2 0 3 h 
ζ 4 5 ¿ i g / m l 
32 4 0 
hou rs a f t e r ingest ion 
Fig Ц.2 Plasma c o n c e n t r a t i o n c u r v e of SP after ingestion of a 
single dose of 3 g SASP (subject no. 2 ) . 
The data available on subject no. 5 were not sufficient for the 
construction of a plasma curve. In subject no. 4, the maximum 
serum SP concentration was not attained until 31 hours after SASP 
ingestion, and the kinetic parameters could therefore not be 
calculated in this case. 
Table 4.5 shows that SP is not demonstrable in the blood until 
4-5 hours after SASP ingestion (t ). This interval corresponds 
with the time required for passage through the small intestine 
(Texter et al, 1968) and therefore indicates that SASP is indeed 
not split until it reaches the colon. Schröder and Campbell found 
a similar t value (3-5 hours). The rate of absorption of SP 
(t,,) was fairly constant in the subjects: 2.4 - 3 hours. With 
regard to the t,, it is to be noted that this is not a pure ab-
?a 
sorption constant because the rate of splitting of SASP also 
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Table 4.5 PHARMACOKINETIC PARAMETERS OF FREE SP IN HEALTHY SUBJECTS AFTER A SINGLE ORAL DOSE 
OF 3 6 SASP, CALCULATED FROM THE PLASMA CURVES 
subject 
no. 
'ia 'Je! о m VF •^Ce^F 
(h) (h) (h) (h) (h) (ug/nil) (yg/ml) (1) (ml/min) 
1 
2 
3 
6 
4.3 
4.0 
4.0 
4.8 
2.4 
2.9 
2.4 
3.0 
8.9 
8.4 
14 
18 
20.6 
20.3 
27.7 
35.0 
11 
11 
И 
14 
22 
18 
26 
29 
49 
45 
45 
48 
52 
64 
50 
47 
67 
88 
41 
30 
mean+SD 4.3+0.4 2.7+0.3 12.3+4.6 25.9+7.0 11.8+1.5 23.8+4.8 46.8+2.1 53.2+7.5 56.5+26.1 
influences the rate of absorption. The maximum serum concentration 
of free SP was attained 11-14 hours after ingestion of SASP. 
SP elimination is determined, not only by renal excretion of 
free SP but also by further metabolization. In the liver, SP can 
be acetylated as well as glucuronidated. The renal clearance of 
these metabolites is significantly higher than that of free SP 
(table 4 . 4 ) . In terms of rate of acetylation, two types can be 
distinguished: slow and fast acetylators. The acetylator phenoty-
pe is genetically determined (54.7). 
The number of blood samples was not sufficient for the con-
struction of a reliable plasma curve of ac-SP. The glucuronida-
ted SP metabolites were not determined in the blood. 
Table 4.6 presents the data on SP and metabolites as obtained 
from the urinary excretion curves. The excretion curve of ac-SP-
gluc was not linear in most test subjects, and kinetic parame-
ters cou^d therefore not be calculated. 
Fig. 4.3 gives a representative example of the urinary excretion 
curves of SP and metabolites (subject no. 5 ) . The kinetic para-
meters of SP as calculated from the urinary excretion curves, are 
in good agreement with the data obtained from the plasma con-
centration curves (table 4 . 5 ) . 
In subject no. 4, defaecation was strikingly slugghish (once 
every 3-4 d a y s ) . The t value in this test subject (8 hours) sug-
gests that passage through the small intestine was likewise re-
tarded, so that it was not until after 8 hours that SASP was pre-
sent in the colon and could be split by colonic bacteria. The 
long absorption half-life for SP (t, = 6.7 hours) indicates 
2a r 
that the supply of SASP to the colon took longer than it normally 
does. 
As expected, the t for the SP metabolites was somewhat longer 
than that for free SP. The renal clearance constant (k,- ) aver-
aged 10.8 ml/min for free SP, and 26.5 ml/min for ac-SP. Because 
serum SP-gluc and ac-SP-gluc levels were not measured, their 
renal clearance constants could not be calculated. 
The total recovery of SP (SP+ac-SP + SP-gluc + ac-SP-gluc) in 
the urine, expressed as percentage of the amount of SP present 
in the administered dose of SASP, ranged from 61% to 95%. 
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SP-gluc^g/min) 
10000 π 
1000 
6 Ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι ι 
0 θ 16 24 32 4 0 
SP(>ig/min) 
10 000 тЧ\ 
I I I 
4Θ 56 
ac-SP (>j.g /mm) 
r-IOOO 
1 0 0 0 
ι ι ι ι ι ι ι 
0 θ 16 24 32 4 0 4Θ 56 
hours after ingestion 
Fig. Ί.3 Urinary excretion curves of SP, a c - S P , SP-gluc and 
a c - S P - g ) u c after ingestion of a single dose of 2 g 
SASP (subject no. 5) . 
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Table 4.6 PHARMACOKINETIC PARAMETERS OF SP AND METABOLITES IN HEALTHY SUBJECTS AFTER INGESTION 
OF A SINGLE ORAL DOSE OF SASP, CALCULATED FROM THE URINARY EXCRETION CURVES 
subject 
no-
SP 1 
2 
3 
4 
5 
6 
mean+SD 
dose of 
SASP 
(g) 
3 
3 
3 
3 
2 
3 
4 
*о 
(h) 
4.6 
5.0 
3.8 
8.0 
3.3 
4.9 
.9+1.6 
Ч.г* 
(h) 
2.1 
3.1 
4.0 
6.7 
2.2 
3.1 
3 . 5 + 1 . 7 1С 
'irei 
(h) 
13 
6.2 
10 
13 
7.8 
13 
1.5 + 3.0 
τ 
(h) 
26.3 
18.4 
24.0 
36.3 
17.7 
28.1 
2 5.1+6.9 
A
r 
(mg/min) 
0. 
0.50 
0.68 
1.17 
0.47 
0.39 
0.53 
.62+0.28 
к
Сг 
(ml/min) 
12 + 2 
9+1 
14 + 3 
12 + 2 
9+1 
9 + 2 
10.8+2. 6 20 
^ 
cal ι 
(%) 
25 
10 
33 
14 
14 
24 
.8+8 
:ul. 
.7 18 
Qr 
cumul 
(%) 
23 
10 
27 
14 
14 
21 
.2+6.5 
ac-SP 1 
2 
3 
4 
5 
6 
4. 
6, 
5. 
15. 
3, 
5. 
13 
6.5 
9.2 
10 
7.5 
15 
30 
21 
26 
38 
17 
34 
0.30 
1.60 
0.80 
0.77 
0.83 
0.28 
23 + 11 
2 1 + 6 
34+ 3 
19+ 3 
4 1 + 8 
21+ 4 
11 
20 
13 
14 
29 
13 
10 
22 
12 
14 
26 
11 
mean+SD 6.6+4.3 4.7+1.4 10.2+3.3 28.2+8.0 0.76+0.48 26.5+8.9 16.7+6.8 15.8+6.6 
Table 4.6 continued. 
SP-gluc 1 
2 
3 
4 
5 
6 
mean+SD 
5, 
5. 
5. 
12 
3, 
4. 
6.3+2.9 
2.3 
3.2 
5.3 
5.8 
3.8 
5.0 
2 + 1.4 
13 
8 
11 
11 
7.3 
11 
10.2+2.1 
21.4 
21.8 
29.2 
36.2 
19.6 
27.9 
26.0+6 
0.80 
0.87 
0.63 
0.42 
0.86 
0.64 
0.70+0.17 
40 
19 
17 
11 
22 
19 
3 + 9.9 
. 
-
17 
-
-
-
38 
17 
16 
9 
20 
17 
19.5+9.8 
7 
14 
14 
26 
35 
12 
18.0+10.. 
ac-SP-gluc 1 
2 
^ 3 
4 
5 
6 
mean+SD 
6.6 2.9 21 41.0 
7.5 
*for ac-SP, SP-gluc and ac-SP-gluc: t, . 
Table 4.7 lists the recovery of SP and metabolites in the urine 
for slow (subjects 1, 3 and 6) and fast acetylators (subjects 2, 
4 and 5) . 
Table 4.7 INFLUENCE OF ACETYLATOR PHENOTYPE ON THE URINARY 
RECOVERY OF SP AND METABOLITES IN HEALTHY SUBJECTS 
AFTER A SINGLE ORAL DOSE OF SASP 
recovery (% of administered dose; mean + SD) 
slow acetylators fast acetylators 
(n-3) (n-3) 
,3) 
.1) 
free SP 1) 
ac-SP 1) 
SP-gluc 1) 
ac-SP glucJ 
total SP 2) 
proportion of 
acetylated SP 
proportion of 
glucuronidi sed SP 
34+ 5 
16+ 3 
33+13 
16+ 6 
70+ 8 
32+ 9 
49+ 7 
18+ 4 
28+ 6 
21+ 6 
33+10 
74 + 18 
62+ 4 
54+ 4 
<0.01 
<0.001 
<0.001 
<0.001 
π .s . 
0.001 
η . s . 
1) % of the total recovery of SP 
2) % of the amount of SP present in the intested dose of SASP 
3) Student's t test. n.s.= not significant, ρ >0.05 
Slow and fast acetylators did not differ in total SP recovery. 
The percentage of acetylated SP metabolites was significantly 
smaller in slow than in fast acetylators (for acetylator phenoty-
pe, see § 4.7) 
The serum level of SP+ac-SP in 11 healthy subjects using a 
maintenance dose of 4.5 g SASP ranged from 22.2 to 59.6 ug/ml 
(46.4 + 10.9 pg/ml; mean + SD). Table 4.4 lists the renal clea­
rance constants of SP and metabolites as calculated from serum 
levels and urinary excretion during a maintenance dose of SASP. 
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The clearance constants found are in good agreement with those 
reported by Schröder and Campbell (1972). 
4.6 Pharmacokinetics of 5-ASA 
The serum 5-ASA and ac-5-ASA concentrations after administra-
tion of a single dose of SASP were always lower than 0.5 and 2.0 
yg/ml, respectively, as in the study of Schröder and Campbell 
(1972), In the urine, only ac-5-ASA was demonstrable, and kinetic 
parameters could therefore only be calculated for ac-5-ASA. 
Table 4.8 summarizes the principal kinetic parameters of ac-
5-ASA, obtained from the urinary excretion curves. The note that 
t, also includes the rate of degradation of SASP, applies to 
5-ASA as well as to SP. Fig 4.4 shows such an excretion curve 
(subject no. 6 ) . 
ac- 5 -ASA (μ9/πηιη)-
1000 
1 0 0 -
ac-5-ASA 
t 0 = i 4 h 
t % . = 3.2 h 
t f c i * SV h 
τ - 18.4 h 
A = 1420 μς I mm 
ι ι ι 
48 64 
hours after ingestion 
Fig Ц.Ц U r i n a r y e x c r e t i o n c u r v e of a c - 5 " A S A after i n g e s t i o n of 
a s i n g l e dose of 3 g SASP (subject no. 6 ) . 
The t 0 values for SP (table 4.6) and ac-5-ASA, calculated from 
the urinary excretion curves, were virtually the same in the va-
75 
subject 
no­
dose of 
SASP 
(Ρ) 
Ч 
(h) 
^аг 
(h) 
Vel 
(h) 
Table 4.8 PHARMACOKINETIC PARAMETERS OF AC-Ç-ASA IN HEALTHY SUBJECTS AFTER INGESTION OF A SINGLE 
ORAL DOSE OF 3 G SASP, CALCULATED FROM THE URINARY EXCRETION CURVES 
Ar kCr % % 
calcul . cumul. 
(h) (mq/min) (ml/min) (%) (%) 
1 3 4.4 2.3 17 32.2 0.30 110+10 19 19 
2 3 6.6 1.4 4.7 15.4 1.23 140+50 24 28 
3 3 4.2 2.7 8.4 20.2 0.82 120+50 27 23 
4 3 9.8 5.3 9.6 23.9 0.70 - 18 21 
6 3 5.6 3.2 5.7 18.4 1.42 130+20 21 24 
mean+SD 6.1+2.3 3.0+1.5 6.0+3.1 22.0+6.5 0.89+0.44 125+34 21.8+3.7 23+3.4 
rious individual subjects. This confirms that SP and 5-ASA are 
indeed simultaneously released (in the c o l o n ) . 
The urinary excretion averaged 23% of the amount of 5-ASA present 
in the administered dose of SASP (always excreted as a c - 5 - A S A ) . 
Schröder and Campbell (1972) found a recovery of about 30%. The 
metabolite ac-5-ASA is rapidly excreted via the kidneys. The 
renal clearance constant (k- ) averaged 125 ml/min, which corres-
ponds with the glomerular filtration rate. 
In the 11 healthy test subjects on a maintenance dose of 4.5 
g SASP per day, the serum 5-ASA and ac-5-ASA levels were likewise 
always lower than 0.5 and 2 pg/ml , respectively. The renal clea-
rance constant of ac-5-ASA was 100 + 20 ml/min in these subjects. 
4.7 Determination of the acetylator phenotype and its influence 
on SP metaboli sm 
After splitting of SASP in the colon, SP is largely absorbed. 
Before being excreted via the kidneys, SP is partly acetylated 
and/or glucuronidated in the liver. Acetylation of the NH^ group 
of SP takes place with the aid of the enzyme N-acetyltransferase. 
This enzyme catalizes the transfer of the acetyl group from ace-
tylcoenzyme A to the acceptor molecule. Acetylation of drugs with 
an aromatic amine group has long been known to show interindivi-
dual differences. This difference in rate of acetylation is gene-
tically determined, and was first described for the tuberculos-
tatic isoniazid (Bonicke and Reif, 1953; Evans et al, 1960). Two 
phenotypes can be distinguished: slow acetylators (autosomal 
recessive) and fast acetylators (autosomal dominant). 
The N-acetyltransferase activity in the liver in fast acetyla-
tors is alleged to be at least twice that in slow acetylators 
(Jenne, 1965; La Du, 1972). Other drugs with an aromatic amine 
group which show the same acetylation polymorphism as INH are: 
sulphadimidine (sulphamethazine) (Evans and White, 1964); hydra-
lazine (Evans and White, 1964; Reidenberg et al, 1973); dapsone 
(Gelder et al, 1974); procainamide (Reidenberg et al, 19 7 5 ) , and 
the amino-metaboli te of nitrazepam (Karim and Evans, 1 9 7 6 ) . 
In 1972, Schroder and Evans demonstrated that SP is likewise ace-
tylated polymorphically. Consequently the acetylator phenotype 
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plays a role in the pharmacokinetics of SASP. 
Acetylated metabolites of a drug are usually excreted more 
rapidly via the kidneys than the intact drug. Acetylation often 
alters the properties of the drug. The rate of acetylation there-
fore exerts an influence both on the efficacy of a druçi and on 
the development of side effects. The incidence of slow and fast 
acetylators shows marked interracial differences. Of the 
(Caucasian) population of Western Europe, about 60% are slow 
and about 40% are fast acetylators. In Japanese and Chinese popu-
lation groups the percentage of slow acetylators is much smaller: 
10-20% ( H l a r d , 1976). 
The acetylator phenotype is usually determined with the aid 
of sulphadimidine (Evans, 1969). The test subject is given an 
oral dose of 40 mg sulphadimidine on an empty stomach, and con-
tinues to fast 2 more hours. Blood or a sample of urine is col-
lected 6-8 hours after ingestion. The percentage of acetylated 
sulphadimidine in relation to the total amount (free and acety-
lated) is a yardstick of the acetylator phenotype. A person is 
regarded as a slow acetylator if less than 32% of the serum sulpha-
dimidine is acetylated. The limit for urine is 65%. Both with the 
aid of serum and with the aid of urine, it is in this way possi-
ble to determine the acetylator phenotype in 95-99% of cases. 
Determination of the acetylation phenotype with the aid of 
sulphadimidine is a rather complicated method. The natient has to 
fast for a considerable time, and blood or urine must be collec-
ted 6-8 hours after sulphadimidine ingestion. We therefore inves-
tigated the possibility of determining the acetylation phenotype 
with the aid of SP after administration of a single dose of SASP 
and during maintenance therapy. 
Thirty-four subjects without diseases of liver or kidneys were 
given a single dose of 3 g SASP (in tablet form) at 8 P.M. Eating 
or drinking ware not restricted. In the course of the next day (12-
20 hours after ingestion) blood was drawn and a sample of urine 
collected. Serum SP and ac-SP concentrations were determined; in 
urine, glucuronidated SP metabolites were determined as well. 
Fig 4.5 shows for each of the subjects the percentage of ac-
SP (versus SP + ac-SP) in the serum, plotted against the percen-
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tage of acetylated SP metabolites in the urine (ac-SP + ac-SP-
glue versus the sum of free SP, ac-SP, SP-gluc and ac-SP-gluc] 
rela 
6 0 -
4 0 -
20 -
ted to SP »ac-SP 
. 
. . . . . 
. . 
SLOW AŒTYLATORS (n = 18) 
1 
I 
I 
I 
• 
• 
I · 
• 
I · 
I · I 
• 
• 
• 
• • • 
• 
.· 
FAST ACETYLATORS(n.16) 
20 40 60 80 100 
•/o acetylated SP metabolites In urine related to total SP 
Fig. 't. 5 P e r c e n t a g e of a c e t y l a t e d SP m e t a b o l i t e s in serum and 
urine of З'· h e a l t h y s u b j e c t s after i n g e s t i o n of a 
si n g l e dose of 3 g S A S P . 
This figure shows that the acetylator phenotype can in this way 
be determined both in serum and in urine. When less that 30% of 
SP in the serum is acetylated, the subject is a slow acetylator. 
In urine, less than 55% of SP consists of acetylated metabolites 
in the slow acetylator phenotype. 
In 61 patients with Crohn's disease or ulcerative colitis using 
a maintenance dose of SASP, the acetylator phenotype was likewise 
determined with the aid of SP. At a follow-up examination in the 
out-patient clinic, blood and urine samples were obtained for 
determination of SP and metabolites. Fig 4.6 shows that the ace­
tylator phenotype can be determined also during maintenance the­
rapy, both in serum and in urine. In this group, too, the distin-
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guishing boundaries between slow and fast acetylators were 30% 
for serum and 55% for urine. 
°/o ac-SP in serum — 
related to SP»ac-SP 
6 0 -
4 0 -
2 0 -
SLOW 
ACETYLATORS 
(η·413 
I 
FAST ACETYLATORS (n = 20) 
τ \ 1 r — ^ — r 
20 40 60 80 Ю0 
°/· acetylated SP-metabolites in urine related to total SP 
Fig. Ц.6 P e r c e n t a g e of a c e t y l a t e d SP m e t a b o l i t e s in serum and 
urin e of 61 p a t i e n t s with i n f l a m m a t o r y bowel d i s e a s e 
using a m a i n t e n a n c e dose of SASP (3-6 g per d a y ) . 
Of tnese 61 patients, 67% were slow acetylators.a percentage 
which corresponds with the data from the literature (Ellard, 
1976). t histogram of per cent of acetylated SP in serum shows 
the typical bimodal frequency distribution (fig 4.7 ) . 
As acetylation phenotype is genetically controlled it should 
be fairly constant in any individual. To verify this postulate, 
the acetylator phenotype was determined on different days in 39 
patients using a maintenance dose of SASP (3-6 g per day). Both 
in serum and in urine, the percentage of acetylated SP metaboli­
tes was found to be strikingly constant. The difference in ace­
tylation percentage in a given patient, expressed as relative 
difference between values measured on two different days, avera­
ged 3.2% in serum and 3.4% in urine. In none of the patients did 
the difference in acetylation percentage lead to a change of the 
acetylator phenotype. 
Я0 
Number of patients 
1 4 -
1 2 -
1 0 -
8 -
6 -
4 
2 
0 20 40 60 
•Í. ac-SP in serum 
related to SP* ac-SP 
F!g. ¿1.7 H i s t o g r a m of percent of a c e t y l a t e d SP in serum of 61 
pa t i e n t s with i n f l a m m a t o r y bowel d i s e a s e using a m a i n -
tenance dose of SASP. 
The above data demonstrate that the acetylator phenotype can 
be determined in a simple way with the aid of SASP. Administra-
tion of a single dose of SASP has the advantage that the patient 
need not fast, as he has to do with sulphadimidine. Orally given 
sulphadimidine is absorbed in the proximal part of the small 
intestine, and relatively quickly excreted via the kidneys. This 
is why a blood or urine sample has to be collected within 6-8 
hours of ingestion. After SASP administration this interval is 
significantly longer: 12-20 hours after ingestion. When 3 g SASP 
is given at 8 P.M., the acetylator phenotype can be determined 
from a serum or urine sample during the next day. In patients on 
maintenance therapy the acetylator phenotype can be determined in 
a random sample of blood or urine. 
In urine, we always determined all SP metabolites (SP, ac-SP, 
SP-gluc and ac-SP-gluc). However, it proved to be quite possible 
l· 
''•W".i 
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to determine the acetylator phenotype solely on the basis of 
free SP and ac-SP. A correct classification was in this way 
achieved in 33 of the 34 persons given a sinnle dose (fig 4.8) 
and in each of the 61 patients using a maintenance dose of SASP 
(3-6 g per day) (fig 4.9). 
·/. ac-SP in urine 
related to SP*ac-SP 
8 0 τ 
6 0 -
4 0 
-r 
20 40 60 80 
»Z« acetylated SP metabolites in urine related to total SP 
Fig. Ί.8 Percentage of acetylation in urine based on ac-SP 
related to SP+ac-SP and percentage of acetylation 
based on ac-SP + ac-SP-gluc related to the total 
amount of SP and metabolites in 3** healthy subjects 
after ingestion of a single dose of 3 g SASP. 
The percentages of ac-SP calculated from free SP and ac-SP did 
not differ significantly from the percentages calculated from 
al 1 four metabolites. 
In literature there is no consensus about the influence of 
the acetylator type on serum SP levels in patients using a main­
tenance dose of SASP. Schröder and Campbell (1972) and Schröder 
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et al (1973) found no difference in serum total SP levels between 
slow and fast acetylators. 
/o d 
related to SP »ac-SP 
100 η 
8 0 -
6 0 -
4 0 -
2 0 -
• 
• 
• 
;>_·: 
• 
- и 
• 
• 
• 
20 40 60 80 
% acetyl at ed SP metabolites in urine related to total SP 
Fig. 't . 9 P e r c e n t a g e of a c e t y l a t i o n in urine based on ac-SP re­
lated to S P + a c - S P and p e r c e n t a g e of a c e t y l a t i o n based 
on a c - S P + a c - S P - g l u c . related to the total amount of 
SP and m e t a b o l i t e s in 61 p a t i e n t s w i t h i n f l a m m a t o r y 
bowel d i s e a s e using a m a i n t e n a n c e dose of SASP (3-6 g 
per day) . 
Das et al (1973), however, found significantly higher serum SP 
levels in slow than in fast acetylators. 
The following procedure was used to study the influence of the 
acetylator phenotype on serum level and urinary excretion of SP 
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and metabolites. Nineteen healthy tost subjects were given ¿.5 g 
S/'SP nor day (1.5 π a t Ρ l· M. , Л P.". and midmnht) durinn 6 
davs. On days 5 and 6, a blood sampie was taken at 11 A.M. and 
24-hour urine was collected SPS? and its metabolites were deter­
mined in all serum and urine samples, and the acetylator phenoty-
pe was determined as described abovn. Ten subjects were slow ace-
tylators and 9 were fast acetylators. Table *.Q lists the mean 
serum levels of SASP and SP metabolites separately for slow and 
for fast acetylators 
Table A.9 U'FLUENCF OF iCETYLiinR PHfNOTYPF ON THE SERUM COM-
CFMTRATION OF SASP, ST /Tí) /T-SP IN ΗΕ/ΈΤΗΥ SUBJECTS 
INGFSTHT 4.5 G SASP DMLY 
serum concentration (рг/ілі ; mean + SD) 
slow acetylators fast acetylators 
(n=10) (n=9) 
,1) 
SASP 
SP 
ac-SP 
SP+ac--SP 
21.4+17.1 
46.2+ 9.? 
P.2+ 2.5 
54.7+ 7.8 
3?.fi+lQ.O 
23.7+ 5.3 
13.3+ 3 6 
37.0+ 8.4 
η . s . 
-0 001 
0 005 
0.001 
1) student's t test, η s. not significant, ρ 0.05 
The serum SASP levels were not s ι on ι f ι cantly different. The se­
rum levels of free and SP+ac-SP were significantly higher in slow 
acetylators. Fig d.10 shows the serum SP and SP+ac-SP levels in 
the individual subjects. 
Twenty-four hour urinary excretion of SASP, total amount of SP 
(SP + metabolι tes ) and of ac-5-ASA did not differ in slow and fast 
acetylators. Slow and fast acetylators did show marked differences 
in the separate SP metabolites (table ¿.10). This table also shows 
that the hydroxylation rate (followed by nlucuromdation) was 
the same in slow and in fast acetylators: about 40) of the total 
amount of SP. In a snail proportion of the population, there is 
8Λ 
slow hydroxy!ation as well as slow acetylation, 
(μ9/ΓηΙ) 
80 
60 
4 0 -
2 0 -
slow acetylators 
( n =10) 
fast acetylators 
(n = 9) 
SP SP 
•ас-SP 
Fig. ^.10 Effect of the a c e t y t a t o r p h e n o t y p e in the serum c o n ­
c e n t r a t i o n of SP and S P + a c - S P in 19 h e a l t h y s u b j e c t s 
ingesting k.S g SASP d a i l y . 
We found this in 2 out of a total of about 200 patients. In these 
2 patients the serum SP+ac-SP level was about twice as high as 
the normal level (table 4.11). In both patients the SASP dosage 
had to be reduced because of side effects (haemolysis, nausea). 
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Table 4.10 INFLUENCE OF ACETYLATOR PHENOTYPE ON TWENTY-FOUR 
HOUR URINARY EXCRETION OF SASP AND METABOLITES IN 
HEALTHY SUBJECTS INGESTING 4.5 G SASP DAILY 
recovery (# of the a d m m s t e r e d dosejmean+SD] 
3 
slow acetylators fast acetylators ρ 
(n=10) (n=9) 
SASP1 
f r e e SP2 
ac-SP 2 
S P - g l u c 2 
ac-SP-g luc ¿ 
t o t a l SP1 
p r o p o r t i o n 
a c e t y l a t e d 
p r o p o r t i o n 
of 
SP 
of 
g l u c u r o m d a t e d SP 
ac-5-ASA1 
3.6+3.8 
36 .6+5 .4 
23 .2+4 .8 
23 .3+7 .0 
16.8+7.9 
71 .4+8.7 
40 .0+6 .0 
40 .1+7 .9 
13.2+6 3 
4.8+ 3.3 
13.5+ 7.4 
43.9+ 8.5 
9.9+ 4.0 
33.3+13.6 
59.0+12.8 
77.2+ 7.8 
43.2+12.4 
10.2+ 4.8 
η .s . 
0.001 
•-0.001 
«-O.OOl 
<0.005 
n.s . 
< 0 . 0 0 1 
n . s . 
n . s . 
1 % of the ingested dose; for SP and 5-ASA based on the molar re­
coveries of SP and 5-ASA respectively, in comparison with SASP 
ingested 
2 % of the total recovery of SP 
3 Student's t test. n.s. = not significant, ρ >0.05 
Table 4.11 SERUM LEVELS OF SASP, SP AND AC-SP IN TWO PATIENTS 
WITH SLOW ACETYLATION AND SLOW HYDROXYLATION 
dose of serum concentration (ug/nl) t in urine of 
SASP(g) SASP SP SP+ac-SP acetyl, glucuron, 
SP SP 
patient 1 
patient 2 
13.4 
11.0 
2.8 
3.6 
149 
63.6 
117 
63.2 
176 
78 
140 0 
77.2 
30 
28 
32 
26 
19 
21 
25 
22 
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4.8 Recovery of SflSP and metabolites in urine and faeces 
The results of pharmacokinetic studies in man suggest that 
after splitting of SASP, the larqer part of S-fSA is excreted 
in the stools (§4.4, §4.5 and §4.6; Schröder and Campbell, 1972). 
The literature, however, comprises few reports on determinations 
of SASP and metabolites in faeces (Schröder and Campbell, 1972; 
Peppercorn and Goldman, 1973). Yet determination of SASP and meta-
bolites in faeces is of importance because the therapeutic effect 
of SASP in patients with inflammatory bowel disease is possibly 
based on a local action of one of its metabolites: 5-ASA (chapter 
6 ) . 
Adequate preservation of the faeces by addition of an enzyme 
inhibitor and an improved method to determine 5-ASA have enabled 
us to obtain reliable data on SASP and its metabolites in faeces 
(§3.3 and § 3 . 4 ) . 
In an effort to gain an impression of the urinary and faecal 
excretion of SASP and metabolites under normal circumstances, the 
recovery of SASP and metabolites was determined after a single 
dose of SASP in 7 healthy subjects. All had a normal pattern of 
defaecation (ranging from once every other day to twice d a i l y ) , 
and none used any other drug. After fasting for 12 hours the 
subjects ingested 3 g SASP (powder) and a standardized breakfast 
at 9 A.M. At 1 P.M. a standard lunch was given and until 6 P.M. 
only water and tea were allowed. Urine (in 24-hour samples) and 
faeces were collected during 4 days after SASP ingestion. The 
faeces were voided directly in a stoppered pot containing 200 ml 
of a 0.2% HgClp solution and shaken vigorously to ensure adequate 
mixing with the solution. 
The recovery in urine and faeces of SASP, total SP (SP+ac-SP+ 
SP-gluc+ac-SP-gluc) and total 5-ASA (5-ASA+ac-5-ASA) was measured. 
The results are listed in table 4.12. These data show that, under 
normal circumstances, SASP is indeed split almost completely into 
SP and 5-ASA. The urinary recovery of SASP was low: 0.5-7.IX of 
the dose administered.In 4 subjects, the faeces contained no de-
monstrable SASP at all; minimal amounts were found in the other 
faecal samples. 
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Table 4.12 THE RECOVERY OF SASP AND METABOLITES IN URINE AND FAECES IN HEALTHY SUBJECTS 
AFTER INGESTION OF A SINGLE ORAL DOSE OF 3 G SASP 
recovery (7, of administered dose) 
subject SASP 
no. urine faeces 
total SP1 
urine faeces 
S-ASA' 
urine faeces 
sp- 5-ASA' 
oo 
oo 
7. 1 
3.4 
2.9 
4.0 
0.5 
3.3 
1.0 
O.ft 
1.5 
0.5 
0 
0.4 
0 
0 
56.2 
56.4 
70.9 
70.2 
71 .6 
61 .5 
54.7 
7.7 
12.4 
5.5 
5.8 
7.9 
7.6 
3.9 
16.6 
13.2 
34.5 
20.6 
18.1 
12.3 
15.5 
66.5 
78.2 
75.3 
81.0 
89.9 
82.7 
49.1 
71.8 
73.7 
79.R 
80.0 
80.4 
72.4 
59.6 
91.0 
96.3 
113.2 
105.6 
108.9 
98.3 
65.6 
mean+SD 3.2+2.2 0.5+0.6 63.1+7.6 7.3+2.7 18.7+7.5 74.7+12.4 74.0+7.4 97.0+15.8 
1 based on the molar recoveries of SP and its dérivâtes in comparison with S^SP incested 
2 as in footnote 1 except that 5-ASA and ac-5-ASA were considered 
3 including the amount of SP or 5-ASA remaininn in the non dissociated compound (SASP). 
About two-thirds of the SP present in SASP was excreted in the 
urine. The faeces contained only free SP(3.9-12.4%), acetylated 
and/or gl u c u r o m d a t e d compounds were not demonstrable. The uri­
nary recovery of 5-ASA (always as ac-5-ASA) ranged from 12.3% to 
34.5%. Most of 5-ASA was recovered in the faeces. 
The total recovery of SP (in urine and faeces, including SP pre­
sent in SASP) averaged 74«. That of 5-ASA averaged 97%. 
The high recovery of 5-ASA indicated that the 5-ASA present in 
the faeces was not further metabolized or degraded The total 
recovery of SP and 5-ASA was remarkably low in subject no 7. This 
finding has remained unexplained 
The urinary recovery of SASP and metabolites in these 7 sub­
jects is in oood agreement with the recovery in the subjects des­
cribed in §4.4, §4.5 and §4 6 (tables 4.2, 4.6 and 4 . 8 ) . 
Table 4 13 shows that our results are also in good agreement with 
those reported by other investigators. However, the faecal recove­
ry of 5-ASA reported by Peppercorn and Goldman (1973) was substan­
tially lower than in our subjects. This may be based on less 
adequate preservation of the faFces.Moreover, Peppercorn and 
Goldman used a different method of determination: thin-layer 
chromatography. 
4.9 Conci usions 
The pharmacokinetic parameters of SASP and its metabolites as 
described in this chapter, correspond well with the data from the 
literature. Both after a single dose and during maintenance thera­
py, the serum SASP levels showed marked ι n t e n n d i v i d u a ! differen­
ces. Only a small fraction of SASP (0.5-7%) was 
excreted unchanged in the urine. During a normal pattern of de-
faecation, the recovery of SASP in the faeces was very low 
(0-1.5°/). 
After a single dose of SASP, SP and 5-ASA were not demonstrable in 
serum or urine until 3-10 hours after ingestion. This interval 
corresponds with the time required for passage through the small 
intestine. The serum total SP levels likewise showed marked inter-
individual differences These can in part be explained by the 
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Table 4.13 SUMMARY OF REPORTS ON THE RECOVERY OF S/SP AND METABOLITES IN URINE AND FAECES 
IN HEALTHY SUBJECTS INGESTING Λ SINGLE DOSE OR A MAINTENANCE DOSE OF SASP 
recovery (% of administered dose) 
investiqators number of dose of 
SASP SP 5-ASA 
subjects SASP 
urine faeces urine faeces urine faeces 
Schröder and 9 
Campbell (1972) 
^ Peppercorn and 5 
Goldman (1973) 
Schröder et al 26 
(1973) 
this study 7 
a maintenance dose of SASP 
b sinole dose of SASP 
4 a 1.7-10 0 
2-3 b 5 1 
2 a 2.7+0.5 ? 
3 b 3.2+2.2 0.5+0.6 
+R0 5.2+2.5 
*1 7 
60.5+4.3 ? 
63.1+7.6 7.3+2.7 
34 + 8 ? 
17 50 
? ? 
18.7+7.5 74.7+13.4 
acetylator phenotype: in slow acetylators the serum level of free 
SP (and therefore the total SP level) was sinnificantly higher 
than in fast acetylators. 
The rate of hydroxy!ation of SP was fairly constant. Slow 
hydroxylation was observed in rare instances. When this occurred 
in slow acetylators, the serum SP levels were about twice as 
high as the normal values. 
Most of SP,partly acetylated and/or glucuronidated, was excreted 
in the urine. A small fraction (4-12%) was excreted in the fae-
ces (always as free S P ) . The serum 5-ASA levels were always be-
low 2 yg/ml . 5-ASA was largely recovered in the faeces {50-901) 
In urine 12-35% was recovered (as ac - 5 - A S A ) . 
With the aid of SASP the acetylator phenotype can be deter-
mined in a simple way by determining the concentrations of free 
SP and ac-SP in serum or urine. For this purpose, a serum or 
urine sample obtained within 12-20 hours of ingestion of a single 
dose of 3 g SASP can be used; during maintenance therapy, any 
random sample or serum and urine will do. 
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Chapter 5 
FACTORS WHICH MAY INFLUENCE MET/'BTLISM AND EFFICACY OF 
SULFASALAZINE 
5.1 Introducti on 
One of the problems in using SASP is the dosage. There are 
major interindividual differences both with respect to effective-
ness and the development of side-effects. Experience has shown 
that some patients with inflammatory bowel disease improve rapid-
ly after administration of 4 to 6 g SASP per day whereas in others 
the same dose or a higher dose has little or no effect. In some 
patients, even a relatively low dose of 3 to 4 g SASP per day 
induces side-effects while in others a high dose is well tolera-
ted. This may be due to differences in splitting of SASP, absorp-
tion of the split products and excretion of these products, not 
only between the different patients but also in the same patient 
under different circumstances. 
Determinations of the serum levels of SASP and metabolites 
in patients using the same dose of SASP soon showed that there 
were great interindividual differences, especially in the serum 
SP levels. Fig 5.1 shows the serum levels of SASP and SP in 12 
patients hospitalized for Crohn's disease or ulcerative colitis. 
All the patients took 6 g SASP per day (1.5 g at 7 A.M., noon, 
5 P.M. and 11 P . M . ) . After this dose had been administered for 
at least one week in hospital, blood samples were taken at 9 A.M., 
3 P.M. and 10 P.M. to determine SASP and SP. The serum SASP con-
centration was generally lower than 20 pg/ml. The serum SP level 
(SP + ac-SP) in the individual patient was reasonably constant in 
thecourse of the day. Serum SP concentrations showed major inter-
individual di fferences,ranging from 13 to 97 ug/ml. These diffe-
rences can be partly explained by differences in acetylation rate 
of SP in the liver (§ 4 . 7 ) . It is in fact probable that other fac-
tors play a part too. For instance, in the 12 patients examined, 
differences were observed with respect to inflammatory activity, 
defaecation frequency, stool consistency and administration form 
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8 0 -
SP»ac-SP(Mg/ml)-
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Fig. 5.1 Serum concentration of SASP and SP+ac-SP in 12 hos p i t a -
lized patients with inflammatory bowel disease ingesting 
6 g SASP daily. 
of SASP. Some patients also used other drugs (e.g. cholestyramine) 
in addition to SASP. It was therefore investigated to which extent 
such factors might influence the splitting of SASP and/or the 
absorption of the split products. 
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5.2 The influence of the intestinal transit time and the inflam-
matory activity iji the colon 
5 . 2 . 1 ^n^ rod j j c j n on 
Controlled trials have established the value of SASP in mild and 
moderately active colitis (Baron et al, 1962, Dick et al, 1964) and 
in maintenance therapy to prevent recurrence of the disease 
(Misiewicz et al, 1965; Dissanayake and Truelove, 1 9 7 3 ) . However, 
in severe inflammation which is virtually always attended with 
profuse diarrhoea, the effect of SASP is much less clear. 
SASP is particularly effective in the treatment of inflammatory 
disease of the large bowel, thus at the site of splitting. This sug-
gests that not SASP but one of the split products might be the ac-
tive component. The question should therefore be raised whether 
SASP's limited effectiveness in patients with severe colitis might 
be due to a reduced splitting of SASP as a result of a rapid passage 
through the colon. 
Results from a preliminary study indicated that the intestinal 
transit time did indeed influence the metabolism of SASP. Fig 5.2 
shows the results of a study involving 11 healthy volunteers in 
whom the serum SP level was determined after administration of 4.5 g 
SASP per day for 7 days, both during normal intestinal transit and 
following administration of a laxative (bisacodyl) which produced a 
defaecation frequency of 3-5 times a day. Six test subjects used 
enteric coated tablets and 5 were given SASP in powder form. In all 
the subjects, the serum SP level was considerably lower during 
accelerated intestinal transit. 
From those findings it wasn't in fact clear whether the change 
in serum SP level was caused by decreased splitting of SASP or by 
decreased absorption of the split products. To obtain a clearer 
picture of this, the recovery in urine and faeces of SASP and its 
metabolites in healthy subjects was measured following administra-
tion of a single dose of SASP during normal and accelerated intes-
ti nal transit. 
In patients with colitis not only the intestinal transit time 
may vary but also the activity of inflammation in the colon. 
Therefore the influence of the inflammatory activity on the meta-
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bolism of SASP was studied in patients with ulcerative colitis 
or Crohn's colitis. 
SASP ingested as 
enteric coated tablets 
SP • ac-SP(>j,g/ml)-
8 0 T 
6 0 -
SASP ingested in 
powder form 
•SP* ac-SP(^g/ml) 
40-
20-
0-1x 3-5x 0-1x 3-5x 
bowel movements/day 
Fig. 5.2 The influence of the intestinal transit time on the 
serum ievel of SP+ac-SP in healthy volunteers inges­
ting a maintenance dose of 4.5 g SASP. Statistical 
analysis (Student's t test) showed a significant de­
crease in serum SP+ac-SP level, both during ingestion 
of SASP as enteric coated tablets and in powder form 
(P <0.05) 
5.2.2 1 е1^_5ub¿e£t£ und me_thod£ 
The influence of the intestinal transit time on the splitting 
of SASP was investigated in 7 healthy male volunteers who were not 
taking any drugs. The trial schedule was as follows. At 9 A.M. on 
day 1, after having fasted for 12 hours, the subjects were given 
a single dose of 3 g SASP in power form together with a 
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standardized breakfast and 5uCi CrClg.At 1 P.M. a standardized 
lunch was given. Except water and tea no other foodstuffs were 
allowed until 6 P . M . on the first day. From 9 A.M. on day 1, 24-
hour urine was collected for 4 days. During the same period every 
stool was deposited directly in a pot containing a 0.2 % H g C K " 
solution. By shaking well, the faeces were mixed with the fluid. 
The time and frequency of defaecation was carefully noted. During 
this period, all the subjects had solid stools with a frequency 
of once every two days to twice daily. 
After a pause of at least one week, the experiment was repeated 
during accelerated intestinal transit. Accelerated passage was 
/ D ) 
induced with the aid of bisacodyl (Dulcolax^ ', 3-6 tablets 
daily). This laxative was chosen because the effect is exerted 
mainly on the colon (Fingi, 1973). During this period all the 
subjects produced 4 or more watery stools per day. 
The intestinal transit time was determined by measuring the radio-
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activity of Cr in each faeces sample. In this way it was possi­
ble to check at the same time whether all the faeces had in fact 
been collected during 4 days. The intestinal transit time was 
defined as the time between intake of С г С Ц and the moment when 
51 
at least 90 % of the Cr was excreted in the stools. 
After measuring the intestinal transit time, the faeces of 4 days 
were pooled and homogenized. The recovery of SASP, total SP (free 
SP + metabolites) and 5-ASA (total amount of 5-ASA and ac-5-ASA) 
in urine and faeces was determined. 
In order to investigate whether the inflammatory activity of 
the colon might influence the metabolism of SASP,serum levels of 
SASP and SP+ac-SP were determined in 18 patients with inflammatory 
disease of the colon,taking a maintenance dose of б g SASP per 
day, during both active and quiescent phases of the disease. In 
9 patients the stool frequency and consistency remained unchanged 
during both periods: 2.6 + 1.2 (mean + SD) soft or solid stools 
per day. These were primarily patients with Crohn's colitis. Nine 
other patients had more severe diarrhoea (watery or soft stools 
4.8 + 2.4 times per day) in the active phase of the disease, and 
virtually normal defaecation (soft or solid stools 2.0 + 0.9 
times a day) during a remission. 
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In order to investigate the possible effects of bisacodyl on 
azo reduction of SASP the following in vitro study was carried out. 
Immediately after defaecation faeces of a healthy subject was 
homogenized and diluted 10 times, partly with a 0.9 % NaCl solu­
tion and partly with a bisacodyl solution (5 mg = 1 tablet in 
50 ml 0.9 % Na C l ) . pH was adjusted to 7.5 by adding 0.02 mol 
veronal buffer. Then SASP was added up to a concentration of 
100 ug/ml faecal suspension. One ml aliquots of these faecal 
suspensions were incubated at 37 С One ml 0.2 % HgClp solution 
was added to 1 ml suspension (to stop the azo reduction of SASP) 
at 0, 10, 30, 60, 120, 180 and 240 minutes after incubation. In 
each faeces sample the concentration of SP was determined. In 
this way the reduction rate of the azo bond of SASP could be deter­
mined both in a faeces suspension without and with bisacodyl. 
In order to study whether the faecal flora of patients with 
severe colitis was capable of reducing SASP at similar rates, 
the faecal concentrations of SASP and SP were determined at dif­
ferent times after defaecation in a patient with active colitis 
and severe diarrhoea (6-8 watery stools per day) using a mainte­
nance dose of 6 g SASP per day. Immediately after defaecation 
the faeces was homogenized and diluted (3 times) as described 
above. One ml aliquots of the faecal suspension were made. 
One ml 0.2 % НдСІ2 solution was added to 1 ml samóles immediate-
ly after defaecation and after incubation at 37 С for 0.5, 1, 
2, 3, 4 and 21 hours. In each faeces sample the concentrations of 
SASP and SP were determined. 
5.2.3 Results 
In the 7 healthy subjects, the total recoveries in urine and 
faeces of SP and 5-ASA, including those remaining in the non dis­
sociated parent compound (SASP) were 82.4 + 11.9 % (mean + SD) 
and 97.7 + 15.4% of the ingested dose, respectively. The recove­
ries of SASP, SP and 5-ASA in urine and faeces during normal and 
accelerated intestinal transit are summarized in table 5.1. In 
case of a normal intestinal transit time (35 to 93 hours) SASP 
was almost completely split in the colon. On average, only 3.2 % 
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Table 5.1 THE INFLUENCE OF THE INTESTINAL TRANSIT TIME ON THF RECOVERIES OF SASP, SP AND 
5-ASA IN URINE AND FAECES IN 7 HEALTHY SUBJECTS, AFTER A SINGLE ORAL DOSE OF 3 G SASP 
recovery (mean+SD) 
normal intestinal transit 
(35-93 hours) 
u r i n e (%) faeces (%) 
decelerated intestinal transit 
(Я-28 hours) 
urine ("i) faeces (*) 
SASP 
SP1 
5-ASA 2 
3.2+2.2 
63.1+7.6 
18.5+7.6 
0.5+ 0.6 
7.3+ 2.7 
74.7+13.4 
2.7+ 1.6 
23.3+14.5 
5.9+ 4.1 
45.4+21.3 
19.4+ 8.4 
45 äi-2b e 
1 SP plus acetylated and glucuronidated metabolites 
2 5-ASA plus ac-5-ASA 
3 percentage of the ingested dose; for SP and 5-ASA based on the molar recove« 'ti of 
SP and 5-ASA respectively, in comparison with SASP ingested. 3 g SASP c o n t a i s 
1877 mg SP and 1133 mg 5-ASA 
of the administered dose of SASP was excreted in unchanged form 
in the urine. In 3 subjects, no SASP was detectable at all in the 
faeces; in the others, minimal quantities: 0.4 - 1.5 % of the 
administered dose. SP was chiefly recovered in the urine (63.1 + 
7.6 % of the total amount of SP present in SASP) while 5-ASA was 
largely excreted with the faeces (74.7 + 13.4 % ) . During accele­
rated intestinal transit (8 to 28 hours) 45.4 + 21.3 % of the 
administered dose was recovered as intact SASP in the faeces. The 
recovery of SASP in the urine did not change. This was not to be 
expected as the absorption of SASP takes place in the pro­
ximal part of the small intestine and is therefore not influenced 
by an accelerated passage through the colon. The recovery of 
5-ASA in the faeces decreased to 45.5 + 25.8 1 during an accele­
rated passage. Although there was diminished splitting of SASP 
in the colon, the faecal SP was found to be increased (7.3 % 
during normal transit versus 19.4 % during accelerated transit. 
These findings indicate that the absorption of SP in the colon 
is reduced as a result of an accelerated transit. 
Figure 5.3, 5.4 and 5.5 show the recoveries of SASP, SP and 
5-ASA, respectively,i η urine and faeces in the individual subjects. 
Especially in subjects with a transit time of less than 16 hours, 
the azo reduction of SASP and consequently the recovery of 5-ASA 
in the faeces was substantially decreased. In 2 test subjects, 
the differences were less pronounced. In these subjects the in­
testinal transit was hardly accelerated during bisacodyl (about 
28 hou r s ) . 
In the 18 patients with ulcerative colitis or Crohn's colitis 
who were on a maintenance dose of 6 g SASP, the SASP serum levels 
did not differ significantly during active and quiescent phase of 
the disease. This applied both to patients with an unchanged de-
faecation frequency and to those whose diarrhoea had disappeared 
after a remission had been obtained (fig. 5 . 6 ) . In 2 patients, 
the serum SASP level was remarkably high (70-80 y g / m l ) . In 9 pa­
tients with unchanged stool characteristics the serum SP concen­
tration in the active phase was the same as the concentration in 
the quiescent phase of the disease. However, in 9 other patients 
who had an improvement of the diarhoeal state during a remission, 
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% ; 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
normal accelerated normal accelerated 
transit transit transit transit 
(35-93 hours) (35-93 hours) 
Fig. 5.3 The urin a r y and fa e c a ) r e c o v e r i e s of SASP In h e a l t h y 
v o l u n t e e r s after i n g e s t i o n of a si n g l e dose of 3 9 
SASP d u r i n g a normal and an a c c e l e r a t e d i n t e s t i n a l 
t r a n s i t . S t a t i s t i c a l a n a l y s i s ( W i l c o x o n s i g n e d - r a n k 
test) revealed a s i g n i f i c a n t i n c r e a s e of SASP e x c r e -
tion In the stools d u r i n g an a c c e l e r a t e d I n t e s t i n a l 
trans It (p < 0.05)· 
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"/о S 
100-
9 0 -
ео-
70-
6 0 -
50 
40 
30 
20 
10 
normal accelerated normal accelerated 
transit transit transit transit 
(35-93 hours) (35-93 hours) 
Fig. 5 · ^ The urinary and faecal r e c o v e r i e s of SP in healthy 
v o l u n t e e r s after ingestion of a si n g l e dose of 3 9 
SASP during a normal and an a c c e l e r a t e d intestinal 
transit. S t a t i s t i c a l a n a l y s i s ( W M c o x o n s i g n e d - r a n k 
test) revealed a s i g n i f i c a n t d e c r e a s e of urinary 
SP e x c r e t i o n (p < 0.05) and a s i g n i f i c a n t increase 
of SP e x c r e t i o n in the stools (p < 0.05) during an 
a c c e l e r a t e d intestinal transit. 
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Fig. 5-5 T h e ur i n a r y and faecal r e c o v e r i e s of 5-ASA in h e a l t h y 
v o l u n t e e r s a f t e r i n g e s t i o n of a s i n g l e d o s e of 3 g 
SASP d u r i n g a normal and an a c c e l e r a t e d i n t e s t i n a l 
t r a n s i t . S t a t i s t i c a l a n a l y s i s ( W l l c o x o n s l g n e d - r a n k 
t e s t ) r e v e a l e d a s i g n i f i c a n t d e c r e a s e of u r i n a r y and 
faecal e x c r e t i o n of 5"ASA d u r i n g an a c c e l e r a t e d intes­
tinal trans It (p < 0.05)· 
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SASP(>xg/ml) 
8 0 - , 
active remission active remission 
stools unchanged diarrhoea no diarrhoea 
Fig. 5·6 The r e l a t i o n b e t w e e n serum SASP l e v e l , d i s e a s e a c t i v i t y 
and stool f r e q u e n c y in p a t i e n t s w i t h i n f l a m m a t o r y 
d i s e a s e of the c o l o n using a da i l y dose of 6 g S A S P . 
S t a t i s t i c a l a n a l y s i s ( W i l c o x o n s i g n e d - r a n k test) re-
ve a l e d no s i g n i f i c a n t c h a n g e in the s e r u m SASP l e v e l , 
n e i t h e r in p a t i e n t s with u n c h a n g e d stool c h a r a c t e r i s t i c s , 
nor in p a t i e n t s w i t h i m p r o v e m e n t of the d i a r r h o e a l s t a t e 
d u r i n g rem i ss i o n . 
the serum SP levels substantially increased (fig. 5 . 7 ) . 
Bisacodyl did not influence the azo reduction of SASP. The re-
duction rate of SASP in a faecal suspension both without and with 
bisacodyl was about 0.4 mg per ml per hour. 
In the patient with active colitis, the concentrations of SASP 
and SP in the faecal suspension, immediately after defaecation 
were 1.2 mg/ml and 1.3 mg/ml respectively. The reduction rate of 
SASP was the same as in a faecal suspension of a healthy subject: 
about 0.4 mg per ml per hour. 
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20-
S P . ac-SP(>jLg/ml) 
1 0 0 n 
active remission 
stools unchanged 
active 
diarrhoea 
remission 
no diarrhoea 
Fig. 5-7 The r e l a t i o n b e t w e e n s e r u m level of 5 P + a c - S P , d i s . a s e 
a c t i v i t y and stool f r e q u e n c y in p a t i e n t s w i t h i n f l a m m a -
tory d i s e a s e of the c o l o n using a daily dose of 6 g 
S A S P . S t a t i s t i c a l a n a l y s i s -(Wilcoxon s i g n e d - r a n k t e s t ) 
r e v e a l e d no s i g n i f i c a n t c h a n g e in the s e r u m level o f 
S P + a c - S P in the p a t i e n t s w i t h u n c h a n g e d stool c h a r a c t e -
r i s t i c s d u r i n g a c t i v e d i s e a s e and d u r i n g r e m i s s i o n . In 
the p a t i e n t s w h o had an i m p r o v e m e n t of the d i a r r h o e a ! 
s t a t e d u r i n g r e m i s s i o n the s e r u m S P + a c - S P level signifi 
c a n t l y i n c r e a s e d (p < 0 . 0 1 ) . 
These results suggest that, at least in vitro, the faecal flora 
in healthy subjects and patients with severe colitis, have the 
same capacity to reduce SASP. 
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5.2.4 Di£custión 
From the studies of Baron et al, 1962 and Dick et al, 1964, it 
has been shown that SASP therapy is effective in mild and moderate 
active colitis. Since the active compound of SASP in treatment of 
inflammatory bowel disease has been suggested to be 5-ASA (Azad 
Khan et al, 1977; van Hees et al, 1978;chapter 6 ) , it is possible 
that the uneffectiveness of SASP in severe colitis (colitis with 
severe diarrhoea) is due to an accelerated intestinal transit, so 
that the opportunity of colonic bacteria to carry out the azo 
reduction of SASP is dimini shed and too little 5-ASA becomes avail-
able. In this study, we have demonstrated that an accelerated 
intestinal transit did indeed reduce the splitting of SASP in the 
large bowel. These results suggest that the intestinal transit 
time may have a key role in determining the therapeutic effect 
of the drug. It seems therefore important to study whether anti-
diarrhoeal drugs might influence the efficacy of SASP in treatment 
of patients with severe colitis. 
Das et al. (1973) determined the serum SP levels in a large 
group of patients with ulcerative colitis who were on a maintenance 
dose of SASP. They found that patients in remission had higher 
SP levels than patients with an active colitis. 
Moreover, it appeared that the serum SP level in patients with 
active colitis who had remission after administration of SASP was 
higher than in patients in whom SASP was ineffective. They conclu-
ded that "the most effective therapeutic concentration of total 
SP for the achievement of clinical remission and not associated 
with side-effects lies within the range of 20-50 ug/ml of serum". 
This suggests that SP is the active ingredient of SASP and that 
a relation exists between the effect and the serum SP level. The 
results of our study make it quite clear that the findings of 
Das et al. can also be explained in a different way. In patients 
with active colitis serum levels are low because of inadequate 
splitting of SASP as a result of diarrhoea. The serum SP level will 
rise when a remission is obtained and diarrhoea disapoears. The 
serum SP level depends on the intestinal transit time. A higher 
serum SP level is therefore not the cause but the result of a 
remi ssi on. 
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5.3 T h e influence of the dosage form of sulfasalazine 
5.3.1 introduction 
SASP is available in three forms: powder, tablets and enteric 
coated tablets. Enteric coated tablets are particularly prescri­
bed to patients who experience gastrointestinal intolerance after 
the first few doses of the drug given as plain tablets. Our clini­
cal experience is that in patients with severe diarrhoea the ente­
ric coated tablets are sometimes recovered in unchanged form in 
the faeces. Therefore a study was made to investigate to which 
extent the dosage form might influence the absorption and azo 
reduction of SASP and the absorption of the split products. The 
study was carried out in healthy volunteers and patients with 
Crohn's disease who had undergone ileocoecal resection. Some of 
these patients had moderate diarrhoea postoperatively as a result 
of an overflow of bile salts into the colon. 
5.3.2 Ieit_subjects and method^ 
Six healthy volunteers took 4.5 g SASP per day (1.5 <] at 8 A.M., 
4 P.M. and at midnight) for 2 periods of 7 days. Three subjects 
first used enteric coated tablets and subsequently powders; the 
other 3 took these in reversed order. There was a pause of at 
least 1 week between the two test periods. All the subjects had 
a normal defaecation pattern during the study and did not take 
any other drugs. At 11 A.M. on day 7, a blood sample was taken and 
24 hour urine was collected for the determination of SASP and 
metaboli tes . 
The same study was performed in 9 patients who had undergone 
ileocoecal resection. Six patients took 4.5 g SASP per day (no. 
1-6), one patient (no.7) 4 g and two (no.8 and 9) 6 g per day. 
Eight patients had mild to moderate diarrhoea: soft stools 2-3 
times a day. Patient no.9 had a defaecation frequency of 6 to 7 
times a day. In each of the patients the defaecation pattern was 
similar during both test periods. 
Finally, in б healthy volunteers the recovery of SASP, SP and 
5-ASA in urine and faeces was determined for each of the three 
107 
administration forms during accelerated intestinal transit after 
ingestion of a single dose of 3 g SASP. The intestinal transit 
51 time was measured at the same time with the aid of CrClg. The 
trial protocol used for determining the recovery of SASP and 
metabolites and for measuring the transit time was the same as 
that described in § 5.2.2. An accelerated transit was indu-
l R ) 
ced by administering bisacodyl (Dulcolax^ ' ) . The subjects tried 
to have a constant defaecation frequency of 3-4 times a day during 
the whole trial period. On day 3, 9 and 15 the subjects ingested 
3 g SASP and 5 yCi CrCl,. Thereafter urine and faeces were col-
lected for 4 days to determine the recovery of SASP and metabo-
lites and the intestinal transit time. Two subjects first used 
enteric coated tablets, then plain tablets and finally SASP in 
powder form. In two subjects the sequence was: plain tablet, 
powder and enteric coated tablet, and in two others: powder, 
enteric coated tablet and plain tablet. 
5.3.3 Resulta .and^  ^ii£cus£ion 
The results in б healthy subjects who were on a maintenance 
dose of 4.5 g SASP per day during a normal intestinal transit 
are given in fig 5.8 and fig. 5.9. The serum levels of SASP and 
SP during the use of the enteric coated tablets and SASP in 
powder form did not show significant differences. The same ap­
plied to the urinary excretion of SASP, SP (total of SP, ac-SP, 
SP-gluc and ac-SP-gluc) and 5-ASA. 
In 7 of 9 patients who had undergone ileocoecal resection, 
the serum SP level was considerably higher during the use of 
SASP in powder form. The serum SASP concentration did not differ 
significantly (Fig. 5.10). Twenty-four hour urinary excretion 
of SASP was very low (0-2 % of the administered dose) in all pa­
tients. The urinary excretion of SP and 5-ASA during the use of 
SASP in powder form was generally higher than following admini­
stration of SASP as enteric coated tablets (fig. 5.11). In one 
patient (no.4) a discrepancy was observed between the serum SP 
levels (somewhat lower during ingestion of SASP in powder form) 
and the urinary excretion of SP and 5-ASA (distinctly increased 
during ingestion of SASP in powder form). 
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5Α5Ρίμ9/ΓπΙ) SP.ac-SP(>ig/ml) 
enteric coated 
tablets 
powder enteric coated 
tablets 
powder 
Fig. 5-8 S e r u m c o n c e n t r a t i o n of SASP and S P + a c - S P in h e a l t h y 
s u b j e c t s i n g e s t i n g k.5 g SASP d a i l y as e n t e r i c c o a t e d 
t a b l e t s or in p o w d e r form. S t a t i s t i c a l a n a l y s i s ( W i l -
co x o n s i g n e d - r a n k test) r e v e a l e d no s i g n i f i c a n t c h a n g e 
in s e r u m level of SASP and S P + a c - S P d u r i n g i n g e s t i o n 
of S A S P in powder form. 
Table b.? gives the mean values of the urinary excretion of GASP, 
SP and 5-ASA (expressed in % of the administered dose) of 6 healthy 
subjects and 9 patients with ileocoecal resection. In patients 
with ileocoecal resection, the 24 hour urinary excretion 
of SP and 5-ASA during ingestion of SASP in powder form was sig­
nificantly higher than during the use of enteric coated tablets 
(p < 0.05; Student's t t e s t ) . Both during ingestion of SASP as 
enteric coated tablets and in powder form, the urinary excretion 
of SP and 5-ASA in patients with ileocoecal resection was consi­
derably lower than in healthy subjects. This might be due to an 
accelerated intestinal transit resulting in a diminished split­
ting of SASP and/or absorption of the split p r o d u c t s . However, 
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SASPC/.) SPC/.) 5-ASAC/o) 
enteric coated powder enteric coated powder enteric coated powder 
Fig. 5.9 U r i n a r y e x c r e t i o n (expressed as p e r c e n t a g e of the ad-
m i n i s t e r e d d o s e ) of SASP, SP and 5-ASA in he a l t h y v o l u n -
teers i n g e s t i n g k . 5 g SASP daily as e n t e r i c coated 
tablets and in powder form. S t a t i s t i c a l a n a l y s i s (Wil-
co x o n s i g n e d - r a n k test) revealed no s i g n i f i c a n t c h a n g e 
in u r i n a r y e x c r e t i o n of S A S P , SP and 5-ASA after inges-
tion of SASP in powder form. 
the results suggest that in patients with ileocoecal resection 
SASP given in powder form is more efficiently split than enteric 
coated tablets. 
Table 5.3 gives a summary of the results of the study involving 
6 healthy subjects in whom recovery of SASP, SP and 5-ASA in urine 
and faeces was determined with each of the three dosage forms 
during accelerated intestinal passage. In all subjects, the urina-
ry recovery of SASP was higher following intake of SASP in powder 
form than after SASP as enteric coated tablets. 
As SASP is probably active via a local effect of 5-ASA (chapter 6 ) , 
especially the recovery of SASP and 5-ASA in the faeces is impor-
tant. The influence of the administration form on the splitting 
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Table 5.2 TWENTY-FOUR HOUR URINARY EXCRETION OF SASP AND METABOLITES IN HEALTHY SUBJECTS 
AND PATIENTS WHO HAVE UNDERGONE AM ILEOCOECAL RESECTION, INGESTING A MAINTENANCE 
DOSE OF SASP AS ENTERIC COATED TABLETS AND IN POWDER FORM 
SASP enteric coated 
healthy patients with 
subjects ileocoecal 
resection 
SASP powder 
healthy patients with 
subjects ileocoecal 
resecti on 
number of 
subjects 
urinary 
excretion {%) 
of SASP 
SP 3 
5-ASA 
1.9+1.3 0.2+0.1 <0.005 
54.6+Я.9 17.3+9.8 <0.001 
14.2+6.8 6.3+3.9 <0.05 
2.6+ 1.7 
49.7+10.7 
17.0+ 7.9 
0.6+ 0.3 
29.5+18.0 
12.8+ 9.3 
<0.005 
<0.05 
η. s . 
1 percentage of the ingested dose (meanjfSD); for SP and 5-ASA based on the amount of SP and 
5-ASA, respectively, present in the ingested dose 
2 Student's t test, n.s. = not significant, ρ >0.05 
3 SP plus acetylated and glucuronidated metabolites 
Table 5.3 THE INFLUENCE OF THE ADMINISTRATION FORM OF SASP ON THE RECOVERY OF SASP, SP AND 
5-ASA IN URINE AND FAECES IN 6 HEALTHY SUBJECTS WITH AN ACCELERATED INTESTINAL 
TRANSIT AFTER A SINGLE ORAL DOSE OF 3 G SASP 
subject 
no. 
1 
2 
3 
4 
5 
6 
administration 
form of SASP 
ent. coated 
tablet 
powder 
ent. coated 
tablet 
powder 
ent. coated 
tablet 
powder 
ent. coated 
tablet 
powder 
ent. coated 
tablet 
powder 
ent. coated 
tablet pow 
powder 
intestinal 
transit time 
22h 
6(125' 
ггиіб' 
lOI^S' 
22hl0· 
9(120' 
llh30' 
29(135' 
20(120' 
IShOS' 
26h05· 
7h25' 
24h30' 
22h40' 
25h 
llh45' 
2^55' 
15h 
recovery in 
SASP 
0.5 
3.1 
8.9 
3.1 
1.9 
4.2 
1.2 
4.0 
5.0 
3.9 
4.2 
10.2 
4.0 
5.7 
19.2 
4.7 
4.9 
7.8 
m¿ 
SP1 
34.5 
30.7 
55.1 
11.8 
25.4 
24.7 
27.7 
30.3 
53.1 
38.6 
63.5 
25.8 
55.2 
36.1 
46.4 
6.7 
20.9 
42.0 
urine 
5-ASA 
6.9 
15.0 
25.7 
4.4 
7.2 
14.0 
10.1 
13.7 
12.8 
12.7 
24.3 
7.3 
14.6 
4.9 
12.1 
2.3 
11.2 
17.0 
recovery in 
SASP 
43.1 
'31.4 
3.9 
78.0 
49.9 
38.8 
38.7 
39.3 
2.8 
24.1 
5.2 
24.0 
19.4 
25.2 
15.S 
64.6 
39.5 
10.1 
(%)¿ 
SP 
15.9 
23.7 
13.3 
4.5 
10.2 
12.8 
20.2 
10.1 
16.6 
14.0 
6.6 
18.6 
4.2 
13.3 
6.9 
14.6 
8.8 
21.1 
faeces 
5-ASA 
25.4 
20.8 
42.9 
10.2 
26.5 
35.8 
26.0 
19.2 
47.7 
30.3 
43.1 
34.6 
34.9 
30.9 
35.5 
15.6 
26.8 
36.7 
total 
SP 
95.0 
89.0 
72.5 
97.4 
87.4 
80.5 
87.8 
83.7 
77.5 
80.6 
79.5 
78.6 
82.8 
80.3 
88.3 
90.6 
74.1 
81.0 
recovery 
m3 
5-ASA 
75.9 
70.3 
81.3 
95.7 
85.5 
92.8 
76.0 
76.2 
68.3 
71.0 
76.8 
76.1 
72.9 
66.7 
82.6 
87.2 
82.4 
71.6 
1 total SP (free SP + acetylated and glucuronidated metabolites) 
2 % of the ingested dose; for SP and 5-ASA based on the molar recoveries of SP and 5-ASA 
respectively, in comparison with SASP ingested 
3 recovery in urine + faeces, including SP and 5-ASA remaining in the non dissociated com-
pound (SASP) 
5Α3Ρ(μ9/ηη1)-
60-t 
SP» ас-5Р{мд/тІ) 
enteric powder enteric powder 
coated coated 
Fig. 5-10 Serum level of SASP and S P + a c - S P in patients w h o had 
u n d e r g o n e an ¡leocoecal r e s e c t i o n , ingesting a m a i n -
tenance dose of SASP as e n t e r i c coated tablets and as 
p o w d e r . Statistical a n a l y s i s (Wilcoxon s i g n e d - r a n k 
test) revealed a s i g n i f i c a n t increase of the serum 
SP+ac-SP level during ingestion of SASP in powder 
form (p < 0.05)· 
of SASP can only be assessed when the intestinal transit time 
in the individual test subject is more or less constant during 
the different dosage forms (the underlined figures in table 5.3) 
In subjects no.l, 2 and 6, the recoveries of SASP as enteric 
coated tablets and as powder are comparable. In each of these 
subjects, less unsplit SASP and more 5-ASA was recovered in the 
faeces, following intake of SASP in powder form. In patient no.4 
the recovery of SASP and 5-ASA in the faeces was about the same 
despite the fact that after ingestion of SASP in powder form 
the intestinal transit time was shorter than after intake of 
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enteric coated powder enteric coated powder enteric coated powder 
Fig. 5·11 Urinary e x c r e t i o n (expressed as p e r c e n t a g e of the ad­
m i n i s t e r e d dose) of SASP, SP and 5-ASA in patients who 
had u n d e r g o n e an ileocoecal r e s e c t i o n , ingesting a 
m a i n t e n a n c e dose of SASP as enteric coated tablets and 
as p o w d e r . Statistical analysis (Wilcoxon s i g n e d - r a n k 
test) revealed a sig n i f i c a n t increase of urinary e x c r e ­
tion of SP and 5-ASA during ingestion of SASP in powder 
form (p < 0.05)· 
enteric coated tablets (7h25' and l&h05' respectively). During 
a very rapid intestinal transit,even after ingestion of SASP in 
powder form a significant amount of unsplit SASP was excreted 
in the stools (subject no.2 and 4 ) . The results in subject no.3 
indicate that during accelerated intestinal transit, plain tablets 
are less well split than SASP in powder form. When intestinal 
transit is only slightly accelerated, the dosage form probably has 
less influence on the azo reduction of SASP. Subject no.5 is an 
example of this. During a transit time of approximately 24 hours, 
the recovery of SASP and 5-ASA in the faeces was about equal with 
each of the three dosage forms of SASP. 
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Assuming that one cf the split products is the active component 
it would seem appropriate to give patients with severe diarrhoea 
SASP in powder form. 
5.4 The influence of elemental diet 
5.4.1 ¿n t/ о d uc^ t i £n 
t R ) 
An elemental diet (for example Vivonex v ') is sometimes pre-
scribed in the treatment of patients with severe ulcerative coli-
tis or Crohn's disease (Stephens et al, 1969, Bury et al, 1971, 
Berg et al, 1972, Axelsson and Jarnum ,1977). Such a diet contains 
a mixure of all the essential and non-essential amino acids, mono-
saccharides, the necessary minerals and vitamins and essential 
fatty acids. As these components are virtually completely absor-
bed in the small intestine, the faeces production will decrease 
considerably. The exclusive use of an elemental diet for a pro-
longed period of time (10 days or more) causes quantitative 
changes in the colon flora. The number of lactobacilli and entero-
cocci is decreased (Winitz et al, 1970, Crowther et al, 1973). 
Although the number of bacteria per gram of faeces remains appro-
ximately the same, the total number of bacteria in the colon 
decreases considerably as a result of the marked reduction in 
the amount of faeces. 
Drug therapy (SASP and/or prednisone) is generally continued 
when a patient is on an elemental diet. An elemental diet might 
influence azo reduction of SASP, via modification of the colon 
flora. On the basis of theoretical considerations (marked reduc-
tion in the total number of bacteria) we assumed that splitting 
of SASP would decrease during the use of an elemental diet. 
5.4.2 Patients_and_methods 
In 5 patients on a constant maintenance dose of SASP (2-6 g per 
day) the serum levels of SASP and SP were determined during normal 
food intake and after Vivonex had been used exclusively, for at 
least 10 days. All patients were hospitalized at the time of the 
study. Table 5.4 reports the main data of these patients. Deter-
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Table 5.4 STOOL CHARACTERISTICS OF 5 PATIENTS USING A MAINTENANCE DOSE OF SASP DURING A 
NORMAL FOOD INTAKE AND DURING THE USE OF AN ELEMENTAL DIET 
patient diagnosis 
no. 
Normal food intake Vivonex 
defaecation defaecation 
dose of 
SASP frequency consistency amount frequency consistency amount 
g number/day g/day number/day g/day 
Crohn's 
col i ti s 
ulcerati ve 
colitis 
diarrhoea 
е.с. i 
M.Crohn 
i leum 
M.Crohn 
i leum 
5-6 watery-soft 150-200 2-4 soft 
watery-soft 170-230 lx per 
3 days 
soft 
8-10 watery-soft 400-550 3-5 soft 
1-2 watery 150-200 lx per 
4 days 
soft 
4.5 1-2 soft-solid 125-150 0-1 soft 
10-40 
minimal 
50-100 
minimal 
minimal 
mination of SASP and metabolites in the faeces was not possible 
because the defaecation frequency and quantity of faeces was ge­
nerally too low during the use of an elemental diet. 
$ А 8 Р ( ц д / т І ) -
100 
• ЗР-.ас-$Р(цд/тІ) 
80 
6 0 -
4 0 -
2 0 -
SASP SASP SASP 
• elemental diet 
SASP 
elemental diet 
Fig. 5-12 The in f l u e n c e of an elemental diet on the s e r u m level 
of SASP and S P + a c - S P in p a t i e n t s i n g e s t i n g a m a i n t e n a n ­
ce dose of SASP. S t a t i s t i c a l a n a l y s i s ( S t u d e n t ' s t test) 
r e v e a l e d a s i g n i f i c a n t increase of the serum S P + a c - S P 
level d u r i n g the use of an elemental diet (p < 0 . 0 5 ) · 
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5.4.3 .Res.'ul_ts^  and dìs_cus^ion 
Fig.5.12 shows the serum levels of SASP and SP (SP + ac-SP) of 
the 5 patients during normal food intake and during an elemental 
diet. The serum SASP level did not differ significantly during 
the two test periods, as could be expected. Contrary to what 
we supposed, the serum SP levels were higher during an elemen-
tal diet than during normal food intake. 
These findings show that despite a marked decrease in the total 
number of bacteria in the colon during an elemental diet SASP is 
sufficiently split. It seems justified to conclude that as a 
result of the much slower passage through the colon during an 
elemental diet azo reduction of SP is even more complete than 
during normal food intake. The administration of SASP during an 
elemental diet is therefore certainly appropriate. Considering 
the high serum SP levels attained in some patients the increased 
risk of side effects should be taken into account (chapter 7 ) . 
5.5 The influence of concomitant administration of amoxycillin 
5.5.1 ^n_trod]j cation 
SASP is split in the colon by the bacteria present there. A 
decrease in the number of bacteria might therefore influence 
the azo reduction of SASP. Peppercorn and Goldman (197E) showed 
that in rats the azo reduction of SASP decreased considerably 
after the administration of neomycin. No studies have been publi-
shed on the effect of concomitant administration of antibiotics 
on the azo reduction of SASP in man. A study of the influence of 
neomycin on the metabolism of SASP was of no practical value as 
this drug is seldom given at the same time. In patients with 
severe inflammatory bowel disease broad spectrum antibiotics 
are sometimes given (Moss et al, 1977; Moss et al, 1978) while 
SASP therapy is continued. The question should therefore be raised 
whether these antibiotics, which may cause changes in the colon 
flora,might influence the azo reduction of SASP and consequently 
the therapeutic effect. Some patients have softer stools or even 
diarrhoea when taking antibiotics. In addition to the effect of 
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antibiotics on the colon flora the splitting of SASP in these 
patients might be reduced as a result of accelerated passage 
through the colon (§ 5 . 2 ) . 
5 .5 .2 Ie¿t_sub¿ec^ts a/id methods 
In 7 healthy subjects not taking any dr u g s , the serum SASP and 
SP levels were determined after ingestion of 4.5 g SASP per day 
(1.5 g in powder form at 8 A.M., 4 P.M. and midn i g h t ) for 
7 days. The study was repeated after the subjects had 
( R1 taken amoxycillin (Clamoxyl v ', one 375 mg capsule t.i.d.) in 
addition to SASP for 7 days. During the period in which only SASP 
was taken all the test subjects had stools of normal consistency 
1-2 times a day. During the use of amoxycillin most test subjects 
had somewhat soft stools. The defaecation frequency did not differ 
signi fi cantly. 
In 4 other subjects the recovery of SASP and metabolites in 
urine and faeces was determined after ingestion of a single oral 
dose of 3 g SASP in powder form. Intestinal transit time was 
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measured at the same time with C r C l j . The trial protocol was 
the same as that described in § 5.2.2. The subjects subsequently 
recieved 375 mg Clamoxyl 3 t.i.d. for 11 days. On day 8, 3 g SASP 
51 
and C r C l 3 w a s given under the same standardized conditions as 
in the first part of the study, and recovery of SASP and metabo-
lites and intestinal transit time were determined again. 
5.5.3 Results a^nd discission 
The serum levels of SASP and SP+ac-SP in the 7 subjects who 
were on a maintenance dose of SASP without and with amoxycillin 
are given in fig. 5.13. Concomitant administration of amoxycillin 
did not influence the serum SASP level. However, in 5 of the 7 
subjects the serum level SP was distincly lower during concomitant 
administration of amoxycillin. 
From these results it was not clear whether the decrease in 
serum SP level during the use of amoxycillin was due to changes 
of the colon flora or to an accelerated passage. The findings 
of the recovery study after a single dose of SASP give a clearer 
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SASP(>ig/ml) SPtac-SP (p .g /ml ) 
SASP SASP 
• amoxycill in 
SASP SASP 
• amoxycillin 
Fig. 5·13 The influence of concomitant oral administration of 
amoxycillin (375 mg t.i.d.) on the serum level of 
SASP and SP+ac-SP in healthy subjects ingesting ^.5 g 
SASP daily. Statistical analysis (Wilcoxon signed-
rank test) revealed a significant decrease of the 
serum SP+ac-SP level during concomitant administration 
of amoxycillin (p < 0.05)· 
picture of this. The results are summarized in table 5.5. There 
were no significant differences in recovery of SASP, SP and 5-ASA 
in urine and faeces in any of the subjects before and during 
administration of amoxyci11 in. In each of the subjects the intestinal 
transit time was roughly the same during both periods. The con-
clusion seems justified that concomitant administration of amo-
xycillin does not influence the azo reduction of SASP provided 
that the intestinal transit time remains the same. 
The results in subject no.4 illustrate once again that the 
intestinal transit time has a major influence on the cleavage 
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Table 5.5 THE INFLUENCE OF CONCOMITANT ORAL ADMINISTRATION OF AMOXYCILLIN (375 MG T.I.D.) ON 
THE RECOVERIES OF SASP, SP AND 5-ASA IN URINE AND FAECES OF 4 HEALTHY VOLUNTEERS 
AFTER A SINGLE ORAL DOSE OF 3 G SASP 
subject amoxycillin intestinal recovery in urine recovery in faeces total recovery 
no. transit time ( X ) 1 (%)1 (%)2 
SASP S P J 5-ASA SASP SP 5-ASA SP 5-ASA 
1 
2 
3 
4 
without 
with 
without 
with 
wi thout 
with 
wi thout 
with 
47h20, 
54h45, 
SSl·^' 
SlhZO' 
73h45, 
4^55' 
2^40' 
г ? ! ^ ' 
5.5 
5.6 
2.3 
3.2 
5.4 
3.4 
0.9 
1.6 
70.8 
77.4 
68.2 
83.3 
56.4 
67.8 
32.3 
30.5 
25.2 
26.3 
33.3 
21.5 
35.9 
26.9 
9.0 
12.9 
0.5 
0.1 
0.4 
0 
0.7 
2 
31.1 
37.6 
6.0 
7.1 
3.9 
3.3 
2.8 
8.8 
11.4 
12.8 
68.6 
72.6 
47.7 
62.7 
57.6 
64.3 
31.4 
30.2 
82.8 
90.2 
74.8 
89.9 
63.3 
82.0 
75.9 
82.5 
99.8 
104.6 
83.7 
87.5 
99.6 
96.6 
72.4 
82.3 
1 percentage of the ingested dose, for SP and 5-ASA based on the molar recoveries of SP and 
5-ASA, respectively, 3 g SASP contains 1877 mg SP and 1133 mg 5-ASA 
2 recovery in urine + faeces, includino SP and 5-ASA remaininn in the non dissociated com­
pound (SASP) 
3 total SP (free SP + acetylated and glucuronidated metabolites) 
cf SASP. This person had a distinctly more rapid passage time than 
the others. As a result, one-third of the administered dose of 
SASP was excreted in unchanged form in the faeces. In the others, 
only minute amounts of SASP were present in the stools. 
In the 7 subjects who were on a maintenance dose of SASP the 
intestinal transit time was not measured. In 6 of the 7 persons 
the consistency of the stools changed during the use of amoxy-
cillin (changed from normal to pulpy). Although there was no 
marked increase in the defaecation frequency it is most likely 
that the reduction in the serum SP level during the use of amoxy-
cillin was caused by an accelerated intestinal passage. 
5.6. The influence of concomitant administration of cholestyramine 
5.6.1 J^roducjbi on 
In many patients with Crohn's disease resection of the affec-
ted part of the intestine is necessary because of complications 
such as stenosis or fistula (Farmer et al, 1975; Truelove and 
Peña,1976). Extensive disease or resection of the ileum damages 
the site of absorption of bile salts which then pass into the 
colon where they increase motility and interfere with water and 
electrolyte absorption, producing watery diarrhoea (Hofmann, 
1967; Meihoff and Kern, 1978). This diarrhoea can be treated by 
administration of cholestyramine, and anion-exchange resin which 
binds bile salts (Hofmann and Poley, 1969). Since the strongly 
basic quaternary ammonium exchange sites on cholestyramine re-
main ionized over the normal pH range of the gastrointestinal 
fluids, the possibility exists that cholestyramine interact with 
and thereby reduce the absorption and therapeutic effect of 
certain coadministered drugs. This has been described for warfarin, 
phenprocoumon, phenylbutazone, chlorothiazide, phénobarbital, di-
goxin and antibiotics (Gallo et al, 1965; Hahn et al, 1972; Johns 
and Bates, 1972; Kauffman and Azarhoff, 1973). 
Many patients with Crohn's disease who have undergone ileo-
coecal resection take a maintenance dose of SASP in addition to 
cholestyramine. Therefore we investigated whether cholestyramine 
might influence the metabolism of SASP. 
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An attempt was made to answer the following questions. 
1. To what extent are SASP, SP and 5-ASA bound to cholestyramine? 
2. Is the colon flora capable of splitting SASP bound to cholesty-
ami ne? 
5.6.2 Test^subjects and method^ 
Binding of SASP, SP and 5-ASA to cholestyramine was investi­
gated in vitro. Aqueous solutions of 0.1, 0.5, 1, 2, 5, 7.5 and 
10 mg SASP/ml were prepared. To 1 ml samples of these solutions 
various quantities of cholestyramine were added: 20, 25, 35 and 
50 mg. 
After shaking for 5 minutes, the SASP concentration was deter­
mined in each of these samples and in a series of samples without 
cholestyramine. Because SASP bound to cholestyramine is not 
soluble only free SASP was determined. The same experiment was 
carried out for SP and 5-ASA. As these substances are less solu­
ble only lower concentrations could be examined. For SP these 
were solutions of 0.1, 0.2, 0.5 and 1 mg/ml ; for 5-ASA solutions 
of 0.1, 0.3, 0.4 and 0.6 mg/ml. To 1 ml samples of these series 
3. 5, 10 and 25 mg cholestyramine was added. By comparing the 
concentrations of SASP, SP and 5-ASA, respectively, in these 
solutions with the concentrations in the series to which no cho­
lestyramine was added, the binding tendency of cholestyramine for 
these substances could be determined. 
To investigate the azo reduction of SASP bound to cholestyra­
mine the following in vitro experiment was carried out. Immedia­
tely after defaecation faeces of a healthy subject was diluted 
10 times (with a 0.9 % NaCl solution) and homogenized. The faecal 
suspension was divided into 3 equal parts: a, b, and c. Then a 
SASP solution was added to suspensions a and b up to a concentra­
tion of 100 yg/ml faecal suspension. A suspension with the same 
amount of SASP bound to cholestyramine was added to suspension с. 
To that purpose a SASP solution was shaken for 5 minutes with an 
excess of cholestyramine (1 mg cholestyramine to 100 uq S A S P ) . 
On the basis of the results from the first experiment it could 
be assumed that under these conditions SASP was virtually comple­
tely bound to cholestyramine. After shaking, a large number of 
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1 ml samples were taken from each of the three faecal suspensions. 
These samples were incubated at 37 С Finally, 1 ml 0.2 % H g C l ? 
solution was added (to prevent further azo reduction) to the 
samples taken from the suspensions a and с after 1, 10, 30 minu­
tes, 1, 2 hours, 3 hours and 15 minutes, 4 and 21 hours. 
To suspension b 1 ml of a 0.2 % HgCl- solution containing 1 mg 
cholestyramine was added. This was done to investigate which 
amount of the liberated SP was bound to cholestyramine. 
In each sample the SP concentration was determined. After 21 
hours of incubation, 50 yg TiCl, 15 % solution was added to a 
sample from each of the 3 series. The amount of SP present in 
these samples was used as reference value (100 % free SP, no 
unsplit SASP). Using this reference value the percentage of free 
SP (related to the total amount of SP present in 100 ug SASP) 
could be determined for each of the faeces samples. 
As the binding capacity of cholestyramine is influenced by the 
pH, all the in vitro experiments were performed at a constant pH 
of 7.5. 
The influence of cholestyramine on the metabolism of SASP in 
vivo was investigated in 4 healthy subjects. The recovery of SASP, 
SP and 5-ASA in urine and faeces was determined after ingestion 
of a single dose of 3 g SASP in powder form. The intestinal tran­
sit time was measured at the same time with CrCl,. The trial 
protocol was the same as that described in § 5.2.2. 
51 On day 1, a single oral dose of 3 g SASP and 5 uCi CrCU was taken 
and urine and faeces were collected for 4 consecutive days. From 
day 5 to 20, the subjects took 8 g cholestyramine per day: 2 g 
at breakfast and lunch and 4 g at dinner. 
51 On days 9 and 16, 3 g SASP and 5 uCi CrCl, were given again, and 
urine and faeces were collected for 4 days. Two subjects took 
2 g cholestyramine together with SASP on day 9, and on day 16 
2 g cholestyramine 2 hours after ingestion of SASP. The other 
2 test subjects did this in reverse order. 
5.6.3 R e ¿ u H £ 
The results of the binding experiments of SASP, SP and 5-ASA 
in vitro are summarized in fig. 5.14, 5.15, 5.16 and 5.17. SASP 
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Fig. 5•1^ The binding tendency of c h o l e s t y r a m i n e for SASP. To 
aqueous solutions of SASP c h o l e s t y r a m i n e was added 
(20 - 50 m g / m l ) . The c o n c e n t r a t i o n (extinction) of 
unbound SASP was m e a s u r e d . 
was found to be not completely soluble at concentrations of 7.5 
and 10 mg/ml. The extinction measured at these concentrations 
was slightly lower than could be expected according to the stand­
ard curve (fig. 5.74). The same applied to a SP concentration of 
1.0 mg/ml (fig. 5.16). 
Fig. 5.14 shows that at higher concentrations of cholestyra­
mine the amount of SASP which was bound increased.At lower con­
centrations of SASP, over 90 % of SASP was bound to cholestyra-
min. At higher SASP concentrations the binding tendency of cho­
lestyramine decreased proportionally (fig. 5.14, table 5 . 6 ) . 
This indicates that the number of binding sites on cholestyramine 
is limited. To determine the maximal binding capacity of choles­
tyramine,the SASP concentration was determined in solutions of 
0.1, 0.5, I, 2 and 3 mg SASP per ml to which 1 mg and 2 mg of 
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Table 5.6 BINDING TENDENCY OF CHOLESTYRAMINE FOR SASP, SP AND 5-ASA AT VARIOUS 
CONCENTRATIONS OF CHOLESTYRAMINE 
concentration of SASP SP 5-ASA 
cholestyramine 
(mg/ml) 2 mg/ml 5 mg/ml 7.5 mg/ml 10 mg/ml 0.1-0.5 mg/ml 0.1-0.6 mg/ml 
percentage bound to cholestyramine 
17 
20 
1° 36 23 
20 90 83 73 58 73 30 
25 
35 
50 
90 
90 
90 
90 
89 
92 
93 
85 
92 
93 
75 
89 
93 
13 
19 
Extinction 
SASP (mg/ml) 
Fig. 5-15 The maximal binding capacity of cholestyramine for 
SASP (see text , page 125) · 
cholestyramine per ml, respectively, was sdded and compared with 
the same SASP solutions to which no cholestyramine was added. 
The method used was the same as described in i 5.6.2. The results 
are given in fig. 5.15. it low concentrations of SASP the extinc-
tions measured were very low, signifying that virtually all the 
SASP was bound to cholestyramine. At higher SPSP concentrations 
the extinction measured was higher and the straight line which 
could be drawn through these points runned parallel with the 
calibration curve. This indicates that all the binding sites of 
cholestyramine were occupied. By extrapolating the parallel to 
the x-axis the maximal binding capacity of cholestyramine could 
be obtained: approximately 0.8 mg SASP per mg cholestyramine. 
The binding tendency of cholestyramine for SP and 5-ASA 
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Fig. 5.16 The binding tendency of cholestyramine for SP. To 
aqueous solutions of SP cholestyramine was added 
(3 - 25 m g / m l ) . The concentration (extinction) of 
unbound SP was measured. 
was lower than for SASP (fig. 5.16; fig. 5.17; table 5.6). As SP 
and 5-ASA are poorly soluble it was not possible to determine 
the maximal binding capacity for these substances. 
Our results (see table 5.6) are comparable with those of 
Pieniaszek and Bates (1976). After addition of cholestyramine 
(1 mg/ml) to SASP (0.8 mg/ml), SP (1.0 mg/ml) and 5-ASA (0.3 mg/ 
ml) they found a binding tendency of 95.9 %, 10.9 % and 26.5 %, 
respectively. Regarding the interpretation of our findings and of 
those of Pieniaszek and Bates, it should be emphasized that these 
data were obtained from in vitro experiments with aqueous solutions. 
In the digestive tract of man there are other substances which 
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without 
cholestyramine 
• 3 mg Chol /ml 
• 5 mg chol./ml 
• 10 mg chol /ml 
• 25 mg chol./ml 
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800 
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Fig. 5-17 The binding tendency of cholestyramine for 5-ASA. To 
aqueous solutions of 5"ASA cholestyramine was added 
(3 " 25 mg/ml). The concentration (extinction) of un­
bound 5-ASA was measured. 
can interact with cholestyramine (e.g. bile salts). The binding 
capacity of cholestyramine for SASP might be influenced by these 
substances. 
The results of the study on the azo reduction of SASP bound to 
cholestyramine in a faecal suspension are summarized in fig. 5.18. 
In suspension a (SASP 100 ug/ml ; no cholestyramine) SASP was com­
pletely split after incubation for 4 hours. The reduction rate of 
SASP bound to cholestyramine (c) was considerably reduced. After 
4 hours only 46 % of SASP was split. When incubation was continued 
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without 
Λ cholestyramine 
3mg chol,/ ml 
• 5 mg Chol./ ml 
10 mg Chol / ml 
• 2 5 m g chol /ml 
SPC/.) 
100 
8 0 
6 0 -
4 0 -
2 0 - b »-
с · -
-о wi thout cholestyramine 
-* HgCIa» cholestyramine 
-· SASP · cholestyramine 
21 
t ( h ) 
Fig. 5.18 The influence of binding of SASP to cholestyramine on 
the azo reduction of SASP in a faecal suspension con­
taining 100 yg SASP/ml. The amount of SP was measured 
and expressed as percentage of the amount present in 
100 pg SASP (see text page 129)· 
for a longer period, SASP bound to cholestyramine was split comple­
tely. Curve b (faecal suspension with 100 pg SASP/ml to which cho­
lestyramine was added together with HgClp at the end of the incuba­
tion period) followed the same path as curve a. This indicates that 
under these conditions binding of SP to cholestyramine is negligible, 
Thus the course of curve с is indeed due to reduced splitting of 
SASP and not to binding of the released SP to cholestyramine. 
The results of the study on the influence of cholestyramine on 
the metabolism of SASP in 4 healthy subjects are summarized in 
table 5.7. In 3 subjects no essential change in intestinal transit 
time occurred during the use of cholestyramine. Subject no.4 evi­
dently had an accelerated intestinal passage (11 0 5 ' ) . During 
ingestion of cholestyramine the intestinal passage was signifi-
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Table 5.7 THE INFLUENCE OF CONCOMITANT ADMINISTRATION OF CHOLESTYRAMINE (8 G PER DAY) ON THE 
RECOVERIES OF SASP, SP AND 5-ASA. IN URINE AND FAECES OF 4 HEALTHY VOLUNTEERS, AFTER 
A SINGLE ORAL DOSE OF 3 G SASP 
subject intestinal 
no. transit time 
recovery in urine 
(%) 2 
SASP SP 1 5-ASA 
recovery in faeces 
(%) 2 
SASP SP 5-ASA 
total 
SP 
recovery 
(%) 3 
5-ASA 
A 
В 
С 
A 
В 
С 
A 
В 
С 
Л 
В 
С 
ЗБИЗО' 
49(130' 
2^45' 
781*45· 
741130' 
SOILS' 
74h35' 
57h05' 
75h35' 
llh05' 
31(105' 
37(130' 
7.8 
3 . 5 
1 
1 0 . 1 
4 . 7 
2 . 5 
1.8 
1.2 
0 . 8 
1 
1.7 
1.5 
7 6 . 4 
4 7 . 7 
3 1 . 5 
6 6 . 7 
2 3 . 4 
2 1 . 4 
7 5 . 0 
3 2 . 1 
3 9 . 8 
2 1 . 6 
1 4 . 8 
2 8 . 1 
21 . 
9. 
5. 
28. 
2, 
3. 
3 1 , 
2 
6, 
10. 
1, 
2. 
.2 
.5 
.6 
.4 
.1 
.8 
.3 
.5 
.1 
.5 
.2 
.0 
0, 
11. 
20 . 
0, 
16. 
16, 
0 
14, 
6, 
41 
28, 
18, 
.2 
.7 
.2 
.4 
.1 
.6 
.6 
.7 
.0 
.5 
.0 
2 
7, 
13, 
1. 
29, 
20, 
3 
20 
15, 
2 
12, 
17, 
.2 
,5 
.6 
.6 
.6 
.4 
.3 
.6 
.3 
.7 
.3 
.8 
62, 
30, 
34. 
57, 
19 
33 
67, 
35 
31 
10 
11 
14, 
.0 
.3 
,2 
.8 
.2 
.8 
.7 
.6 
.3 
.3 
.6 
.7 
8 6 . 6 
7 0 . 4 
6 6 . 3 
7 8 . 8 
7 3 . 8 
6 0 . 9 
8 0 . 1 
6 8 . 5 
6 2 . 6 
6 6 . 3 
5 7 . 5 
6 5 . 4 
9 1 . 2 
5 5 . 0 
6 1 . 0 
9 6 . 7 
4 2 . 1 
5 6 . 7 
1 0 0 . 8 
5 3 . 9 
4 4 . 9 
6 2 . 8 
4 3 . 0 
3 6 . 2 
A = without cholestyramine; В = SASP and morning dose of cholestyramine ingested the same time; 
С = morning dose of cholestyramine 2 hours after ingestion of SASP 
1 total SP (free SP + acetylated and glucuronidated metabolites) 
2 % of the ingested dose; for SP and 5-ASA based on the molar recoveries of SP and 5-ASA, 
respectively, in comparison with SASP invested 
3 recovery in urine + faeces, including SP and 5-ASA remaining in the non dissociated compound 
(SASP) 
cantly slower (21 05' and 37 3 0 ' ) . In all the subjects the total 
recovery of SP and 5-ASA (in urine + f a e c e s ) , including those re­
maining in the non dissociated parent compound (SASP) was lower 
during the use of cholestyramine. Without cholestyramine the total 
recovery of 5-ASA was 88 + 17 % (mean + S D ) , and with cholestyra­
mine 48 + 9 1 (p < 0.05; Student's t t e s t ) . For SP the recovery 
without and with cholestyramine was 78 + 8 % and 66 + 5 %,respec­
tively (p < 0.05). This indicates that in faeces part of SASP, SP 
and 5-ASA is bound to cholestyramine (SASP or metabolites bound 
to cholestyramine are insoluble and not measured at determination). 
It made no difference whether cholestyramine was taken together 
with SASP or 2 hours later (B and С in table 5 . 7 ) . 
In subjects no.l, 2 and 3, the recovery of SASP, SP and 5-ASA in 
the urine was considerably lower during ingestion of cholestyra­
mine. The recovery of SASP and SP in the faeces was higher during 
ingestion of cholestyramine. On the contrary the recovery of 5-ASA 
in the faeces was considerably lower during the use of cholestyra-
mi ne. 
From these findings it may be concluded that the azo reduction 
of SASP and the absorption of SP decreases during the use of 
cholestyramine. This is probably due to binding to cholestyramine. 
The increased excretion of SASP and SP in the faeces during the 
use of cholestyramine indicates that, in vivo, the binding to 
cholestyramine may be partly reversible. In fact, only SASP and 
SP which is not bound to cholestyramine is measured. The low ex­
cretion of 5-ASA in the faeces during ingestion of cholestyramine 
can partly be explained by a decreased splitting of SASP. Consi­
dering the marked reduction in the total recovery of 5-ASA (in 
urine and faeces) it must be assumed that a major part of 5-ASA 
in the colon is bound to cholestyramine. 
Subject no.4 had a distinctly accelerated intestinal transit 
(11 05') without using cholestyramine. As a result, an substantial 
part of the administered dose of SASP was excreted unsplit in the 
faeces (41 %) whereas the recovery of 5-ASA was low (10 t ) . In 
take of cholestyramine resulted in a slower intestinal transit 
(31 h05' and 3 7 h 3 0 ' ) . During this period the excretion of SASP in 
the faeces was considerably lower. This might be explained by 
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increased splitting of SASP but also by binding of SASP to 
cholestyramine. Although increased excretion of 5-ASA in faeces 
was expected during a slower intestinal passage (by increased 
splitting of SASP) this was not found. Probably because part of 
5-ASA was bound to cholestyramine. 
5.6.4 Discussion 
In patients using SASP and cholestyramine the metabolism of 
SASP will be influenced by at least three factors. On the one 
hand, as a result of administration of cholestyramine, the passa-
ge through the colon may be slower and thus more SASP can be split, 
on the other hand splitting of SASP will be inhibited by choles-
tyramine. Finally, a substantial part of the split products (espe-
cially 5-ASA) will be bound to cholestyramine. It is difficult 
to predict the net effect of these factors. 
In subject no.4 a situation was present similar to patients 
with ileocoecal resection. Intestinal transit was slower after 
administration of cholestyramine. The excretion of SASP in the 
faeces decreased. Nevertheless the excretion of 5-ASA did not in-
crease. The findings in the other three subjects showed that du-
ring a normal intestinal passage the azo reduction of SASP was 
inhibited and 5-ASA was partially bound to cholestyramine resul-
ting in a marked decrease in the amount of 5-ASA excreted with 
the faeces. 
It is probable that 5-ASA is the active moiety of SASP (chapter 
6 ) . Cholestyramine may therefore have an unfavourable influence 
on the therapeutic effect of SASP. The diarrhoea in patients who 
have undergone an ileocoecal resection is often transient. When 
only a limited part of the ileum is removed, in many patients the 
defaecation pattern becomes practically normal within a few months. 
Especially in those patients using a maintenance dose of SASP it 
seems useful to investigate whether cholestyramine is in fact 
still necessary. 
5.7 The influence of total colectomy 
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5.7.1 ^rrtrod^cti o^n 
From the studies of Schröder and Campbell (1972) and Peppercorn 
and Goldman (1973) it may be concluded that in man the colon is 
the principal site of cleavage of the azo bond of SASP. Consequent-
ly, in individuals in whom the colon had been removed the split-
ting of SASP will be decreased considerably. 
To confirm this supposition the metabolism of SASP was investiga-
ted in patients both before and after colectomy. 
5.7.2 £ati ents_aηd_meth^oc[s 
In 6 patients with Crohn's colitis or ulcerative colitis, the 
serum levels of SASP and SP were determined prior to and several 
months after colectomy. In 4 patients 24-hour urinary excre­
tion of SASP, total SP and 5-ASA was also determined. In 4 pa­
tients (table 5.8 no.1-4) a panproctocolectomy was performed. 
Colectomy with ileorectal anastomosis was carried out on two pa­
tients (no.5 and 6 ) . Each patient took the same maintenance dose 
of SASP before and after colectomy. No other drugs were used. 
Blood samples were taken between 9 and 10 A.M. 
5.7.3 R e ^ u H £ and^ di s^ cu^ ss^ io^ n 
The serum levels of SASP and SP (SP+ac-SP) before and after 
colectomy are given in table 5.8; the urinary excretion of SASP, 
total SP and 5-ASA in table 5.9. The serum SASP level and 24-hour 
urinary excretion of SASP before and after colectomy did not dif­
fer significantly. Hence unsplit SASP is not absorbed from the 
colon. The serum SP level decreased after colectomy to a very low 
level. The same applied to the urinary excretion of SP and 5-ASA, 
from 36.3 to 2.2 and from 9.8 to 0.8 % of the administered dose, 
respectively. These findings illustrate that the presence of colo­
nic bacteria is essential for azo splitting. The small amounts of 
SP and 5-ASA recovered in the urine after colectomy may be derived 
from SASP split by liver azo reductases. 
In patients with an ileorectal anastomosis the urinary excretion 
of SP and 5-ASA was somewhat higher than in ileosto-
mized patients. This might be due to a slower passage and/or to 
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Table 5.8 THE SERUM LEVELS OF SASP AND SP+AC-SP IN 6 PATIENTS USING A MAINTENANCE DOSE OF 
SASP BEFORE AND AFTER COLECTOMY 
pati ent 
no. 
dose of 
SASP(g) 
SASP 
serum concentration (ng/ml ) 
SP+ac-SP SASP SP+ac-SP 
3 
4.5 
6 
3 
before panproctocolectomy 
3.1 
4.2 
55.6 
12.2 
15.3 
40.8 
31.6 
46.8 
before ileorectc.1 anastomosis 
30.4 
25.4 
40.8 
29.8 
after panproctocolectomy 
2.9 0 
2.5 0 
26.5 1.3 
10.0 0 
after ileorectal anastomosis 
29.2 
15.6 
3.8 
1.4 
Table 5.9 TWENTY-FOUR URINARY EXCRETION OF SASP, TOTAL SP AND 5-ASA IN 4 PATIENTS 
USING A MAINTENANCE DOSE OF SASP, BEFORE AND AFTER COLECTOMY 
24-hour urinary excretion (%) 
patient dose of SASP total SP 5-ASA SASP total SP 5-ASA 
no. SASP(g) 
before panproctocolectomy after panproctocolectomy 
3 6 3.0 36.6 13.8 2.8 0.7 0.6 
4 3 3.5 56.3 11.0 3.0 0.9 0.4 
before ileorectal anastomosis after ileorectal anastomosis 
5 6 2.7 38.4 6.6 2.5 6.0 1.2 
6 6 8 13.8 7.8 6.4 1.2 0.8 
mean+SD 4.3+2.5 36.3+17.4 9.8+3.2 3.8+1.8 2.2+2.5 0.8+0.3 
1 percentage of the ingested dose; for SP and 5-ASA based on the amount of SP and 5-ASA, 
respectively, present in the ingested dose 
a greater number of bacteria in the rectum and distal part of 
the small intestine in patients with an ileorectal anastomosis. 
Our results are in accordance with those of Schröder et al 
(1973) and Das et al (1974). They too found a marked decrease 
in the serum SP level and urinary excretion of SP following colec-
tomy while the serum SASP level and urinary excretion of SASP re-
mained unchanged. Both authors determined the excretion of SASP 
and SP in ileostomy fluid.About 70 of the administered dose was ex-
creted as intact SASP in the ileostomy effluents. 
Assuming that one of the split products of SASP is the active 
moiety (chapter 6 ) , it is unlikely that SASP has a therapeutic 
effect in colectomized patients. 
5.8 The influence of bacterial overgrowth in the small intestine 
5.8.1 I^ntroducti on 
SASP is widely used in the treatment of Crohn's disease. In con-
trast with ulcerative colitis, no controlled therapeutic trials 
have been published so far to confirm the efficacy of SASP in 
Crohn's disease. However, the general impression is that SASP has 
a beneficial effect in a considerable number of patients (Lennard-
Jones,1970, Nugent,1971; Goldstein et al, 1975; van Tongeren and 
Eekhout,1976) . 
SASP is split into SP and 5-ASA by colonic bacteria. One may won-
der in which way SASP can be effective in Crohn's disease of the 
small bowel. Under normal conditions the number of bacteria in the 
small intestine is small. Hence, the splitting of SASP will be 
negligible. In Crohn's disease of the small intestine there is 
often a marked increase in the number of bacteria at the site of 
inflammation as a result of stasis of intestinal fluid due to in-
filtration or stenosis of the intestinal wall. 
Our hypothesis is that in Crohn's disease of the small intes-
tine SASP may be active thanks to this bacterial overgrowth whereby 
sufficient SASP can be split at the site of inflammation 
The study described below was carried out to investigate whether 
splitting of SASP really occurs in case of bacterial overgrowth 
in the small intestine. 
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5.8.2 Ie^t_sub¿e£t£ ап^ met^hods^ 
As far as the small intestine is concerned, Crohn's disease 
is usually localized in the distal part of it. To demonstrate 
splitting of SASP in this part of the small intestine is difficult 
because of its localization close to the colon. It is not possible 
to differentiate between splitting of SASP in the distal part of 
the small bowel and in the colon. Therefore, the azo reduction of 
SASP in the small intestine was studied in a patient with bacte­
rial overgrowth in the proximal part of the small bowel. The pa­
tient was a 67-year old man with chronic idiopathic intestinal 
pseudo-obstruction. This is a chronic illness characterized by 
atonia and gross dilatation of parts of the small intestine and 
sometimes the colon (Maldonado et al, 1 9 7 0 ) . This may re­
sult in accumulation of small intestinal fluid with subsequent 
bacterial overgrowth. 
In our patient the disease was localized in the oesophagus, pro­
ximal part of the small intestine and the colon. Bacteriological 
studies of jejunal fluid revealed an anaerobic count of 10 per 
ml and an aerobic count over 10 per ml. At 8 A.M., after fasting 
for 12 hours, the patient ingested a single oral dose of 3 g SASP 
together with a standard breakfast. At 1 P.M. a standard lunch was 
given. No other food was allowed until 6 P.M. From 8 A.M. to 
11 P.M. urine was collected every 30 minutes if possible or at 
least every hour. To guarantee a sufficiently high urine produc­
tion the patient drank about 200 ml of water or tea every hour. 
Three hours after intake of SASP the patient ingested 50 ml Mixo-
bar (barium m e a l ) . Subsequently, the patient was x-rayed at regu­
lar intervals to establish when the contrast medium reached the 
coecum. In this way the transit time from the mouth to the coecum 
could be determined. The barium meal was not given until 3 hours 
after intake of SASP to prevent interference with azo reduction of 
SASP and absorption of SASP and split products. 
The same study (except cultures from small intestinal fluid) was 
carried out in two healthy male subjects. 
In each portion of urine, the excretion of total SP determined 
and expressed in yg SP per minute. 
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5.8.3 Results of discussion 
The results are summarized in fig. 5.19. De arrows in the fi­
gure indicate the transit time from mouth to coecum. In the two 
healthy subjects this transit time was 4 hours and 45 minutes 
and 5 hours and 15 minutes, respectively. Before the coecum was 
reached only a minimal amount of SP was excreted in the urine. 
After reaching the coecum, a marked increase in SP excretion occur­
red within a few hours. 
unnary excretion rate of SP 
(дд/тіп) 
1000 
8 0 0 
6 0 0 
400-
2 0 0 
Ί ι ι ' ' I 
10 15(h) 15(h) 5 Ю (h) 
after ingestion of 3g SASP 
Fig. 5-19 The i n f l u e n c e of b a c t e r i a ) o v e r g r o w t h in the small 
i n t e s t i n e on azo r e d u c t i o n of S A S P . T h e u r i n a r y e x ­
c r e t i o n rate of SP w a s d e t e r m i n e d a f t e r i n g e s t i o n of 
a s i n g l e d o s e of 3 g SASP in a p a t i e n t w i t h b a c t e r i a l 
o v e r g r o w t h in the small bowel (l) and 2 h e a l t h y s u b ­
j e c t s (2 and 3)· T h e a r r o w s i n d i c a t e the trans i t time 
from m o u t h to c o e c u m . 
!n the patient with idiopathic intestinal pseudo-obstruction and 
bacterial overgrowth in the small intestine, the transit time 
from the mouth to the coecum was much longer: about 9 hours. 
During the first 9 hours after intake of SASP, thus in the period 
in which it could be assumed that the SASP was still present in 
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the small intestine, a considerable amount of SP was already ex-
creted in the urine. After the coecum had been reached there was 
a further increase in SP excretion but this was less marked than 
in the healthy subjects. This was probably due to the fact that 
as a result of the slow passage through the small intestine the 
supply of SASP to the colon was more gradual and, moreover, part 
of the SASP had already been split before the colon was reached. 
The findings of this study suggest that under normal condi-
tions virtually no SASP is split in the small intestine. When 
there is an increase in the number of bacteria, SASP may be split 
in the small intestine. In Crohn's disease of the small intestine 
SASP might be effective thanks to bacterial overgrowth which is 
often present. 
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Chapter 6 
THE EFFECT OF SULFAPYRIDINE, 5-AMINOSALICYLIС ACID AND PLACEBO 
IN PATIENTS WITH IDIOPATHIC PROCTITIS. A STUDY TO DETERMINE THE 
ACTIVE THERAPEUTIC MOIETY OF SULFASALAZINE. 
6.1 Introduction 
SASP has been widely used in the treatment of ulcerative 
colitis and Crohn's disease. Several controlled trials have 
established the value of SASP in mild and moderate active 
ulcerative colitis (Baron et al, 1962; Dick et al, 1964) and 
in maintenance therapy to prevent recurrence of the disease 
(Misiewicz et al, 1965; Dissanayake and Truelove, 19 7 3 ) . Its 
value in Crohn's disease has not been ascertained as yet. 
SASP is composed of SP in azo linkaqe with 5-ASA. After an 
oral dose of SASP in man, only a small fraction has been found 
to be absorbed in the small bowel. The greater part of the 
drug reaches the colon and is almost completely split at the 
diazo bond by bacterial azo reductases into SP and 5-ASA 
(Schröder and Campbell, 1972; Peppercorn and Goldman, 1973). 
SP is then mostly absorbed and subsequently partially metaboli-
zed in the liver (acetylation and glucuronidation) before 
excretion in the urine. The 5-ASA moiety is largely recovered 
in the faeces and only a small portion is found in the urine 
as acetylated form (chapter 4; van Hees et al, 1 9 7 9 ) . 
The mode of action of SASP is still unknown. As SASP is 
particularly effective in the treatment of inflammatory disease 
of the large bowel, it has been suggested that one of the meta-
bolites, rather than SASP itself, is responsible for the drug's 
activity at the site of breakdown. 
The present study was devised in order to determine the 
active therapeutic moiety of SASP. Since SP and 5-ASA are 
almost completely absorbed in the small intestine (Schröder 
and Campbell, 1972) it is not possible to study the effect of 
these compounds after oral administration in patients with 
ulcerative colitis or Crohn's disease. Therefore we investigated 
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the effect of rectally administered SP, 5-ASA and a placebo in 
patients with idiopathic proctitis. Rectal administration of 
SASP was felt to be inappropriate as splitting of SASP also 
occurs in the rectum. 
6.2 Patients and methods 
Idiopathic proctitis is defined as an inflammatory condition 
of the rectal mucosa for which no specific cause can be found, 
with on sigmoidoscopy a clear upper limit beyond which the mu­
cosa appears normal and an apparently normal colon on barium 
enema x-ray examination. 
All patients, seen at the out-patient department from November 
1976 to November 1978, who fulfilled these criteria were included 
in the trial. Patients who had used some form of therapy (rectal 
or orally) during the previous month were excluded. Investiga­
tions, besides sigmoidoscopy and barium enema, included labora­
tory tests (haemoglobin, ESR, leukocytes and serum albumin) and 
culture of the stools. 
All patients experienced rectal bleeding which was not im­
proving spontaneously and an active inflammation of the rectal 
mucosa was seen on sigmoidoscopy. There were no systemic mani­
festations of inflammation. 
The sigmoidoscopic appearances before and after treatment were 
graded according to a modified scheme of Baron et al (1964). 
Grade 0: normal mucosa 
Grade 1: mild proctitis. Hyperaemic, friable mucosa with loss 
of the normal vascular pattern. No spontaneous bleeding, no pus, 
no ulcers. 
Grade 2: moderately severe proctitis. Hyperaemic, friable mucosa 
with loss of normal vascular pattern and spontaneous bleeding. 
Small amounts of mucus and/or pus. No ulcers. 
Grade 3: severe proctitis. Severely haemorrhagic mucosa. Ulcers 
and/or an excess of mucus and/or pus. 
The patients found suitable for the trial were randomly 
divided into the following 3 therapy groups: placebo (2.75 g 
Estarine В suppositories = Adeps Solidus D A B ) ; 5-ASA su p p o s i -
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t o n e s (200 mg 5-ASA in 2.75 g E s t a r m e В) and SP (300 mg in 
2.75 g E s t a n n e В ) . It was decided to use 200 mg 5-ASA and 300 
mg SP per suppository as these substances are present in about 
the same quantities in 0.5 g SASP. The study was conducted as 
a double-blind trial. The patients used one suppository twice 
daily for 4 weeks. They were examined after 2 and 4 weeks as out­
patients. In addition, 24-hour urine was collected for SP and 
5-ASA determination to check drug intake. These determinations 
were made after the end of the trial. Sigmoidoscopiс examina­
tions were p e r f o m e d before and at the end of the trial period. 
All out-patient examinations and sigmoidoscopies were done by 
the same person (author). 
At the end of the trial period, after sigmoidoscopy was done, 
the patients were asked to indicate their clinical progress by 
choosing one of the following words: no symptoms, distinct im­
provement, unchanged or worsened. 
The treatment was rated as successful if there was a complete 
disappearance of clinical symptoms and a normal rectal mucosa at 
sigmoidoscopy. 
Forty-five patients took part in the trial. Twenty-one pa­
tients were included once and 12 patients twice (due to relapse 
of proctitis). Each therapy group contained 15 patients. Table 
6.1 shows that the 3 groups were comparable in age, first attack 
or relapse and duration of symptoms. The groups were not compa­
rable vith respect to sex distribution. In the 5-ASA group there 
were no patients with grade 1 and more patients with grade 3 
proctiti s . 
The results were analysed with the aid of the χ - and sign 
test. 
6. 3 Results 
Table 6.2 shows the change in patients' symptoms and table 
6.3 the change in the sigmoidoscopic appearances after treatment 
for 4 weeks. All patients who had a normal rectal mucosa at sig­
moidoscopy were free of symptoms also, so that the effect of 
therapy in these patients could be rated as successful (table 6 . 4 ) . 
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Table 6.1 CLINICAL DETAILS OF THE PATIENTS WITH IDIOPATHIC PROCTITIS,INCLUDED IN THE TRIAL 
AND COMPARABILITY OF THE TREATMENT GROUPS 
5-ASA 
type of suppository 
SP 
grade 1 = mild proctitis 
grade 2 = moderately severe proctitis 
grade 3 = severe proctitis 
pi acebo 
-Ρ» 
•с* 
number of patients 
mean age (years) 
sex: 
male 
female 
condi tion: 
first attack 
relapse 
duration of symptoms 
before therapy (months) 
extent of inflammation 
before therapy (cm) 
sigmoidoscopiс appearance 
grade 1 
grade 2 
grade 3 
15 
34(20-51) 
2 
13 
2 
13 
2.7(0.5-12) 
12.0(7-20) 
0 
9 
6 
15 
36( 
8 
7 
2 
13 
3. 
12. 
3 
8 
4 
22-: 
2(0 
3(6 
55) 
.5-16) 
-18) 
15 
39(20-54) 
10 
5 
1 
14 
2.5(0.5-6) 
11.0(5-15) 
2 
10 
3 
Table 6.2 CLINICAL PROGRESS AFTER TREATMENT FOR 4 WEEKS 
type of suppository 
5-ASA SP placebo 
no. of patients 
no symptoms 
improved 
unchanged 
worsened 
15 
9 
1 
4 
1 
15 
2 
1 
9 
3 
15 
4 
0 
7 
4 
Table 6.3 SIGMOIDOSCOPIС APPEARANCE AFTER TREATMENT FOR 4 WEEKS 
type of supposi tory 
5-ASA SP placebo 
no. of patients 
normal 
improved 
unchanged 
worsened 
15 
9 
2 
4 
0 
15 
2 
2 
9 
2 
15 
4 
1 
8 
2 
Table 6.4 THE RESULTS OF TREATMENT WITH 5-ASA, SP AND PLACEBO 
t y p e o f no. of no. in % in s i g n i f i c a n c e o f 
suppository patients remission remission differences 
5-ASA 
SP 
pi acebo 
15 
15 
15 
9 
2 
4 
60 
13.3 
26.7 
7.θ; DF = 2 
0.020 
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Of the 9 patients in the 5-ASA group who had a remission, 8 had 
moderately severe proctitis and only 1 severe proctitis. Of the 
patients in the other therapy groups who had a remission there 
was also only 1 patient with severe proctitis. 
In 2 patients in whom administration of 5-ASA suppositories 
was ineffective, ulcerative colitis developed a few weeks later. 
One of these patients underwent a total colectomy because of 
failure of medical therapy. In a third patient both sigmoidoscopy 
and barium enema examination showed extension of the inflammation 
into the sigmoid after 4 weeks 5-ASA therapy. 
The change in the sigmoidoscopic appearances in 12 patients 
who were included twice in the trial, are summarized in table 6.5, 
Table 6.5 CHANGE IN SIGMOIDOSCOPIC APPEARANCE IN 12 PATIENTS WHO 
WERE INCLUDED TWICE IN THE TRIAL 
type of suppository 
sigmoidoscopic appearance 
5-ASA SP placebo 
P. iti en 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
t 
2 + 0 
2 -> 0 
2 ->- 0 
2 •+ 0 
2 - 0 
2 + 0 
2 + 0 
2 + 0 
3 + 2 
2 + 2 
1 + 2 
2 + 2 
2 + 0 
3 + 2 
2 + 1 
2 + 1 
2 + 2 
2 + 2 
2 + 3 
2 + 1 
2 + 2 
2 + 2 
2 + 1 
2 + 2 
0 = normal rectal mucosa; 1 = mild; 2 = moderately severe; 3 
severe proctitis; before + after therapy for 4 weeks 
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Patients with a normal rectal mucosa at the end of the trial 
period were free of symptoms also. In 9 patients the type of 
therapy differed durinq the 2 periods of active proctitis. These 
patients could therefore serve as their own controls. These 
results also favour the 5-ASA suppositories (sign test: ρ <0.05) 
In all the patients in the SP and 5-ASA group, SP and 5-ASA 
were demonstrable in the urine,respectively. After 4 weeks 
therapy, SP excretion in 24 hour urine ranged from 47 to 181 mg 
(mean + SD: 110 + 55 m g ) . In patients on 5-ASA therapy, the 5-ASA 
excretion ranged from 28 to 204 mg (mean + SD: 93 + 59 m g ) . No 
SASP, SP or 5-ASA was demonstrable in the urine of the patients 
in the placebo group. 
6.4 Discussion 
The results of this study strongly suggest that 5-ASA is the 
therapeutically active moiety of SASP. SP was no more effective 
than a placebo. 
Idiopathic proctitis is generally considered to be the same 
disease as ulcerative colitis which is localized to the rectum 
(Truelove, 1959; Lennard-Jones et al, 1962; Sparberg et al, 1966; 
Farmer and Brown, 1966; Folley, 1970). After oral administration, 
SASP is almost completely split into SP and 5-ASA by colonic bac­
teria. It may therefore be assumed that in ulcerative colitis too, 
SASP is active due to a local effect of 5-ASA. 
Our findings accord with those of Azad Khan et al (1977). These 
authors investigated the effect of locally administered SASP, SP 
and 5-ASA in 47 patients with mild to moderately severe ulcerative 
colitis and in 15 patients who were in clinical remission but 
whose colons were found to be inflamed at sigmoidoscopy. The pa­
tients used one retention enema every night for 2 weeks, contai­
ning 2 g SASP, 1.3 g SP or 0.7 g 5-ASA. Fifty-four of the 62 pa­
tients were already on oral maintenance therapy with 2 g SASP 
daily. This treatment was continued during the trial. After ad­
ministration of SASP and 5-ASA, improvement was observed in about 
70% of the patients, both with respect to clinical symptoms and 
sigmoidoscopic appearance. For SP this was 38%. Pronounced his­
tological improvement was observed in approximately 30% of the 
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patients receiving SASP or 5-ASA and in only 5% of those recei-
ving SP. 
An objection to the study of Azad Khan et al (1977) is that the 
majority of patients continued to take an oral maintenance dose of 
SASP during the trial . 
The use of SASP is not infrequently limited by the appearance 
of side-effects which are almost all attributable to the SP 
moiety. Now that it appears that 5-ASA is the active moiety 
of SASP and SP functions as a carrier to ensure sufficiently 
high concentrations of 5-ASA in the colon, it would be of great 
value to synthesize a new compound whereby SP is replaced by a 
less toxic (preferably inert) carrier. The advantage of such a 
medicine would be that higher doses can be administered (only a 
small fraction of 5-ASA is absorbed from the colon) with the 
possibility of better therapeutic results than those with SASP, 
but with less side-effects as a result of the absence of SP.Furthermore, 
time has come to investigate 5-ASA's pharmacodynamic characte-
ristics and its mode of action in patients with inflammatory bowel 
disease. 
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Chapter 7 
ADVERSE REACTIONS PURING SULFASALf/1NF THEi'APY 
7 l Gen eral symptoms 
7.1.1 introduction 
Since the introduction in 1 9 л 2 , various side-effects have been 
reported durino SASP therapy (&2 4) The most common complaints 
are nausea, vomitino, epigastric discomfort, anorexia, and gene­
ral malaise. The incidence of adverse reactions varied in reports 
from 9 to 60°/ (Collins, 19 6 4 ) . It is often difficult to compare 
the various studies because of differences in patient popula­
tion (in-patients or out-patients, patients with active inflamma­
tion or in remission) and in the dose of SASP administered. 
Schroder and Evans (1972)and Das et al (1973) found that most 
of the toxic symptoms of SASP could be related to high serun 
concentrations of ST. 
During the last 4 years we reoularly determined serum levels 
of SASP and SP in almost all of our patients with inflammatory 
bowel disease who were using SASP. This enabled us to investigate 
in a large group of patients the incidence and nature of side-
effects and their relation to the serum levels of SASP and SP 
7 . 1 . 2 Pat ients_and_niethoc[s 
The study had a retrospective character. In all the patients 
with Crohn's disease or ulcerative colitis who were seen as in­
patients or out-patients between 1 1.74 and 1 10 78 it was 
checked whether they were using or had used SAS" All patieits 
in whom the serum level of SASP and SP had been determined at 
least once within 3 months after the start of SASP therapy or 
after an increase in the dose were included in the study. The 
total number of patients was 212 In each of these patients it 
was checked whether on the dates on which serun levels of SASP 
or SP were determined, side-effects were reported which could 
have ensued from the use of SASP. Only those complaints which 
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disappeared after S/^SP was stopped (usually temporarily) or re-
duced in dosage, were considered side-effects of SÍSP. 
In all patients the acetylator phenotype was determined. In 11 
patients administration of SASP was stopped within a few days 
after start of the therapy because of serious complaints. In 
these patients serum levels of SASP and SP were not available. 
7.1.3 Res^u^ts 
The entire group comprised 223 patients. The dosage of SASP 
ranged from 3-6 g per day. Forty-six patients (20.6%) reported 
adverse symptoms during SASP therapy. In most of the patients 
side-effects occurred in the first few weeks of therapy or fol-
lowing a recent increase in the dosage of SASP. Three patients 
reported adverse effects not until 6-8 weeks after the start of 
SASP therapy. These patients initially had severe diarrhoea and 
a low serum SP level despite 6 g SASP per day. The complaints 
developed after diarrhoea had ceased and the serum SP levels had 
risen considerably. Fleven patients were nauseated by the first 
few doses of SASP therapy. In 6 of these patients the symptoms 
disappeared after SASP had been administered as enteric coated 
tablets. In the other 5 patients enteric coated tablets did not 
relieve the symptoms and SASP therapy had to be stopped. In all 
the other patients the adverse effects could be overcome by tem-
porarily stopping or reduction of the dosage (3-4 g per d a y ) . 
The nature and incidence of subjective complaints are presented 
in fig 7.1. Nausea was the most frequent symptom ( 1 5 . 2 % ) . Twenty-
one patients had more than one side-effect. Nausea was in fact 
often attended with anorexia and/or vomiting. 
Table 7.1 shows the mean dose of SASP and the serum concen-
tration of SASP, free SP and SP+ac-SP in patients with and with-
out side-effects. The mean dose of SASP was significantly hioher 
in patients with side-effects. 
Thirty-two patients used a maintenance dose of 3 g SASP. None 
of them reported side-effects. Seventy-three patients took 4-4.5 
g SASP per day. Eight of them (11%) had subjective complaints. In 
the remaining group of 107 patients ingesting 6 g SASP per day, 
27 (25.2%) reported adverse reactions. 
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Nature of Incidence ot 
adverse effect adverse effect ("/«) 
О 10 ?0 
1 
N a u s e a — I M IHHMIÜI * llllilllllllllllHIIIIIllll 
Headache І Д І ІІІІ8ІІІІІІІІІИІ 
Vomiting • — 
Anorexia — 
Epigastric discomfort ИИШШ 
Dizziness Ш 
Fig. 7-1 Nature and incidence ot adverse e f feels in '23 patients 
ingesting 3"6 9 SASP per day 
Side-effects only occurred in patients with a serum SP+ac-SP level 
higher than 50 μη/ml (fin 7 . 2 ) . Generally, in these patients the 
serum level of free SP was also hiriher than 50 μπ/ιηΐ (fig 7 . 3 ) . 
Only 6 patients with side-effects had a serum level of free SP 
less than 50 ug/ml (25-48 ng/ml ) . 
Also among patients without adverse reactions serum levels of 
free SP and SP + ac-SP over 50 ul/i"! were often present. Altogether 
there were 86 patients with a serum SP+ac-SP level over 50 цд/ml 
Thirty-five of them (40.7t) had subjective complaints Twenty-
eight of 52 patients (53.8^") with a serum level of free SP higher 
than 50 yg/ml reported adverse effects. Out of 212 patients, 121 
(57.1%) were slow acetylators. However, of 35 patients with side-
effects, 28 (80%) had slow acetylator phenotypes (table 7 . 1 ) . 
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SIDE EFFECTS 
,
SP
-
ac
-
SP
 absent (μς/ηΙ) (η.177) 
Fig. 7-2 R e l a t i o n b e t w e e n s i d e - e f ­
fects and serum c o n c e n t r a ­
tion of S P + a c - S P in 2 12 
p a t i e n t s , taking 3-6 g SASP 
per day 
Fig. 7-3 R e l a t i o n b e t w e e n s i d e -
e f f e c t s and s e r u m c o n c e n ­
tration of SP in 2 12 p a -
t i e n t s , taking 3-6 g 
SASP per day 
SP 
(μς/ηηΙ) 
120 
100 
8 0 
e о 
4 0 
го 
SIDE EFFECTS 
absent present 
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Table 7.1 DOSAGE OF SASP, SEPUM CONCENTRATIONS OF SASP AND SP, 
AMD ACETYLATOP PHENOTYPE IN 177 PATIENTS WITHOUT AND 
35 PATIENTS WITH SIDE EFFECTS DURING SASP THERAPY 
patients 
without with 
side effects side effects ρ 
no. of patients 177 35 
dosane of SASPig/day)1 4.8+ J 3 5.6+ 0.8 <0.001 
serum cone. (ug/ml) 
SASP 9.6+10.6 13.3+11.6 n.s. 
free SP 29.0+18.4 63.9+19.0 <0.001 
SP+ac-SP 42.1+20.0 79.4+18.6 <0.001 
acetylator phenotype 
slow 93(52.5%) 28(80%) 
rapid 84(47.5%) 7(20%) 
1 mean+SD 
2 Student's t test. n.s. = not significant, ρ >0.05 
7.1.4 Dis^sjHon 
Our results show that subjective complaints during the use of 
3 to 6 g SASP per day are rather common (in 20.6% of the patients] 
In a few patients the complaints might be ascribed to a local 
effect of SASP on the gastric mucosa (nausea and vomiting after 
the first doses of SASP).In some of these patients the symptoms 
disappeared after administration of enteric coated tablets. In 
all but 5 patients with side-effects SASP therapy could be con­
tinued after temporary interruption or reduction of the dosage. 
There was a significant association of serum SP and SP+ac-SP 
level of more than 50 pg/ml with adverse effects. Our findings 
indicate that the side-effects that occur in patients on SASP 
therapy may be caused mainly by SP and that the acetylator pheno­
type is important in relation to the development of adverse 
reactions. 
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/Mthouqh our patients generally took high doses of S/^SP the 
incidence of side-effects compares favourably with previous re­
ports (table 7.2) . 
Table 7.2 INCIDENCE OF ADVERSE REACTIONS TO SASP 
investigators no. of dosage of incidence of sub-
patients SASP jective complaints 
(g/day) (%) 
Morrison, 1952 
Moertel and Bargen, ] 
Lennard Jones et al , 
Truelove et al, 1962 
Baron et al, 1962 
Dick et al, 1964 
L959 
1960 
Misiewicz et al, 1965 
Das et al , 1973 
this study 
52 
183 
20 
60 
20 
40 
34 
133 
223 
9 
6-8 
4 
8 
4 
4-6 
2 
1.5-8 
3-6 
18 
16 
55 
35 
40 
45 
9 
5 
20 
Only Misiewicz et al (1965) and Das et al (1972) found a consi­
derably lower percentage of subjective complaints. These patients 
usually took a lower dose of SASP. As in our study nausea was the 
most common side-effect in the reports mentioned in table 7.2. 
Only in the study by Das et al (1973) serum levels of SASP and 
SP were determined. They too found a serum level of SP+ac-SP 
higher than 50 ng/ml (63.6+16.6 мп/ті) in the majority of pa­
tients with side-effects. However, no mention was made of the 
number of patients without adverse reactions who had a serum SP 
level higher than 50 ug/ml. 
Because SASP is an important drug in the management of inflam­
matory bowel disease it is important to recognize and avoid 
side-effects during the treatment with this drug. In patients 
complaining of adverse reactions during SASP therapy it is use­
ful to determine the serum level of SP+ac-SP. When the serum 
level is higher than 50 gg/ml the dosage of SASP should be redu-
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eed. If the serum level of SP+ac-SP is lower than 50 мд/ті it 
is less probable that the complaints are caused by SASP. 
7 . 2 Haemolysis 
7.2.1 l_ntroàuctTon 
It is well known that sulfonamides, particularly sulfanilamide 
and SP may cause oxidative haemolysis of the erythrocytes (Harvey 
and Janeway, 1 9 3 7 ) . As early as 1940 Moeschlin described 7 pa-
tients with frank haemolysis associated with the use of SP. The 
erythrocytes of some of these patients contained inclusion bodies 
(Heinz b o d i e s ) . Haemolytic anaemia during SASP therapy has been 
described by some authors (Spriggs et al, 1959; Dick et al, 1964; 
Böttiger and Kesterholm, 1973; Das et al, 19 7 3 ) , but the incidence 
seems to be low. 
From our own experience haemolysis during SASP therapy was 
strikingly frequent especially when patients without frank anae-
mia were also investigated for haemolysis. The aim of the present 
study was to investigate the incidence of haemolysis during SASP 
maintenance therapy and to see whether there was a correlation 
between haemolysis and the serum level of SASP, SP and ac-SP. 
7.2 2 Patnent^andjnethoc^s 
Thirty-six unselected patients with ulcerative colitis or 
Crohn's disease taking 4.5-6 g SASP per day were studied. Eleven 
patients were seen as in-patients and 25 as out-patients At the 
time of the study the patients were taking SASP for a period 
varying from 2 weeks to more than 1 year. There were 17 males and 
19 fema 1es aged 14-65 years (mean 32.9 y e a r s ) . Four patients had 
underrone an ileocoecal resection. None of them had undergone a 
total or partial colectomy. None of the patients received other 
drugs that may cause haemolysis. In all patients liver and renal 
functions were normal. 
Besides determination of the serum level of SASP, SP and ac-SP 
the following laboratory tests were carried out in all patients: 
haemoglobin, reticulocytes, Heinz bodies, haptoglobin and LDH. 
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The acetylator phenotype was determined according to the method 
described in §4.7. 
The serum haptoglobin level, a sensitive indicator of haemolysis 
(Brus and Lewis, 1959; Nyman et al, 1959; Owen et al, 1960), was 
determined by radial immunodiffusion; normal value 1.8+0.4 g/1 
(meanj^SD). However, in папу natients with Crohn's disease or 
ulcerative colitis the serum haptoglobin level is increased due 
to the c h r o m e inflammation. A serum haptoqlobin level lower than 
0.8 g/1 was considered indicative for haemolysis. Normal values 
for haemoglobin in our laboratory were 8.7-10.9 mmol/1 for man 
and 7.9-9.8 mmol/1 for women. In healthy subjects LDH levels 
were always lower than 175 Li/1 . Reticulocytes and Heinz bodies 
were stained with brilliant cresyl blue. Sul fonamide-induced 
haemolysis may be severe in patients with glucose-6-phosphate 
dehydrogenase deficiency. However, estimations of G6PD were not 
carried out because a deficiency of this enzyme is extremely 
rare in the population native to the Netherlands. 
7.2.3 Results 
Out of 36 patients 19 showed evidence of haemolysis (serum 
haptoglobin level below Ρ 8 g / l ) . In 10 patients haptoglobin 
was not detectable at all 
The serum level of free SP was significantly higher in patients 
with haemolysis (fig 7.4, table 7 3 ) . There was no correlation 
between the serum haptoglobin level and the serum concentra­
tions of S/^SP or of ac-SP (fig 7.5 and 7 6 ) . All patients with 
a serum level of free SP more than 37 pg/ml showed evidence of 
haemolysis as compared to only 4 of 21 patients with a serum 
level of free SP below 37 ug/nl (fie 7 . 4 ) . Other parameters indi­
cating haemolysis such as reticulocyte index and serum LDH also 
showed a correlation with the serum haptoglobin level (table 7 3, 
fig 7.7 and 7 . 8 ) . The mean haemoglobin level did not differ sig­
nificantly in the two groups of patients. Four patients however, 
had evidence of haemolytic anaemia (table 7 . 4 ) . These patients 
belonged to the slow acetylator phenotype and were taking 6 g 
SASP per day for 2 to 5 weeks The serum level of free SP in these 
patients was higher than 55 pg/ml. 
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Table 7.3 RESULTS RELATED TO THE PRESENCE ΟΓ HAEMOLYSIS IN 36 PATIENTS WITH CROHN'S DISEASE 
OR ULCERATIVE COLITIS TAKING 4.5-6 G SASP PEP DAY. 
haemolysis present haemolysis absent 
serum haptoglobin <0.8 g/1 serum haptoglobin >0.8 n/l 
(mean 0.19,range 0-0.77 g/1) (mean 2.23,range 0.99-4.36 9/1) 
no. of patients 
haemoglobin (mmole/l) 
reticulocytes (0/oo) 
LDH (U/l) 
serum level of SASP (yg/ml ) 
serum level of free SP (yg/ml) 
serum level of ac-SP (ug/ml) 
serum level of SP+ac-SP (pg/ml) 
acetylator phenotype: fast 
si ow 
19 
7.7+ 1.2 
57.1+43.4 
195.0+38.8 
13.2+13.6 
53.8+24.5 
6.0+ 4.1 
59.8 + 25. 1 
1 
18 
1 
17 
8.2+ 0.8 
26.4+22.4 
141.3+38.0 
11.2+11.2 
15.9+12.3 
5.9+ 5.0 
21.8+14.3 
11 
6 
η. s . 
-0.02 
<0.001 
η. s . 
-0.001 
η. s . 
<0.001 
1 mean+ SD 
2 Student's t test. η.s. = not significant, ρ >0.05 
SP (>ig /ml) · 
100-
8 0 
6 0 
до-
го-
haptoglobin 
> 0,8 g / l 
haptoglobin 
< 0 8 g / l 
Fig. 7.'t R e l a t i o n b e t w e e n s e r u m h a p t o g l o b i n level and se r u m level 
of free SP in 36 p a t i e n t s w i t h C r o h n ' s d i s e a s e or u l c e ­
r a t i v e c o l i t i s , taking 't.5-6 g SASP per day. 
60 η 
4 0 -
20-
haptoglobin 
> 0 8 g/l 
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Fig. 7.5 R e l a t i o n b e t w e e n s e r u m h a p t o g l o b i n level and se r u m level 
of SASP in 27 p a t i e n t s w i t h C r o h n ' s d i s e a s e or u l c e r a t i v e 
c o l i t i s , taking i|.5-6 g SASP per d a y . 
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Fig. 7.6 R e l a t i o n b e t w e e n s e r u m h a p t o g l o b i n level and s e r u m 
level of a c - S P in 36 p a t i e n t s w i t h C r o h n ' s d i s e a s e or 
u l c e r a t i v e c o l i t i s taking 't.5-6 g SASP per d a y . 
SP ( μ ο / m l ) -
1 0 0 -
y = 0 36 χ . 19 97 
n= 36 
г = 0.61 
p < 0 . 0 0 1 
4 0 8 0 120 160 
R e t i c u l o c y t e s (·/..) 
Fig. 7-7 R e l a t i o n b e t w e e n r e t i c u l o c y t e c o u n t and the s e r u m con­
c e n t r a t i o n of SP in 36 p a t i e n t s w i t h C r o h n ' s d i s e a s e 
or u l c e r a t i v e c o l i t i s taking k.S-b g SASP per d a y . 
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Table 7.4 THE EFFECT OF A REDUCTION OF THE SASP DOSAGE UPON HAEMOLYSIS AND HAEMOGLOBIN LEVEL 
IN 4 PATIENTS WITH HAEMOLYTIC ANAEMIA 
patient sex 
no. 
SASP intake serum free SP haemoglobin reticulocytes LDH haptoglobin 
(g/day) (yO/ml) (mmole/1) (0/oo) (U/l) (g/1 ) 
male 
female 
female 
female 
6 
3 
6 
4.5 
6 
2 
6 
3 
92.0 
21.1 
68.2 
44.3 
80.0 
27.8 
55.2 
24.0 
7.4 
7.8 
5.7 
7.5 
7.1 
8.8 
5.8 
7.8 
73 
17 
152 
27 
150 
17 
88 
35 
224 
132 
164 
157 
330 
140 
0 
1.48 
0 
0.77 
0 
0 
0 
1.65 
SP (μς/ΓπΙ) 
100-
80 
60 
40 
20 
80 120 160 200 240 
LDH(U/I) 
F!g. 7.8 R e l a t i o n b e t w e e n s e r u m LDH and serum SP level in 30 
p a t i e n t s with C r o h n ' s d i s e a s e or u l c e r a t i v e c o l i t i s 
taking k.^-b g SASP per d a y . 
After reduction or temporary cessation of the SASP dosage the 
symptoms of haemolysis disappeared and in the patients with hae-
molytic anaemia the haemoglobin level rose to normal levels 
(table 7 .4). 
Heinz bodies in the red cells were found in 7 patients (in 1-4% 
of the erythrocytes). There was no correlation between serum SP 
level and the occurrence of Heinz bodies. The mean serum level 
of free SP in patients without Heinz bodies was 40 yg/ml (range: 
0-98 p g / m l ) . In patients with Heinz bodies the mean level was 
43 yg/ml (range: 7.9-93.2 y g / m l ) . 
7.2.4 Di£cu^s¿ion 
Haemolytic anaemia associated with the use of SASP was first 
reported by Spriggs et al (1959). They found frank haemolysis in 
two of 32 patients receiving SASP. The dosage of SASP was not men-
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* y = 043 χ-36 3b 
η = 30 
г = 0.67 
p < 0 0 0 1 
tioned Dick et al (14 64) observed h a e πι о 1 y 11 с anaemia in only 
one of 40 patients taking 4-6 η SASP por day During the period 
1966-1970 five patients with haemolytic anaemia caused by SASP 
have been reported to the Swedish Adverse Druo Reaction Committee 
(Bottiqer and Hesterholm, 1 9 7 3 ) . Das et al (1973) described hae-
molytic anaemia in 5 of 133 patients taking 1 5-8 g SASP per day. 
The serum level of total SP in these patients was higher than 
4?.5 ug/ml Miller et al (1971) described mild haemolysis without 
aiiaemia in 28/ of the patients taking 2-8 g SASP per day. Apart 
from this reiort.there are no studies about the incidence of mild 
haemolysis without anaemia during SASP therapy 
The results of our study show that there is a high incidence 
of haemolysis d u n g inoestion of 4 5-6 π SASP per day (in 53% of 
the patients) ard that this haemolysis is related to the serum 
level of free SP In most cases haemolysis is compensated for 
by an increased erythropoiesis but especially in patients with a 
serum level of free SP over 55 ug/ml there is a serious risk of 
haemolytic anaemia 
The serum level of free SP depends, apart fron the dosage of 
SASP, mainly on the acetylation rats of SP in the liver Serum 
SP levels are considprably higher in slow acetylators (about 6 0 " 
of the west-european population) than in fast acetylators (i)4.7). 
Table 7.3 shows that 1? out of 19 patients with haemolysis were 
slow acetylators whereas only 6 out of 17 patients without hae­
molysis were slow acetylators 
The incidence of haemolysis in our oroup of patients is higher 
than described in earlier reports One of the explanations may 
be that patients with increased red eel' destitiction but without 
anaemia, are not investigatPd for s m n s of haemolysis On thd 
other hand in patients with ulcerative colitis or Crohn's disease 
anaemia is often ascribed to blood loss in the faeces or chronic 
inflammation Finally it should be noted that our study was limi­
ted to patients taking a hiah maintenance dose of SASP (4 5-6 g 
per d a y ) . 
To a certain extent our findings agree with those of Pounder 
et al (1975) They found contracted red cells in 23 out of 50 pa­
tients receivinq a mean dose of 2 b q SASP per day as maintenance 
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therapy for ulcerative colitis. The results sungested that the 
observed red cell contraction was associated with mild haemolysis. 
The patients with contracted red cells had a significantly higher 
serum total SP level than those with undamaged red cells. 
This study shows that determination of the acetylator phenotype 
is important in patients receiving a high dose of SASP because 
the majority of slow acetylators taking 4.5-6 g SASP per day 
will reach serum levels of free SP that cause haemolysis. Espe­
cially in patients with serum levels of free SP over 55 pg/ml 
haemolytic anaemia frequently occurs. 
Haemolysis should therefore be considered in any patient 
with Crohn's disease or ulcerative colitis taking SASP when 
loss of blood in the faeces or chronic inflammation fail to 
account for the anaemia. 
7.3 Fol i с acid deficiency 
7.3.1 ^nt^rodi¿ct^i on 
Malabsorption of folate in patients with inflammatory disease 
of the small bowel has been reported with variable frequency 
(Hoffbrand et al, 19f8; Dotevall and Kock, 1968; Andersson et 
al, 1971; Dawson, 1 9 7 1 ) , but the incidence of megaloblastic anae-
mia due to folate deficiency seems to be rare. 
From a study of Franklin and Rosenberg (1973) it appeared that 
also patients with inflammatory disease of the colon only fre-
quently exhibit impaired folic acid absorption and that folate 
malabsorption is aggravated by SASP therapy. Folic acid defi-
ciency and megaloblastic anaemia due to SASP therapy has been 
mentioned in the literature only once (Schneider and Beeley, 
19 7 7 ) . 
However, in the last 6 years we found severe megaloblastic 
anaemia due to folic acid deficiency in 5 patients with inflam-
matory bowel disease, using SASP. In all patients SASP was (at 
least partially) responsible for the folic acid deficiency. 
In §7.3.2 the clinical histories of these patients are des-
cribed.In §7.3.3 the pathogenesis of the folic acid deficiency 
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and especially the influence of SASP on folic acid metabolism in 
our patients are discussed. 
7.3.2 Çase_re ports 
Patient no. 1, a 24-year old man (reg.no. 0812481J) was admit-
ted to the hospital in February 1972 because of severe 
anaemia. A diagnosis of Crohn's disease of the colon was made in 
1969. He was treated with SASP (3-4 g per day) and prednisone 
(5 m g / d a y ) . In October 1971 prednisone therapy was stopped and 
the dose of SASP was increased to 6 g per day. At thac time, 
haemoglobin was normal (8.7 mmole/1) .There was a history of anore-
xia since December 1971. One month before entry nausea, vomiting 
and weakness developed. 
On examination the patient was pale but appeared well. Physical 
examination was negative. 
The haemoglobin was low: 3.6 mmole/1(normal value: 8.7-10.9 
mmole/l).The reticulocyte count was 15 0/oo. Lactic dehydroge-
nase (LDH) was increased to 1000 U/l (n <175 U / l ) . The serum 
folate level was low: 1.1 nmole/l(n 6 .8-26.2nmol e/"i ) .The serum 
vitamin B12 level was 128 pmole/l(n 220-440 pmole/1 )but absorp-
tion of vit. B12 proved to be normal. Administration of vit. B12 
was not followed by a reticulocytosis of an increase in haemoglobin. 
The stained periferal blood film and the bone marrow showed mega-
loblastic changes. There were no signs of malabsorption. The biop-
sy specimens from the jejunum showed normal villi. An upper gas-
trointestinal series with small-bowel study was negative. The 
Crohn's colitis was not active. 
Inquiries revealed that the patient took an unbalanced diet for 
many years. He rarely ate meat or nreen vegetables. The folic 
acid deficiency in this patient was therefore explained by an 
inadequate intake of folic acid. After administration of folic 
acid haemoglobin returned to normal within a few weeks. 
Patient no. 2, a 27 year old man (reg.no. 0606461D) was ad-
mitted to the hospital in November 1973 because of severe 
anaemia. Twelve years previously Crohn's disease of the ileum 
was diagnosed. In 1968, 1972 and 1973 partial resections of the 
small bowel were performed because of recurrent Crohn's disease 
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and stenosis. The r e m a i m n n part of the proximal small bowel measured 
about 100 cm. Since June 1972 the patient took a maintenance 
dose of б g SÍSP per day. At that time, despite sions of malab-
sorption serum vit. B12 and folic acid levels were normal (without 
substitution). Two months before entry the haemoglobin was 7 6 
mmole/1. During the last months there were no abdominal symptoms 
and the patient passed solid or soft stools twice daily. 
On examination the patient was thin and pale. Physical exami-
nation was negative. 
The haemoqTobin was very low: 2.1 mmole/1. The reticulocyte 
count was 2 0 / o o . The white-cell count was 2000/mm 3 (n 4000-10000/ 
m m 3 ) ; the platelet count was 55000/mm 3 (n 150000-350000). The 
p e n f e r a l blood film showed megaloblastic channes. LDH was in-
creased to 3^40 U/l. The serum albumin level was 38 c/l (n 45-
55 a / 1 ) . The serum folic acid level was very low: 0.4 nmole/1. 
The serum vit. B12 level was normal. A low serum cholesterol 
level (2.2 mmole/1; η 4.7-7.3 mmole/l)and an abnormal D-xylose 
test (3 g in 5 hours urine; π >5 g) indicated mild malabsorption 
As dietary inta-ke of folates was normal, malabsorption was con­
sidered the possible cause of folic acid deficiency in this pa­
tient. He was treated with 2 units of packed cells and folic acid. 
Since that time haemoglobin has been normal during treatment with 
3 g SASP and 10 mq folic acid per day. 
Patient no. 3, a 17-year old woman (reg.no. 2904572M) was ad­
mitted to the hospital in November 1974 because of persistent 
diarrhoea. Seven months previously Crohn's disease of the proxi­
mal part of the duodenum, the distal part of the jejunum and the 
terminal ileum was diagnosed. She was treated with 6 g SASP (en­
teric coated tablets) per day. 
The haemoglobin was 6.4 mmole/1 (n 7.9-9.8 m m o l e / 1 ) . The reti­
culocyte counts were 45-73 0 / o o . The LDH was slightly increased: 
240 U/l. The serum folate level was low: 1.6 nmole/1. The Schil­
ling test revealed malabsorption of vit. B12: 7.5% Co-vit. B12 
excretion in 48-hours urine (n 1 5 - 3 5 7 ) . There were no other symp­
toms of malabsorption. A jejunal biopsy specimen showed normal 
villi. The bone marrow showed mild megaloblastic chances Crohn's 
disease was inactive (ESR: 23 mm, serum albumin: 43 g / 1 ) . 
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The patient was discharned on December 3rd 1974. The haemoolobi η 
at that time was 7.0 mmole/1. It was decided to evaluate the ef­
fect of vit. B12 administration on the haemoqlobin and to supple­
ment folic acid if necessary, fis enteric coated tablets were re­
covered in the stools, SPSP was given as plain tablets (6 g per 
d a y ) . 
The patient was readmitted on January 28 th, 3975 because of 
severe anaemia. She was well until 1 month previously, when nau­
sea, vomiting and fatique developed. There were no symptoms of 
active Crohn's disease. 
The haemoqlobin was decreased to 2.6 mmole/1. The reticulocyte 
count was only 2 0 / o o . In 68 0/oo of the erythrocytes Heinz bodies 
were present. The LDH was increased to 6440 U/l. The serum folate 
level was less than 1 nmole/1. The serum vit. B12 was normal. 
As intake of folates was normal, malabsorption due to Crohn's 
disease in the proximal part of the small bowel and SASP therapy 
were considered to be possible causes of folic acid deficiency in 
this patient.After administration of folic acid haemoglobin returned 
to normal within a few weeks.Since that time the haemoglobin has been 
normal durino treatment with 6 g SASP and 10 mg folic acid per day. 
Patient no. 4, was a 30-year old woman (reg.no. 2202472V). 
In 1971 a diagnosis of ulcerative colitis was made. She was trea­
ted with SASP (2-4 g per d a y ) . In July 1976 she was admitted to 
the hospital because of a relapse of colitis. 
The erythrocyte sedimentation rate was 40 mm per hour. The 
serum albumin level was decreased to 28 ci/1. The serum folate 
level was normal: 13.0 nmole/1. 
A barium-enema examination and a small-bowel series revealed ac­
tive Crohn's disease of the terminal ileum and colon. 
During administration of SASP (6 g per day) and prednisone her 
condition improved rapidly. 
On March 31 1977, the patient was readmitted because of severe 
anaemia. One month before entry general weakness and a burning 
sensation in mouth, anus and vulva developed. She was still ta­
king 6 о SASP and 25 mg prednisone per day. 
Physical examination revealed aphthous lesions in mouth and 
vulva There were no signs of active Crohn's disease. 
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The haemoglobin was decreased to 3.9 m m o l e / l . The r e t i c u l o c y t e 
count was 18 0 / o o . The LDH was 1088 U / l . The serum folate level, 
determined after the patient had received 2 units of blood, was 
2.1 nmole/1. The serum vit. B12 level was decreased to 110 p m o l e / 1 . 
The Schilling test(carried out after ingestion of folic acid for 
2 weeks) showed a normal absorption of vit. B12. The stained peri-
feral blood film and the bone marrow showed megaloblastic chan­
ges. There were no sinns of m a l a b s o r p t i o n . A jejunal biopsy spe­
cimen showed normal villi. Λ small bowel series revealed no ab­
normalities except for Crohn's disease in the terminal ileum. 
After administration of folic acid the haemonlobin became normal 
within a few w e e k s . As dietary deficiency could be e x c l u d e d , the 
use of SASP was considered the only possible cause of folic acid 
defι ciency. 
After discharge the patient took 6 q SASP and 10 mg folic acid 
daily. Since that time the haemoglobin has been normal. 
Patient no. 5, a 49-year old woman (reg.no. 1901292D) was ad­
mitted to the hospital at the end of December 1978 because of 
severe anaemia. A diagnosis of ulcerative colitis was made in 
1969. Since March 1977 she was on a maintenance dose of 4 g SASP 
per day. Four months before entry fatigue and general weakness 
developed. 
Physical examination was n e g a t i v e . There were no signs of 
active ulcerative colitis. 
The haemoglobin was 3.7 m m o l e / l . The reticulocyte count was 
130/oo.The LDH was increased to 3480 U/l. The serum folate level 
was low: 1.1 n m o l e / 1 . The serum vit. B12 level was normal. The 
p e n f e r a l blood film and the bone marrow showed m e g a l o b l a s t i c 
changes. There were no signs of malabsorption The biopsy s p e c i ­
mens from the jejunum showed normal villi A small bowel series 
was negative. 
During ε d m i m s t r a t i o n of folic acid the haemoglobin returned to 
normal within a few weeks. 
As dietary intake of folates was normal, the use of SASP appea­
red to be the only possible cause of folic acid deficiency in 
this patient. 
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7.3.3 The influence of sulfasalazine on folic acid metabolism 
Folate is found in a wide variety of foodstuffs. The richest 
sources are yeast, liver, fruit and green vegetables. Our food 
contains mainly folates (pteroylpolynlutamates) and only small 
quantities of folic acid (pteroylmonoglutamic a c i d ) . Since man 
is totally unable to synthetize his estimated daily requirement 
of about 50 ug per day (Herbert, 1 9 6 8 ) , he is dependent upon 
efficient digestion and absorption of folates. The normal diet 
as a rule provides more than enough folates: about 800 ug/day 
(Chanarin et al, 1968). Total body stores of folate are estima-
ted to be 5-10 mg. Severe defects in dietary intake or absorption 
and increased utilization may result in manifestations of folate 
deficiency within a few months (Herbert, 1962). 
Folate absorption occurs in the proximal small intestine. 
Pteroylpolynlutamates are deconjugated to monoglutamates by en-
zymes. This deconjugation takes place in the enterocytes (Baugh 
et al, 1 9 7 5 ) . The intracellular transport of folates probably 
occurs with the aid of carriers (Rosenberg, 1976). 
Possible causes for folate deficiency in inflammatory bowel 
disease are: inadequate dietary intake as a result of anorexia or 
dietary restrictions, increased tissue utilization as a result 
of inflammation and impaired absorption, especially in patients 
with Crohn's disease in the proximal small intestine (Cox et al, 
1958; Hoffbrand et al, 1 9 6 8 ) . 
Franklin and Rosenberg (1973) performed absorption studies of 
folic acid in patients with inflammatory bowel disease which was 
primarily defined to the large intestine. Absorption studies 
utilizing tritiated ( H-) folic acid revealed that absorption of 
folic acid was impaired in patients with ulcerative colitis and 
granulomatous colitis (fig 7 . 9 ) . Analysis of absorption studies 
performed sequentially on and off SASP indicated further reduction 
in folate absorption associated with administration of this drug. 
The dose of SASP was not mentioned. This observation was confir-
med by oral folic acid tolerance tests. Nine healthy, fasting 
volunteers were given 500 pg of folic acid. Blood samples were 
drawn 1, 2 and 3 hours after the administration of oral folate. 
The test was repeated on all 9 individuals after several days 
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rest, but the folic acid was administered 15 minutes after a 1 g 
oral dose of SASP. 
Folic acid absorption (°/·)-
100-
8 0 -
6 0 
4 0 -
2 0 -
control off on 
subjects azulfidme therapy 
l l.B.D. patients) 
Fig. 7.9 H - f o I a c e a b s o r p t i o n in p a t i e n t s w i t h i n f l a m m a t o r y 
bowel d i s e a s e w h e n t e s t e d w h i l e on a n d / o r off A z u l f i d i n e . 
Each v e r t i c a l c o l u m n r e p r e s e n t s m e a n p e r c e n t a g e of ad-
m i n i s t e r e d d o s e a b s o r b e d . Bars i n d i c a t e s t a n d a r d d e v i a t i o n . 
From F r a n k l i n JL and R o s e n b e r g IH ( 1 9 7 3 ) · I m p a i r e d f o l i c 
a c i d a b s o r p t i o n in i n f l a m m a t o r y bowel d i s e a s e : E f f e c t s 
of s a 1 icy1 a z o s u 1 f a p y r i d i ne ( A z u l f i d i n e ) . R e p r o d u c e d 
w i t h p e r m i s s i o n of the e d i t o r , W i l l i a m and W i l k i n s 
C o . , Baiti mo re. 
The results are presented in fig 7.10. The elevation in serum 
folate over fasting values at 1 and 2 hours after a 500 ug dose of 
folic acid was 20.7 and 10.6 ng/ml , respectively. This was signi-
ficantly higher than the elevation in serum folate when folic acid 
was ingested with SASP: 8 ng/ml at 1 hour and 5.7 ng/ml at 2 hours, 
Finally, Franklin and Rosenbero demonstrated by in vitro expe-
riments with everted rings of rat jejunum that the inhibitory ef-
fect was specific for SASP and not seen with its cleavage products 
SP and 5-ASA. 
Franklin and Rosenberg concluded that SASP is a competitive 
inhibitor of folate transport. A study of Selhub et al (1978) indi-
cated thatSASP interferes with folate recognition sites for en-
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zyities necessary for folate metabolism and intestinal transport. 
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Fig. 7.10 The effect of Azulfidine on folic acid absorption in 
9 norma) subjects. Each point represents the mean+SD 
of the increment in serum folate above pretest base line, 
From Franklin JL and Rosenberg IH()973). Impaired 
folic acid absorption in inflammatory bowel disease: 
Effects of sa 1 icyIazosu1 fаруr!di ne (Azulfidine). Re­
produced with permission of the editor. The William 
and Wilkins Co., Baltimore. 
We also investigated the effect of STSP on folic acid metabolism. 
In 10 healthy subjects oral folic acid tolerance tests, were per­
formed sequentially on and of SASP therapy as described by Franklin 
and Posenberg. The sera were analysed for folate by the 
method of Waters and Mollin (1961). The addition of SASP (50 ug/ 
ml); SP (50-100 Mg/ml) and ac-SP (50-100 pg/ml) , to the microbi­
ological assay system using Lactobacillus casei did not inhibit 
the growth of this organism (table 7.5). 
We could not confirm the results of Franklin and Rosenberg. In 
all the subjects the elevation in serum folate over fasting levels 
with and without ЗЛ5Р was broadly the same (fig 7.11). 
170 
Table 7.5 EFFECT OF SASP, SP AND AC-SP ON THE MICROBIOLOGICAL 
ASSAY OF FOLIC ACID (LACTOBACILLUS CASEI). 
serum equivalent of 
drug added to assay 
(yg/ml) 
fol ate 
concentration 
(nmole/1) 
serum sample 
+ SASP 
+ SP 
+ SP 
+ ac-SP 
+ ac-SP 
60 
50 
100 
50 
100 
20.7 
20.7 
17.3 
17.3 
20.7 
20.7 
Δ η mole/I serum folate 
30 
Fig. 7.11 T h e e f f e c t of SASP on folic acid a b s o r p t i o n in 10 
normal s u b j e c t s . Each point r e p r e s e n t s the m e a n + S D 
of i n c r e m e n t in s e r u m f o l a t e a b o v e p r e t e s t b a s e line. 
A factor which is not mentioned in the literature as a cause 
of folic acid deficiency during SASP therapy is chronic haemoly-
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sis. As described m Ь7.2 c h r o m e haemolysis is common in pa­
tients usinn a maintenance dose of SiSP especially in patients 
with a serum level of free SP over 37 uq/ml. During haemolysis 
utilization of folic acid is considerably increased (Chanarin 
et al, 1459; Willoughby et al, 1961, Lindenbaum and Klipstein, 
1 9 6 3 ) . 
In the case histories of the patients described in 
^7.3.2 symptoms of haemolysis were present. 
Fig 7.12 presents the main data regarding patient no. 1 This 
patient took an unbalanced diet for many years so, a deficient 
dietary folate intake could not be excluded. 
However, megaloblastic anaemia developed 3 months after the dose 
of SASÊ had been increased fron 4 to 6 g per day. This suggests 
that SASP was a contributing factor in the pathogenesis of folic 
acid deficiency. Follow-up at the out-patient department confir-
med this supposition. In February 1972 SASP was started again. 
Subsequently the haemoglobin and serum folate levels decreased 
gradually. Since 1972 dietary folate intake was adequate After 
interruption of the SASP therapy the haemonlobin became normal 
ard the serum folate level increased to 4.7 nmole/1 (without 
substitut! on).Because of an exacerbation of Crohn's colitis SASP 
therapy was restarted in July 1974. igain the haemoglobin and 
serum folate levels showed a gradual decrease. In January 1975 
the serum folate level was 0 nmole/1 and the p e n f e r a l blood 
film showed megaloblastic changes. At that time,during ingestion 
of 4 о SASP per day, the serum level of free SP was about 40 
pg/ml. Laboratory test revealed haemolysis during SASP therapy 
(increased reticulocyte count, increased LDH and decreased serum 
haptoglobin l e v e l ) . After SASP withdrawal reticulocyte counts 
and serum LDH levels bécane normal.Therefore, increased folate 
utilization as a result of chronic haemolysis and possibly also 
impaired absorption of folate during SASP therapy seem the most 
likely cause of this patient's folic acid deficiency 
In patient no. 2 megaloblastic anaemia developed during a main-
tenance dose of 6 g SASP per day(table 7.6).SASP therapy was restar 
ted, initially in a dosage of 6 g per day. Because of a very high 
serum level of free SP the dose of SASP was reduced to 4 g and 
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Table 7.6 CLINICAL DATA OF PATIENT ПО. 2 WITH FOLIC ACID DEFICIENCY DURING SASP THERAPY 
date 28.11.73 22.1.74 3.9 6.11 17.12 29.12.76 31.5.77 
haemoglobin (mmole/l) 
reticulocytes (0/oo) 
LDH (U/l) 
haptoglobi η (g/1) 
serum SP (ug/ml) 
SASP (g/day) 
folic acid (mg/day) 
2.1 
2 
440 
0.2 
6 
-
8.7 
175 
0 
93.5 
6 
10 
8.3 
84 
202 
0 
52.4 
4 
10 
R.O 
37 
0.72 
4 
10 
7.8 
88 
117 
0.40 
45.0 
4 
10 
8.4 
62 
198 
0.29 
45.0 
3 
10 
8.0 
48 
39.6 
3 
10 
Table 7.7 CLINICAL DATA OF PATIENT NO. 5 WITH FOLIC ACID DEFICIENCY DURING SASP THERAPY 
date 19.1.72 22.3 13.9 ?.1.73 9.6.75 23.2 30.5 27.12.77 4.4 29.12.78 
haemoglobin (mmole/l) 
reticulocytes (0/oo) 
LDH (U/l) 
haptoglobi η (g/1) 
serum SP (ug/ml) 
SASP (g/day) 
7.6 9.2 9.0 7.0 7.8 
39 
174 
26.0 
3 
9.7 
0 
8.0 
35.6 
4 
6.7 
0.20 
4 
7.8 
0.22 
4 
3.1 
3480 
0.09 
57 .0 
4 
later 3 g per day.With these dosares the serum level of free SP 
ranged from 40 to 50 pq/ml and haemolysis was still present (in­
creased reticulocyte count, increased LDH and decreased serum 
haptoglobiη 1evels ) . 
This patient had undergone extensive small bowel resections, 
so impaired absorption could not be excluded. SASP therapy might 
have aggravated folate malabsorption. Megaloblastic anaemia de­
veloped not until the patient ingested a maintenance dose of 6 g 
SASP per day. Even at a 3 σ dose signs of haemolysis were pre­
sent. Therefore, it is likely that increased folate utilisation 
as a result of chronic haemolysis during SASP therapy played a 
bin part in the development of folic acid deficiency in this pa­
tient . 
In patient no. 3 megaloblastic anaemia developed after treat­
ment with SASP (6 g per day) for 7 months. Crohn's disease was not 
localised in the proximal part of the jejunum and there were no 
signs of malabsorption. Although serum levels of free SP were 
low (<10 ug/ml)Heinz bodies were found in 68 0 / o o of the ery­
throcytes, i n d i c a t m o toxic damane of the red cells. During SASP 
therapy signs of haemolysis were present. In this patient too, 
increased utilisation and possibly impaired absorption of folate 
due to SASP therapy seems the most likely cause of folic acid 
deficiency. 
Fig 7.13 presentsan outline of the main data regarding patient 
no. 4. In June 1976, during ingestion of 4 g SASP per day the 
haemoglobin and serum folate level were normal. The patient ad­
mitted that she did not take the prescribed dose at that time. 
Soon after restart of SASP therapy (6 π per day) the haemoglobin 
decreased to subnormal levais and signs of haemolysis were pre­
sent. Initially the serum levels of free SP were rather low, 
probably as a result of diarrhoea Simultaneously with improve­
ment of the diarrhoea the serum SP level rose to about 40 pg/ml 
In a later phase of the disease (August 1977) signs of haemolysis 
were also present during ingestion of 3 α SASP per day. 
As any other cause could be excluded, c h r o m e haemolysis du­
ring SASP therapy seems the most likely cause of this patient's 
folic acid deficiency. 
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. severe 
Disease moderate 
no 
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In table 7.7 some data are presented regarding patient no. 5 
from the period prior to the development of megaloblastic anaemia. 
It was remarkable that the haemoglobin was always lower during 
the use of SASP than in periods without SASP. The decrease of 
haemoglobin was not caused by blood loss via the digestive tract 
or active inflammation. During ingestion of 4 g SASP per day 
(serum free SP level 35-57 pg/ml) the serum haptoglobin level 
was decreased. 
As other causes could be excluded SASP therapy (with chronic 
haemolysis and possibly impaired folate absorption) seems the only 
possible cause of folic acid deficiency in this patient. 
7.3.4 Di^C£S£ion 
A review of the literature fails to yield a clear picture of 
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the frequency and causes of folate deficiency in patients with 
inflammatory bowel disease. Inadequate dietary intake and in­
creased utilisation may play a part in some patients. Folate mal­
absorption may occur in patients with Crohn's disease with jejunal 
involvement. Franklin and Rosenbern (1973) reported impaired 
folate absorption in patients with inflammatory disease of the 
3 
colon only (mean absorption of H-folate 44 5°/ compaired to 65.6% 
in healthy subjects). Considering the excess of folate in a normal 
diet it is unlikely that this will be the only factor in the gene­
sis of folate deficiency in inflammatory bowel disease. Franklin 
and Rosenberg stated that folate malabsorption is aooravated by 
SASP therapy. Oral folic acid tolerance tests showed decreased 
absorption of folic acid durinq concomitant administration of SASP. 
However, we could not confirm these results (fiq 7.11). 
There is a hiqh incidence of haemolysis during ingestion of 
4.5-6 α SASP per day (§7 2 ) . From the data of the patients des­
cribed in the previous paragraph it may be concluded that c h r o m e 
haemolysis during SASP therapy may result in severe folic acid 
defι с ιency. 
In the literature only one patient with folic acid deficiency and 
megaloblastic anaemia has been described (Schneider and Beeley, 
1977). Over a period of 6 years we observed 5 patients with severe 
folic acid deficiency (at least partially) caused by SASP. This 
indicates that folic acid deficiency durino SASP therapy is not 
so rare As patients without anaemia using SA^P usually are not 
investigated for signs of haemolysis, it is possible that in 
these patient folic acid deficiency is wrongly ascribed to die­
tary deficiency or increased utilisation due to chronic inflam­
mation. 
The results of our study indicate that surveillance of folate 
status in patients usino a maintenance dose of SASP may be im­
portant. In patients with subclinical folic acid deficiency and 
signs of haemolysis during SASP therapy reduction of the dosage 
or subsitution of folic acid is recommended. 
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7 . 4 Uncommon s i d e - e f f e c t s 
7.4.1 2П1Г°.(1У.СІ''0П 
Minor adverse reactions are common durino SASP therapy but 
serious complications have rarely been reported (І2.Д). In the 
past 15 years we observed only 2 patients with serious side-ef­
fects due to SASP; one patient with pancytopenia and one patient 
with SASP-induced luno disease. 
In the following paragraphs the case reports of these patients are 
presented and discussed. 
7.4.2 j^ a n^ cy to pen j_a 
Case report. 
The patient, a 28-year old woman (reç.no. 0910482G) was ad-
mitted to the hospital in September 1975 because of severe anae-
mia. In 1971 Crohn's disease of terminal ileum and colon was diag-
nosed. Since that time she took 6-8 g SASP per day. 
There was a history of weakness and general malaise since one 
month. Besides SASP she used prednisone, diazepam, nitrazepam, 
glafenine and an oral contraceptive. 
Physical examination revealed a pale and sick woman with gene-
ralised haematomas and petechiae. 
The haemoglobin was 3.1 mmole/1. In 9% of the erythrocytes 
Heinz bodies were present. Blood counts showed a severe leucope-
nia (700 white cells per mm" with 7ΐ% segmented neutrophils and 
24% lymphocytes) and thrombocytopenia (platelet count 18.000 per 
mm ). The bone marrow showed a marked maturation arrest of the 
myelopoesis,a decreased erythropoesis and only a few megakaryocy­
tes. Although the patient used 6-8 с SASP per day the serum SP 
levels were less than 20 ug/ml, probable as a result of severe 
diarrhoea. As drug hypersensitivity was the most probable cause 
of the pancytopenia in this patient all medication was disconti­
nued. The course of the haematological parameters are presented 
in fin 7 . 1 d . Because of persistent anaemia the patient was given 
5 litres of blood. About 9 days after withdrawal of all medication 
the white cell count increased, a few days later followed by an 
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Fig. 7 . 1'ί Clinical data of a patient with p a n c y t o p e n i a during 
SASP therapy 
increase of the platelet count. 
SASP was the most probable cause of pancytopenia in this pa­
tient. However, she had used several other drugs. Since SASP is an 
important drug in the treatment of inflammatory bowel disease it 
was important to confirm that this drug was responsible for the 
pancytopenia. The patient was therefore rechallenged with 3 g SASP 
per day. After 13 days, the platelet count decreased to 57.000 
and administration of SASP was discontinued. 
All the other drugs taken on admission were ingested by the pa­
tient in recent years without occurrence of haematological chan­
ges . 
Comment 
A causal relationship between SASP and pancytopenia could be 
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proved in this patient by rechallence with the drug. 
It is likely that pancytopenia was caused by the JP moiety 
of SÍSP. SP has lonq been recognised as one of the most toxic 
sulfonamdes Pccordinq to a survey of Lono et al (1940) granu-
locytopenia or aqranulocytosis was seen in about 0.6* of the pa-
tients using SP. However, agranulocytosis is a rare complica-
tion of SASP therapy (^2.4) and pancytopenia has been reported 
only once (Koskinen, 1954). The patient reported by that author 
developed pancytopenia within one week after start of the SASP 
therapy. In the bone marrow no myeloid cells nor red cell pre-
cursors were seen. After SASP withdrawal the patient recovered 
completely in about 5 weeks. 
In our patient it is remarkable that pancytopenia developed after 
SASP therapy for 4 years. 
7.4.3 SuJ_f£säJ az ι ne-j^nd^uc^ed^ l uil (]_d2 s£ al e_ 
Case report 
The patient, a 44-year old man (reg.no. 1609281K) was admit­
ted to a hospital elsewhere in Oktober 1972 because of a 4 month 
history of bloody diarrhoea. In the past he was treated with SASP 
because of periods of diarrhoea. Physical examination of chest, 
heart and abdomen was negative. Proctoscopic examination was con­
sistent with ulcerative colitis and barium-enema study demonstra­
ted total colonic involvement. An X-ray film of the chest was nor­
mal. He was treated with 6 π SASP per day with prompt improve­
ment. One week after discharge (6 weeks after the start of SASP 
therapy) the patient was readmitted because of fever and short­
ness of breath. The chest radiograph showed extensive confluent 
infiltrates predominantly in the upper half of the lungs (fig 
7.15). Because of marked blood eosinophilia and fever, hyper­
sensitivity to SASP was considered, and the drug was withdrawn. 
The patient was treated with 30 mg prednisone per day. Uithin a 
few days the temperature fell to a normal level and there was a 
gradual disappearance of the dyspnoea and the pulmonary infil­
trates . 
In March 1973 the patient was admitted to our hospital because 
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Fig. 7-15 Chest radiograph showing bilateral p u l m o n a r y intil 
trates after ingestion of 6 g SASP per day for 6 
weeks 
Fig. 7-16 Chest radiograph k Fig. 7.17 Chest r a d i o g r a p h af-
m o n t h s after w i t h - ter r e c h a l l e n g e with 
drawal of SASP 1 5 α SASP per day for 
1 6 days 
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of a relapse of colitis. On examination the patient was thin and 
pale. Physical examination of the chest was negative. 
The haemoglobin level was 5.9 mmole/1. The white cell count and 
3 Ί 
eosinophil count were normal; R300/mm and 50/mm .respectively. 
The ESR was 70 mm in one hour. The serum albumin level was de­
creased to 2? g/1 . The sputum contained no pathogenic bacteria 
or funni . No tubercle bacilli were cultured from the sputum. 
Aspergillus and Pneumocystis nrecipitin tests gave negative results. 
A chest radiograph revealed no abnormal ities(fig 7 . 1 6 ) . A barium-
enema study disclosed severe colitis of the entire colon. 
Since SASP is an important drug in the treatment of ulcerative 
colitis and in the prevention of relapses it was important to con­
firm that the drug was responsible for the pulmonary infiltrates. 
The patient was therefore given 1.5 g SASP per day. The effect of 
rechallenge with SASP on symptoms, blood white cell count, eosi­
nophil count, pulmonary function and chest radiographs are shown 
in table 7.8. 
On day 6 a chest radiograph revealed patchy infiltrates in the 
upper part of the lunq. Infiltrative changes were maximal on day 
16 (fig 7 . 1 7 ) . Pulmonary function test remained normal except for 
a decreased P.O- on day 16. The blood eosinophil count rose sharp­
ly on day 11. By day 13 the patient was aware of dyspnoea and he 
developed a cough productive of mucoid sputum. On day 14 he de­
veloped a skin rash, one day later followed by fever. Physical 
examination of the chest on day 16 was negative. Withdrawal of 
SASP resulted in disappearance of dyspnoea, cough, skin rash and 
fever within one week but blood eosinophilia and pulmonary in­
filtrates were still present 2 weeks after the rechallenge. 
Comment 
There is no doubt that blood eosinophilia and pulmonary in­
filtrates in our patient were due to hypersensitivity to SASP 
or on of the split products Pulmonary lesions have been descri­
bed due to salicylates (Ford, 1966) and sulfonamides (Fiegenberg 
et al, 1967). The syndrome produced by these drugs closely re­
sembles simple pulmonary eosinophilia. a cough productive of mu­
coid sputum accompanied by characteristic radiographic appearances 
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Table 7.8 EFFECT OF RECHALLENGE OF SULFASALAZINE ON SYMPTOMS,BLOOD EOSINOPHIL COUNT, PULMONARY 
FUNCTION AND CHEST RADIOGRAPHS 
SASP (g/day) 
1 3 
days after onset of exposure to sulfasalazine 
6 13 14 16 17 19 20 21 24 25 29 
0 1.5 1.5 1.5 1.5 1.5 1.5 0 0 0 0 
symptoms 
-dyspnoea 
-skin rash 
-temp.(0C) 
+ 
+ 
39^ 39 1 37' 
chest 
radiograph 
η abn abn abn abn abn 
total WCC/mnT 7900 13300 17400 8300 
eosinophils/mm 50 90 100 300 1200 5100 6300 4900 1800 1300 700 
pulmonary 
function 
P
a
0 2 (mmHg) 95 73 86 
n= normal, abn = abnormal 
Table 7.9 SUMMARY OF REPORTS OF CASES WITH SULFASALAZINE INDUCED 
first author Jones 1972 Hutton 1973 х Davies 1974 
sex and age 
dose of SASP 
(g) 
M 36 M 58 F 47 
б 
length of exposure 2 
(months) 
symptoms dyspnoea 
fever 
weight loss 
dyspnoea dyspnoea 
blood eosinophil 
count/mm 
1090 95 440 
radiographic 
appearances 
widespread widespread extensive 
infiltrative infiltrates lazy 
opacities shadowing 
period before 
radiograph 
returned to normal 
(weeks) 
fatal 
* unpublished data 
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LUNG DISEASE 
this 
Thomas 1974 Mahler 1974* Tydd 1976 Constant ι nidι s 1976 patient 
M àS M 58 M 58 23 M 44 
1.5 
1.5 1.5 
dyspnoea dyspnoea dyspnoea dyspnoea dyspnoea 
cough fever cough cough cough 
fever fever fever fever 
weight loss weiqht loss skin rash 
normal 5900 6500 6300 
alv. filling extensive extensive widespread 
and nodular bilateral confluent ill-defined 
opacities opacities infiltrates infiltrates 
bi1ateral 
ill-defi-
ned inf i 1 
trates 
16 >2 
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of fairly homoqeneous fan-shaped opacities with indefinite bor­
ders, blood eosinophilia and frequently without significant fin­
dings on physical examination of the chest. 
Λ review of the literature produced only 7 other cases of SASP-
induced lung disease, two of which were unpublished. The main data of 
these patients are summarized in table 7.9. The duration of SASP 
treatment before onset of respiratory symptoms was 2-7 nonths. 
Dyspnoea was the dominant symptom in every case. Blood eosinophi­
lia was present in 5 patients. The chest radiographs usually 
showed infiltrative opaci ties .sometimes with background nodula-
ti on. 
The symptoms usually disappear when SASP is stopped but prompt 
recognition of early respiratory symptoms is essential for per­
manent lung damage (Jones and Malone, 1972) or even death (Davies 
and MacFarlane, 1974) have been reported. 
SASP-induced lung disease should be thought of when dyspnoea, 
cough,or chest abnormalities appear in patients taking this drug, 
particularly during the early months of treatment. 
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Chapter 8 
COMPLIANCE TO THERAPY IN PATIENTS TAKING A MAINTENANCE DOSE OF 
SULFASALAZINE 
8.1 Introduction 
Both clinical experience and published reports suggest that 
a significant fraction of patients do not take their medicine 
as directed. A review of over 50 studies found that complete 
failure to take medication often occurred in between 25 and over 
50% of all out-patients (Blackwell, 1972). Another type of poor 
compliance, which may be even more frequent, is errors in dosage. 
A variety of methods have been used to detect the drug defaulter 
such as interrogation of the patient, counting of pills used or 
bottles of medication emptied and addition of a marker to the 
tablets (e.g. riboflavine, phenolred) that can be detected in 
urine. These methods are often not very reliable. The most cer-
tain method is quantitative determination of the drug or a meta-
bolite in serum or 24-hour urine (Leve, 1958; Maddock, 1967; Oakes 
et al, 1 9 7 3 ) . 
Up to now no studies have been published on compliance to therapy 
in patients with inflammatory bowel disease taking a maintenance 
dose of SASP. 
In our department serum levels of SP+ac-SP were determined in a 
large number of patients who were on a maintenance dose of SASP. 
This enabled us to study the rate of drug defaulting in these 
patients. 
8.2 Patients and methods 
To determine the day-to-day variation of the serum SP level, 
the serum level of SP+ac-SP was measured on two different days 
within a period of 1 week in 24 hospitalized patient using a 
maintenance dose of SASP (3-6 g per d a y ) . During this period and 
several days before, the conditions in each patient were con-
stant. Blood samples were drawn between 9 and 10 A.M. In 18 of 
the 24 patients 24-hour urinary excretion of SP was determined 
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also. 
To check patient compliance serum levels of SP+ac-SP were 
determined in 51 patients with inflammatory bowel disease using 
a constant maintenance dose of SASP both shortly before dischar-
ge from the hospital and at a follow-up at the out-patient depart-
ment 1-6 months later. Out-patients who had a substantial in-
crease in stool frequency and those who had received after dis-
charge other drugs which might influence the metabolism of SASP 
(antibiotics, cholestyramine) were excluded. 
Finally, serum levels of SP+ac-SP were determined repeatedly 
in 171 out-patients taking a constant maintenance dose of SASP 
(3-6 g per d a y ) . 
8.3 Results 
The results of the study on day-to-day variation of the serum 
level and 24-hour urinary excretion of SP are presented in table 
8.1. 
Table 8.1 SERUM LEVEL AND ¿4-HOUR URINARY EXCRETION OF SP DETER-
MINED ON TWO DIFFERENT DAYS IN HOSPITALIZED PATIENTS 
USING A CONSTANT MAINTENANCE DOSE OF SASP 
serum S P ( n = 2 4 ) 1 urine S P ( n = 1 8 ) 2 
yg/ml (mean+SD) mg/mmole creat. (mean+SD) 
determination 1 38.7+4.2 
determination 2 39.6+4.5 
mean of 1 and 2 39.1+4.3 
relative di fference(%) 11.4+1.9 
119+13.4 
119+13.0 
119+13.2 
11.9+ 2.6 
1 SP+ac-SP 
2 SP+metaboli tes 
The day-to-day variation of serum SP level and urinary SP excretion 
in a given patient under constant conditions was small. The dif-
ference in serum SP level in a given patient, expressed as rela-
tive difference between values measured on two different days. 
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was 11.4+1.9% (mean+SD). For 24-hour urinary excretion of SP the 
relative difference was 11.9 + 2.6°/. Both methods can therefore be 
used to check patient compliance. As described in §5.1 the serum 
SP level in the individual patient was reasonably constant in the 
course of the day. It is therefore not necessary to take blood 
samples always at the same time of the day. 
To obtain the outside limit of the 95% confidence interval for 
the 97.5 percentile line, the standard deviation of the relative 
difference should be multiplied by a factor 2.69 (Rumke and 
Bezemer, 1972a; Rumke and Bezemer 19 7 2 b ) . By using a relative 
difference of 25% between two determinations of SP in the indivi-
dual patient (e.g. during hospitalization and at follow-up as 
out-patient) as a limit, the probability of wrongly concluding 
that a given patient does not take the prescribed dose of SASP 
is small (much less than 5 % ) . 
Fig 8.1 presents the serum levels of SP+ac-SP in 51 patients 
both during hospitalization and during out-patient follow-up.In 
some patients the serum SP level was higher after discharge as a 
result of decreased diarrhoea. In 21 patients (41.2%) the serum 
SP level was considerably lower at out-patient follow-up compared 
to the serum level before discharge (relative difference >25%; 
mean+SD: 102+54%). The serum SP level in these patients dropped 
from 53.7+18.4 pg/ml to 18.5+13 pg/ml (mean+SD). In none of these 
patients the decrease in serum SP level could be explained by wor-
sening of diarrhoea or concomitant administration of other drugs. 
The only possible explanation therefore was that these patients 
did not take the prescribed dose of SASP. It is important to note 
that all the patients were fully informed about their illness, 
the need for treatment and the likely consequences of both. 
In 21 (12%) of the 175 out-patients using a maintenance dose of 
SASP, SP in serum was not detectable at all at repeated deter-
minations during follow-up. When interrogated, most patients clai-
med that they took SASP as prescribed. In some patients the serum 
SP level rose (usually temporarily) during a relapse of the dis-
ease or after repeated explanation to the patient about the im-
portance of the prescribed medication. 
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in-patient out-patient in-patient out-patient in-patient out-patient 
Relative difference Í 25·/. >25°/Л >2Ъ'Ц 
Fig. 8.1 Serum level of S P + a c - S P in 51 p a t i e n t s with i n f l a m m a ­
tory bowel d i s e a s e using a c o n s t a n t m a i n t e n a n c e dose of 
SA S P , both during h o s p i t a l i z a t i o n and at o u t - p a t i e n t 
f o l l o w up 1-6 m o n t h s later 
Fig 8.1 shows that in 50 of 51 hospitalized patients taking a 
maintenance dose of 3-6 g SASP per day, the serum level of SP+ac-
SP was higher than 20 pg/ml . When lower serum SP levels are found 
in out-patients without severe diarrhoea using similar doses of 
SASP it may be assumed that these patients do not take the pres­
cribed dose. 
8.4 Discussion 
The results of this study indicate that a substantial fraction 
of patients on maintenance therapy with SASP do not take the 
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prescribed dose. 
Knowledge of the extent of patient non-compliance is important 
not only for the treatment of the individual but also in order to 
assess the efficacy of the drugs given. As long ago as 1957 Dixon 
et al noted that "many chemotherapy trials based on unsupervised 
oral medication have probably been built on very unsure founda-
tions". This point has been emphasized by several other investi-
gators. Porter (1969), for instance, stated on the basis of a 
study on patient compliance in a general practice, that "drug 
defaulting during a drug trial must not be allowed to escape 
attention; if it passes unnoticed serious harm may be done to 
the conclusions reached". 
Both Joyce (1962) and Uhlenhuth et al (1965) have shown that a 
rate of noncompliance as found in our patients may modify the 
outcome of controlled studies. 
However, none of the drug trials in patients with inflammatory 
bowel disease published up to now incorporated methods of detec-
ti ng defaulters . 
The results of our study clearly show that a reliable method for 
determination of compliance to therapy is essential in out-patient 
trial s. 
It is in fact not surprising that patients do not take the 
prescribed dose of SASP. SASP must be taken for a prolonged pe-
riod of time (usually several years) and at a high dose (6-12 
tablets per d a y ) , while side effects are not uncommon. 
Patients using SASP maintenance therapy are prone to lapses in 
compliance because after a remission has been achieved the treat-
ment is more or less prophylactic and consequences of stopping 
therapy may be delayed. 
In order to improve compliance to therapy in patients with 
inflammatory bowel disease using a maintenance dose of SASP some 
points should be stressed. It is very important that the patient 
is fully informed regarding the nature of his illness, the impor-
tance of the drug prescribed and the side-effects which may occur. 
The patient should be explained why SASP must be taken for a 
prolonged period of time, even when the symptoms have disappeared. 
As SASP usually has to be taken for years it is important to 
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motivate the patient again and again. Francis et al (1969) and 
Hecht (1970) considered the patient's lack of understanding one 
of the major causes of noncompliance. 
The occurrence of side-effects can be expected to discourage com-
pi iance .Si nee most side-effects of SASP are related to the serum 
SP level, the majority of side-effects might be avoided or overcome 
by monitoring serum SP levels during SASP therapy. Of importance 
too, is to choose the simplest treatment regimen compatible with 
the patient's everyday habits. Whether a person is at work and 
how often he eats his meals can affect the ease with which in-
structions to take drugs at certain times are followed. SASP is 
usually given in 3 or 4 doses per day. Several studies have shown 
that compliance is much higher when the patients have only one or 
two doses each day (Lationas and Berry, 1969; Blackwell, 1973; 
Parkins et al, 19 7 6 ) . Therefore, it seems useful to investigate 
whether SASP can be given twice daily without diminution of its 
efficacy. 
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SUMMARY 
Chapter 1 
INTRODUCTION AND PROBLEM STATEMENT 
This chapter gives an outline of the investigations carried out 
to answer the following questions. 
1 Are the methods for determination of SASP and metabolites des-
cribed in the literature reliable and suitable for routine use? 
2 In which way is orally administered SASP absorbed, metabolized 
and excreted in healthy subjects and in patients with inflammatory 
bowel disease? 
3 Which of the following factors may influence the metabolism and 
consequently the efficacy of SASP? Administration form of SASP; 
intestinal transit time; inflammatory activity of the bowel; con-
comitant administration of amoxycillin and of cholestyramine; use 
of an elemental diet; total colectomy; bacterial overgrowth in the 
small intestine. 
4 Which of the split products of SASP is the therapeutically 
active moiety? 
5 What is the incidence and nature of side-effects during SASP 
therapy and does a relation exist with the serum levels of SASP 
and SP? 
6 What is the rate of drug defaulting during SASP maintenance 
therapy? 
Chapter 2 
REVIEW OF THE LITERATURE 
This chapter presents a survey of the literature concerning 
the metabolism of SASP,assumptions about the mode of action,its 
value in the treatment of inflammatory bowel disease and side-
effects of the drug. The studies of Schröder and Campbell (1972) 
and of Peppercorn and Goldman ( 1972) indicating that the larger 
part of SASP is split at the diazo bond by colonic bacteria strong-
ly stimulated further research into the metabolism and mode of 
action of SASP. 
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Chapter 3 
DETERMINATION OF SULFASALAZINE AND METABOLITES IN SERUM, URINE 
AND FAECES 
SASP and SP were determined according to the methods described 
by Hansson and Sandberg (1973) and Sandberg and Hansson (1973). 
Regarding determination in serum and urine these methods proved 
to be reliable and suitable for routine use. SASP in the faeces 
was measured via the SP metabolite after splitting of the azo 
bond by addition of TiCl^. Determination of 5-ASA was carried 
out according to Pieniaszek and Bates (1975). This method was 
considerably improved by the introduction of some modifications. 
With regard to determination of SASP and metabolites in faeces 
it is necessary to prevent azo reduction of SASP during storage. 
The effect of various methods of preservation on azo reduction of 
SASP in faeces was investigated. The results of these studies 
indicated that azo reduction in faeces could be blocked comple-
tely by adding an approximately equal amount of a 0.2% HgCl-
solution. In experiments of other investigators(Schröder and 
Campbell, 1972; Peppercorn and Goldman, 1973) the stools were 
stored at -20 C. The results of these studies should be regarded 
with some reserve as from our experiments it could be concluded 
that during the process of freezing and defrosting a considerable 
amount of SASP is split. 
Chapter 4 
PHARMACOKINETICS AND METABOLISM OF SULFASALAZINE 
This chapter describes the results of a number of studies made 
in an effort to obtain more information about absorption .metabolism 
and excretion of SASP in healthy subjects. Both after a single dose 
and during maintenance therapy the serum SASP levels showed marked 
interindividual differences. Only a small fraction of SASP (0.5-7%) 
was excreted unchanged in the stools. During a normal pattern of 
defaecation, the recovery of SASP in the faeces was very low 
( 0 - 1 . 5 % ) . The serum levels of SP and SP+ac-SP likewise showed 
marked interindividual differences. These could in part be ex-
plained by the acetylator phenotype. In slow acetylators the serum 
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level of free SP (and therefore the total SP level) was signi-
ficantly higher than in fast acetyla tors. 
After ingestion of a single dose of SASP most of SP (55-72%) was 
recovered in the urine. Only a small fraction (4-12%) was excre-
ted in the faeces. 5-ASA was largely recovered in the faeces (50-
9 0 % ) . The urinary excretion was 12-35%. Both after a single dose 
of SASP and during maintenance therapy, the serum 5-ASA level was 
always below 2 yg/ml. 
With the aid of SASP the acetylator phenotype could be deter-
mined in a simple way by determining the concentrations of free 
SP and ac-SP in serum or urine. For this purpose a serum or urine 
sample obtained within 12-20 hours after ingestion of a single 
3 g dose of SASP can be used; during maintenance therapy any 
random sample. When less than 30% of SP in serum is acetylated, 
the subject is a slow acetylator. In urine, less than 55% of 
SP consists of acetylated metabolites in the slow acetylator 
phenotype. 
Chapter 5 
FACTORS WHICH MAY INFLUENCE METABOLISM AND EFFICACY OF SULFASALA-
ZINE 
In 7 healthy subjects, the recovery of SASP and metabolites in 
urine and faeces was determined after ingestion of a single oral 
dose of 3 g SASP, both during a normal and an accelerated intes-
tinal transit. In case of a normal intestinal transit time (35-93 
hours) SASP was almost completely split in the colon. Only 3.2+ 
2.2% (mean+SD) of the given dose was found as SASP in urine and 
0.5+0.6% in faeces. SP was mainly recovered in the urine (63.1+ 
7.6%) whereas 5-ASA was largely excreted in the faeces (74.7+ 
13.4%). During accelerated intestinal transit (8-28 hours) 45.4 
+21.3% of the administered dose was recovered as intact SASP in 
the faeces. The recovery of 5-ASA in the faeces decreased to 
45.5+25.8%. Although there was a diminished splitting of SASP 
the recovery of SP in the faeces increased. 
Especially in subjects with a transit time of less than 16 hours 
the azo reduction of SASP and consequently the recovery of 5-ASA 
in the faeces was substantially decreased. In 18 patients with 
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inflammatory bowel disease it could be demonstrated that the serum 
SP levels were related to the diarrhoeal state and did not corre-
late with the disease activity. 
Since the active compound of SASP has been suggested to be 5-ASA 
it is possible that the lack of efficacy of SASP in patients with 
severe colitis is due to the reduced release of 5-ASA as a result 
of profuse diarrhoea. 
In subjects with an accelerated intestinal transit the azo re-
duction of SASP appeared to be influenced by the administration 
form of SASP. Under these circumstances SASP administered in pow-
der form was more completely split compared to enteric coated 
tablets. During a normal transit the splitting of SASP was not 
influenced by the administration form. 
In 5 patients the serum levels of SP were determined both du-
ring normal food intake and during an elemental diet. The serum 
SP levels were higher during an elemental diet than during normal 
food intake. These findings indicate that despite a decrease in 
the total number of bacteria in the colon during an elemental 
diet SASP is sufficiently split (probably as a result of a 
slower passage through the c o l o n ) . The administration of SASP 
during an elemental diet is therefore certainly appropriate. 
Concomitant administration of amoxycillin did not influence 
the azo reduction of SASP, provided that the intestinal transit 
time did not change. 
The influence of concomitant administration of cholestyramine 
on the azo reduction was studied in vitro and in vivo. In aqueous 
solutions 90% of SASP, 70% of SP and 30% of 5-ASA was bound to 
cholestyramine. 
The reduction rate of SASP bound to cholestyramine was conside-
rably reduced. In a faecal suspension without cholestyramine SASP 
was completely split after incubation for 4 hours. Of SASP bound 
to cholestyramine only 46% was split after 4 hours. In healthy 
subjects with a normal intestinal transit the recovery of 5-ASA 
inthe faeces was decreased by about 50% during concomitant admi-
nistration of cholestyramine. It is probable that 5-ASA is the 
active moiety of SASP. Cholestyramine may therefore have an un-
favourable influence on the efficacy of SASP. In patients who 
196 
have undergone an ileocoecal resection, diarrhoea is often tran­
sient. When only a limited part of the ileum is removed, in many 
patients the defaecation pattern becomes practically normal within 
a few months. Especially in those patients using a maintenance 
dose of SASP it seems useful to investigate whether cholestyramine 
is in fact still necessary. 
In 6 patients with Crohn's colitis or ulcerative colitis using 
a maintenance dose of SASP, the serum level and urinary excretion 
of SASP and metabolites were determined prior to and several months 
after colectomy. 
The serum level and 24-hour urinary excretion of SASP did not dif­
fer significantly before and after colectomy. After colectomy 
the serum SP level decreased to a very low level. The same applied 
to the urinary excretion of SP and 5-ASA, from 36.3 to 2.2% and 
from 9.8 to 0.8% of the administered dose, respectively. 
Assuming that one of the split products of SASP is the active 
moiety, it is unlikely that SASP has a therapeutic effect in 
colectomized patients. 
Azo reduction of SASP in the small intestine was studied in 
two healthy subjects and in a patient with bacterial overgrowth 
in the smal 1 bowel. 
Under normal conditions virtually no SASP was split in the small 
intestine. In the patient with bacterial overgrowth in the small 
bowel a considerable amount of SASP was split before the colon 
had been reached. 
In Crohn's disease of the small intestine there is often a marked 
increase in the number of bacteria at the site of inflammation as 
a result of stasis of intestinal fluid due to infiltration or 
stenosis of the intestinal wall. In these patients SASP might be 
therapeutically active thanks to the bacterial overgrowth which 
is often present. 
Chapter 6 THE EFFECT OF SULFAPYRIDINE, 5-AMINOSALICYL1С ACID AND 
PLACEBO IN PATIENT WITH IDIOPATHIC PROCTITIS.A STUDY TO 
DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULFASALAZINE. 
To determine the therapeutically active moiety of SASP, suppo­
sitories of SP, 5-ASA or placebo were given to 45 patients with 
idiopathic proctiti s.The experiment was conducted as a double blind 
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controlled therapeutic trial, each patient having one of the test 
suppositories twice daily for 4 weeks. Remission (defined 
as complete disappearance of clinical symptoms and a normal rectal 
mucosa at sigmoidoscopy) was observed in 60% of the patients re-
ceiving 5-ASA suppositories and in only 13.3% and 26.7% of those 
receiving SP and placebo, respectively (p=0.020). Twelve patients 
were included twice. Eight of them received one time 5-ASA and 
another time SP (2 patients) or placebo (6 patients). All 8 pa-
tients went into remission during 5-ASA therapy compared to only 
once during other therapy ( p < 0 . 0 5 ) . The results of this study 
strongly suggest that 5-ASA is the active therapeutic moiety of 
SASP. 
The use of SASP is not infrequently limited by the appearance 
of side-effects which are almost all attributable to the SP moie-
ty. It would be of great value to synthetize a new compound where-
by SP is replaced by a less toxic (preferably inert) carrier. The 
advantage of such a drug would be that higher doses can be admi-
nistered with the possibility of better therapeutic results than 
those with SASP, but with fewer side-effects. 
Chapter 7 
ADVERSE REACTIONS DURING SULFASALAZINE THERAPY 
In 223 patients with Crohn's disease or ulcerative colitis using 
a maintenance dose of SASP (3-6 g per day) the incidence and nature 
of subjective complaints and their relation to the serum level of 
SASP and SP was studied. Forty-six patients (20.6%) reported ad-
verse symptoms during SASP therapy. In most of the patients side-
effects occurred in the first weeks of therapy or following a 
recent increase in the dosage of SASP. Eleven patients were nause-
ated by the first few doses of SASP. In 6 of these patients the 
symptoms disappeared after SASP had been administered as enteric 
coated tablets. In almost all patients the adverse symptoms could 
be overcome by temporarily stopping or reduction of the dosage 
(3-4 g per d a y ) . 
Nausea was the most frequent symptom (in 15.2% of the patients). 
Adverse reactions only occurred in patients with a serum level 
of SP+ac-SP over 50 ug/ml. Generally, the serum level of free SP 
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was also higher than 50 yg/ml in these patients. 
Of 86 patients with a serum SP+ac-SP level over 50 wg/ml , 35 
(40.7%) reported subjective complaints. Fifty-seven percent of the 
patients were slow acetylators. However, of the patients with 
side-effects 80% had slow acetylator phenotype. 
Because SASP is an important drug in the management of inflamma-
tory bowel disease it is important to recognize and to avoid side-
effects during the treatment with this drug. In patients complai-
ning of adverse reactions during SASP therapy it is useful to de-
termine the serum level of SP+ac-SP. When the serum level is hig-
her than 50 yg/ml the dose of SASP should be reduced. 
In 36 unselected patients with Crohn's disease or ulcerative 
colitis taking a maintenance dose of 4.5-6 g SASP per day the 
incidence of haemolysis and its relation to the serum level of 
SASP and SP was investigated. In 19 patients (53%) haemolysis 
was present. All patients with a serum level of free SP higher 
than 37 vig/ml had haemolysis as compared to only 4 of 21 patients 
with a serum SP level below 37 pg/ml. Four patients had evidence 
of haemolytic anaemia. In these patients the serum level of free 
SP was higher than 55 ug/ml. Eighteen of the 19 patients with 
haemolysis were slow acetylators while only 6 of 17 patients 
without haemolysis belonged to the slow acetylator phenotype. 
Haemolysis should be considered in any patient with Crohn's 
disease or ulcerative colitis if loss of blood or chronic in-
flammation fails to account for the anaemia. 
In the literature, only one case of megaloblastic anaemia due 
to folic acid deficiency during SASP therapy has been described. 
Over a period of 6 years we found 5 patients with severe folic 
acid deficiency during SASP therapy. The data of these patients 
suggested that increased utilization of folate due to chronic 
haemolysis during SASP therapy was the major cause of folic acid 
deficiency. 
Chapter 8 
COMPLIANCE TO THERAPY IN PATIENTS TAKING A MAINTENANCE DOSE OF 
SULFASALAZINE 
To investigate compliance to therapy serum levels of SP+ac-SP 
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were determined in 51 patients with inflammatory bowel disease 
using a constant maintenance dose of SASP both shortly before 
discharge from the hospital and at a follow-up at the out-patient 
department 1-6 months later. In 21 patients (41.2%) the serum 
SP level was considerably lower at out-patient follow-up compa-
red to the serum level before discharge. The only possible expla-
nation for the decrease in serum SP level was drug defaulting. 
In 21 {12%) of 175 out-patients using a constant maintenance 
dose of SASP, SP in serum was not detectable at all at repeated 
determinations during follow-up. 
These results indicate that a substantial fraction of patients 
on maintenance therapy with SASP do not take the prescribed dose. 
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STELLINGEN 
1 De passagesnelheid door het colon bepaalt in hoge mate de azo 
reductie van sulfasalazine en daardoor het therapeutische effect 
van dit geneesmiddel. 
2 Er zijn duidelijke aanwijzingen dat 5-aminosalicylzuur het werk-
zame bestanddeel is van sulfasalazine. 
3 Bij studies omtrent de werkzaamheid van sulfasalazine is een con-
trole op het innemen van de voorgeschreven dosis een onmisbaar 
onderdeel . 
4 Ondanks de goede resultaten die door de behandeling met ^ - r e c e p -
tor antagonisten worden bereikt ter voorkoming van recidiverende 
ulcera duodeni zijn de indicaties voor chirurgische therapie m e t 
ingrijpend gewijzigd. 
5 Het syndroom van Conn vereist een snelle en adequate behandeling 
ten einde de opvallend vaak optredende cardiovasculaire complica-
ties te voorkomen. 
Hoefnagels WHL e.a. Lancet I. 978-979, 1979 
6 Disodiumcromoglycaat is niet effectief bij de behandeling van co-
litis ui cerosa . 
Willoughby CP e.a. Lancet I: 119-122, 1979 
7 Chemotherapie met een combinatie van cis-platina, vinblastine 
en b l e o m y c m e is de beste behandeling voor het gemetastaseerde 
testis teratoom In 60 tot 70% van de patiënten wordt een complete 
remissie bereikt. 
Einhorn LH. Proc Am Soc clin Oncol: 308-313, 1978 
Stoter G e a Lancet I: 941-945, 1979 
8 Bij patiënten met colitis ulcerosa behandeld met corticosteroiden 
in de vorm van clysma's is soms zowel röntgenologisch als endo-
scopisch het rectum en sigmoid geheel normaal terwijl in het meer 
proximale deel van het colon wel ontstekingsverschijnselen aan-
wezig zijn . 
Onbekendheid met deze locale therapie kan er toe leiden dat ten 
onrechte de diagnose Crohn'se colitis wordt gesteld. 
9 Bij patiënten met colitis ulcerosa of Crohn'se colitis die een 
totale colectomie moeten ondergaan verdient i n t e r s f i n c t e n s c h e 
excisie van het rectum de voorkeur boven ruimere excisie omdat de 
genezing van de perineale wond voorspoediger verloopt en functio-
nele stoornissen zoals impotentie na deze techniek minder vaak 
voorkomen. 
Lyttle JH and Parks AG. Br J Surg 64: 413-416, 1977 
10 Een asymptomatische souffle over de arteria carotis interna die 
het gevolg is van een arteriosklerotische laesie van deze arterie 
dient reeds in een asymptomatisch stadium geopereerd te worden. 
Thompson JE e.a. Ann Surg 188: 308-315, 1978 
11 Het verdient aanbeveling zowel omwille van de kwaliteit van de 
behandeling als om psychohygienisehe redenen het personeel dat 
werkzaam is op een intensive care afdeling de mogelijkheid te 
bieden gebruik te maken van de consultatieve diensten van een 
psychosociaal team. 
Schors R. Psyche 33: 343-363, 1979 
12 In het jaar van het kind zouden de volwassenen behalve meer aan-
dacht aan het kind ook meer aandacht aan hun eigen kinderlijke 
belevingen moeten schenken indien ze een beter gevoelsmatig con-
tact met het kind wensen. 
P.A.M, van Hees 
28 j u m 1979 


